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ABSTRACT 
 
Christopher Dennis Packey: Disruption of complex enteric commensal microbial communities 
and their mutualistic functions with the host contributes to the severity of common intestinal 
disorders and serves as a promising therapeutic target 
(Under the direction of R. Balfour Sartor) 
 
 Many people were surprised when the Human Genome Project revealed that the human 
genome contains only about 20,000 protein-coding genes, comparable to the number in the fruit 
fly genome. The complexities of human health and disease may lie in the human microbiota, the 
constellation of microbes living inside and on the body that harbors at least 3.3 million non-
redundant genes. 
The human gut is the natural environment for a diverse and dynamic microbial 
ecosystem. A better understanding of the human intestinal microbiota and how to manipulate it 
safely may lead to better ways to prevent harm and promote health. An overall goal of this work 
was to generate data that guides the design and implementation of diagnostic and therapeutic 
strategies that intentionally manipulate the human microbiota to optimize its performance in the 
context of an individual’s physiology. 
We utilized novel, high-throughput technologies with next-generation gene sequencing 
and powerful bioinformatics analysis tools integrated with metagenomics, gnotobiology and 
microbiota transplantation to provide deep insights into the composition, structure and activities 
of the gut microbiota over time in rodents and humans with injury and inflammation in the small 
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intestine and colon. We characterized significant shifts in the composition of the microbiota in 
several forms of intestinal disease, including irritable bowel syndrome, spontaneous, chronic, 
immune-mediated colitis, and radiation enteropathy. We identified interventions that alter 
dysbiosis and the course of intestinal disease, including antibiotics, probiotics and fecal 
microbiota transplantation. Host innate immune molecules including antimicrobial peptides 
produced by cells in the small intestinal mucosa contribute to phenotypes.  
Our studies have improved the knowledge of how the host and bacteria interact during 
intestinal inflammation and injury and how the microbiota responds and is regulated. Given the 
abrupt rise in incidence of intestinal disorders that appears to have coincided with socioeconomic 
development and dietary changes, expeditious progress in this area of research is crucial in order 
to impede the dramatic acceleration of the prevalence of these diseases. These data may yield 
valuable clinical tools in restoring a healthy microbiota to prevent or treat intestinal disorders 
without administering broad, immunosuppressive medications that are accompanied by severe 
side effects. 
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Introduction 
 The incidence of some important gastrointestinal (GI) disorders is increasing, including 
that of irritable bowel syndrome (IBS), radiation enteropathy, and the inflammatory bowel 
diseases (IBD). These three sets of intestinal diseases share some key features: They are 
associated with a similar group of symptoms, (nausea, abdominal pain, changes in bowel habits) 
(1-3), they are common reasons for seeking treatment (4-6), they have a high correlation with 
poor health-related quality of life (7-9), they are responsible for substantial costs to society (10-
12), and intestinal microbes may contribute to their development (13-15). 
 IBS is the most common cause of lower GI illness (16). Diarrhea-predominant IBS (D-
IBS) accounts for approximately 40% of all IBS patients and has an estimated 5% prevalence in 
the general population (1). D-IBS is defined by abdominal pain and diarrhea, in the absence of 
organic disease that is likely to explain the symptoms (16). It is a symptom-based condition that 
lacks biomarkers that can be used for diagnostic or monitoring purposes. 
 Intestinal radiation injury is a significant clinical issue that is increasing in prevalence 
due to improved survival of cancer patients and increased availability of radiotherapy as an 
affordable treatment. Radiation therapy is a part of the treatment regimen for approximately 70% 
of all cancer patients (17). GI radiation injury is an important problem for two main reasons. 
First, it limits the dose that is administered to the patient, which can compromise efficacy of 
treatment and malignancy cure rate. Second, it can lead to the radiation GI syndrome, which is 
the cause of initial morbidity and mortality following a nuclear accident, terrorist attack or other 
large dose radiation exposure. Radiation enteropathy is still a significant problem despite efforts 
to decrease damage to normal intestinal tissue by utilizing physical maneuvers, tissue expanders, 
prophylactic surgical techniques, and optimized planning and delivery techniques (5). Biological 
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strategies have been largely ineffective, as today there is still no prophylactic or therapeutic 
agent available that is proven to mitigate the acute and chronic symptoms of GI radiation injury 
or to allow safe radiation dose escalation for better control of malignancies. This is, in large part, 
due to the fact that relatively little is known about the pathophysiology of radiation intestinal 
injury.  
 IBD, immune-mediated disorders that include Crohn’s disease and ulcerative colitis, have 
been steadily increasing in incidence in North America and Northern Europe since World War II, 
with rates doubling during several decades (6). Rapid increases in incidence are now also being 
recorded in Southern Europe, Australia, New Zealand, Japan, South Korea, China, and India. It 
has been proposed that IBD will emerge as a worldwide epidemic in the near future. Unlike IBS 
and radiation enteropathy, it is well established that commensal gut bacteria play a critical role in 
the pathogenesis of IBD (18, 19). However, exactly what role they play is still in need of further 
clarification (20). 
 Some researchers had predicted in the past that the human genome might be comprised of 
more than 100,000 genes. So many were surprised when the Human Genome Project revealed 
that the human genome contains only about 20,000 protein-coding genes, comparable to the 
number in the fruit fly genome. The complexities of human health and disease may lie in the 
human microbiota, the constellation of microbes living inside and on the body that harbors at 
least 3.3 million non-redundant genes (21).  
 My studies focus on the role of commensal bacteria in the pathogenesis of the 
aforementioned three intestinal disorders. The GI tract has a large mucosal interface (300-400 
m
2
) that has structures and functions for the immunological recognition of the external 
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environment (19). This tract is the principal site of permanent microbial colonization in the 
human body, teeming with 10-100 trillion microorganisms that exceed the total number of host 
cells by at least one order of magnitude (22). Most of these microbes belong to the domain 
Bacteria. 98% of genes in the human gut microbiome are bacterial, and the gut is home to at least 
1150 prevalent bacterial species (21). Yet, only seven to nine of the 55 phyla of the domain 
Bacteria are detected in the human intestine (21, 23-25). More than 90% of all phylotypes 
(sequences with 97% identity, assumed to represent a single species) belong to two divisions: 
Bacteroidetes and Firmicutes (24). The other divisions that have been consistently found in 
samples from the human distal gut are Proteobacteria, Verrucomicrobia, Actinobacteria, and 
Fusobacteria.   
 The concept of the gut microbiota as a regulator of health and disease is not a new one. In 
fact, Elie Metchnikoff hypothesized over a century ago that toxic colonic microbes that 
accelerate senescence could be replaced with beneficial microbes for the betterment of the host 
(26). Metchnikoff may have provided the foundation for the notion of probiotics when he 
advertised claims of improved health upon introducing sour milk to his diet, following the 
example of notoriously long-enduring Eastern European farmers who consumed large quantities 
of acrid dairy products (27).  
 The relationship between the mammalian host and microorganisms that colonize the 
intestinal tract is the product of a lengthy and complex co-evolution. Experimental studies in 
germ-free animals have revealed the importance of commensal microbial communities for 
normal host growth and development and for the maintenance of health. There are important 
anatomical and physiological differences between germ-free and colonized animals, and 
reconstitution of germ-free animals with a microbiota from conventional counterparts restores 
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most of the deficiencies (28). The main functions of the gut microbiota are ascribed into three 
categories: Metabolic, protective and trophic functions (29). Germ-free mice are 
immunodeficient and highly susceptible to infections caused by pathogens or opportunistic 
organisms (30-33).  
 Certain organisms, such as Lactobacillus spp. (34) and Faecalibacterium prausnitzii (35), 
are considered beneficial for health. The gut community also harbors organisms that have the 
capacity for adverse effects, via their gene products, metabolic outputs, or potential for 
pathogenicity (36). The balance of benefit and harm for the host therefore depends on the overall 
state of the microbial community in terms of its species composition, diversity and distribution 
(37, 38). While there is significant inter-individual variation in the composition of the 
microbiota, fecal microbiota profiles in healthy adults seem to have substantial stability over 
time (38-40). 
 Not surprisingly then, a “dysbiosis”, or imbalanced state of the gut microbial ecosystem, 
including overgrowth of more “pro-inflammatory” commensals and loss of protective microbes, 
has been associated with several diseases, including IBD (18, 41), obesity (42) and metabolic 
syndrome (43, 44). However, how changes in microbial communities contribute to disease 
etiology remains poorly defined. 
 The study of isolated bacteria by culture techniques does not help us describe complex, 
mostly anaerobic microbial communities in the human body, as most of the mammalian 
microbiota is not easily cultured in a laboratory, mainly owing to the lack of appropriate culture 
media (19). Furthermore, laboratory in vitro cultivation does not permit characterization of the 
biology of these organisms in their natural environment. Therefore, we utilized several 16S 
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rRNA-based approaches to answer questions about the interaction of the host and gut microbes 
in intestinal injury.  
 High-throughput technologies with next-generation sequencing enabling a deep 
characterization of the microbiota functions have been developed and implemented for the first 
time in the last few years (45). Next-generation sequencing techniques use beads, slides or solid 
surfaces to produce millions of sequences at once. A single run of the 454 Life Sciences 
pyrosequencing platform, which we utilized in our studies, can produce 1.2 million sequences in 
8 hours (46). We used this sequencing technology in combination with advanced computational 
platforms and analytical techniques to characterize the role of microbial communities in human 
patients and animals with several forms of intestinal injury and inflammation. We then employed 
approaches integrating metagenomics, gnotobiology and microbiota transplantation to assess the 
function of complex microbial communities in the context of intestinal disorders, as well as that 
of individual constituent members of these assemblages. 
 An overall goal of this work was to generate data that can guide the design and 
implementation of diagnostic and therapeutic strategies that intentionally manipulate the human 
microbiota to optimize its performance in the context of an individual’s physiology, and 
specifically when the host encounters threatening conditions presented by functional bowel 
disorders, spontaneous, immune-mediated intestinal inflammation, or radiation exposure. 
 
 
 
6 
 
REFERENCES 
1. Camilleri M. Current and future pharmacological treatments for diarrhea-predominant 
irritable bowel syndrome. Expert Opin Pharmacother 2013; 14(9): 1151-60.  
 
2. Tho LM, Glegg M, Paterson J, et al. Acute small bowel toxicity and preoperative 
chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for 
inverse planning. Int J Radiat Oncol Biol Phys 2006; 66: 505-513. 
 
3. Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory 
bowel disease therapy. Curr Opin Gastroenterol 2013; 29(4): 397-404.  
 
4. Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the 
functional GI disorders: a population-based study. Am J Gastroenterol 2002; 97: 2290-9. 
 
5. Shadad AK, Sullivan FJ, Martin JD. Egan LJ. Gastrointestinal radiation injury: 
Prevention and treatment. World J Gastroenterol 2013; 19(2): 199-208. 
 
6. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the 
inflammatory bowel diseases with time, based on systematic review. Gastroenterology 
2012; 142: 46-54. 
 
7. Simren M, Svedlund J, Posserud I, et al. Health-related quality of life in patients 
attending a gastroenterology outpatient clinic: functional disorders versus organic 
diseases. Clin Gastroentrol Hepatol 2006; 4: 187-95. 
 
8. Bismar MM, Sinicrope FA. Radiation enteritis. Curr Gastroenterol Rep 2002; 4: 361-365. 
 
9. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Disability in inflammatory bowel 
diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based 
on the International Classification of Functioning, Disability, and Health. Inflamm Bowel 
Dis 2010; 16: 15–22.  
 
7 
 
10. Hillila MT, Farkkila NJ, Farkkila MA. Societal costs for irritable bowel syndrome- a 
population based study. Scand J Gastroenterol 2010; 45: 582-91. 
 
11. Gunnlaugsson A, Kjellen E, Nilsson P, et al. Dose-volume relationships between enteritis 
and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based 
chemoradiotherapy in locally advanced rectal cancer. Acta Oncol 2007; 46: 937-944. 
 
12. Kappelman M, Rifas-Shiman SL, Porter CQ, et al. Direct healthcare costs of Crohn’s 
disease and ulcerative colitis in US children and adults. Gastroenterology 2008; 135: 
1907-1913.  
 
13. Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: 
a Rome foundation report. Gut 2013; 62: 159-176. 
 
14. Crawford PA, Gordon JI. Microbial regulation of intestinal radiosensitivity. Proc Natl 
Acad Sci U S A 2005; 102: 13254-13259. 
 
15. Loh G, Blaut M. Role of commensal gut bacteria in inflammatory bowel diseases. Gut 
Microbes 2012; 3(6): 544-55.  
 
16. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. 
Gastroenterology 2006; 130: 1480–91. 
 
17. Wang J, Boerma M, Fu Q, Hauer-Jensen M. Significance of endothelial dysfunction in 
the pathogenesis of early and delayed radiation enteropathy. World J Gastroenterol 2007; 
13: 3047-3055. 
 
18. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 
134 (2): 577-94. 
 
8 
 
19. Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nature Rev 
Gastroenterol Hepatol 2012; 9: 599-608. 
 
20. Frank DN, Zhu W, Sartor RB, Li E. Investigating the biological and clinical significance 
of human dysbioses. Trends Microbiol 2011; 19(9): 427-34. 
 
21. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by 
metagenomic sequencing. Nature 2010; 464: 59-65. 
 
22. Backhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human 
intestine. Science 2005; 307: 1915-1920. 
 
23. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial 
flora. Science 2005; 308: 1635-1638. 
 
24. Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature 2007; 
804-810. 
 
25. Frank DN, Pace NR. Gastrointestinal microbiology enters the metagenomics era. Curr 
Opin Gastroenterol 2008; 24: 4-10. 
 
26. Metchnikoff II. The prolongation of life optimistic studies. The English translation edited 
by PC Mitchell. 1907. 
 
27. Salminen S, Bouley C, Boutron-Ruault MC, et al. Functional food science and 
gastrointestinal physiology and function. Br J Nutr 1998; 80: S147-S171. 
 
9 
 
28. O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006; 7: 688-
693. 
 
29. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512-519. 
 
30. Umesaki Y, Setoyama H, Matsumoto S, et al. Differential roles of segmented filamentous 
bacteria and clostridia in development of the intestinal immune system. Infect Immun 
1999; 67: 3504-3511. 
 
31. Cebra JJ. Influences of microbiota on intestinal immune system development. Am J Clin 
Nutr 1999; 69: 1046S-1051S. 
 
32. Umesaki Y, Setoyama H. Structure of the intestinal flora responsible for development of 
the gut immune system in a rodent model. Microbes Infect 2000; 2: 1343-1351. 
 
33. Eberl G, Lochner M. The development of intestinal lymphoid tissues at the interface of 
self and microbiota. Mucosal Immunol 2009; 2: 478-485. 
 
34. Baarlen PV, Wells JM, Kleerebezem M. Regulation of intestinal homeostasis and 
immunity with probiotic Lactobacilli. Trends Immunol 2013; 34(5): 208-215. 
 
35. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-
inflammatory commensal bacterium identified by gut microbiota analysis of Crohn 
disease patients. Proc Natl Acad Sci 2008; 105: 16731-16736. 
 
36. Blaser MJ, Kirschner D. The equilibria that allow bacterial persistence in human hosts. 
Nature 2007; 449: 843-849. 
 
37. Flint HJ, Scott KP, Louis P, Duncan SH. The role of the gut microbiota in nutrition and 
health. Nat Rev Gastroenterol Hepatol 2012; 9: 577-589. 
 
10 
 
38. De Medina FS, Ortega-Gonzales M, Gonzales-Perez R, et al. Host-microbe interactions: 
the difficult yet peaceful coexistence of the microbiota and the intestinal mucosa. Br J 
Nutr 2013; 109: S12-S20. 
 
39. Zoetnedal EG, Akkermans ADK, De Vos WM. Temperature gradient gel electrophoresis 
analysis of 16S rRNA from human fecal samples reveals stable and host-specific 
communities of active bacteria. Appl Environ Microbiol 1998; 64: 3854-3859. 
 
40. Costello EK, Lauber CL, Hamady M, et al. Bacterial community variation in human body 
habitats across space and time. Science 2009; 326: 1694-1697. 
 
41. Frank DN, St Amand Al, Feldman RA, et al. Molecular-phylogenetic characterization of 
microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad 
Sci 2007; 104: 13780-13785. 
 
42. Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated 
with obesity. Nature 2006; 444: 1022-1023. 
 
43. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 
2 diabetes. Nature 2012; 490: 55-58. 
 
44. Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut 
microbiota in mice lacking Toll-like receptor 5. Science 2010; 328(5975): 228-31.  
 
45. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut 
microbiome. Science 2006; 312: 1355-1359. 
 
11 
 
46. Wu X, Berkow K, Frank DN, et al. Comparative analysis of microbiome measurement 
platforms using latent variable structural equation modeling. BMC Bioinformatics 2013; 
14: 79. 
  
12 
 
 
 
CHAPTER 1: COMMENSAL BACTERIA, TRADITIONAL AND OPPORTUNISTIC 
PATHOGENS, DYSBIOSIS AND BACTERIAL KILLING IN INFLAMMATORY 
BOWEL DISEASES
1
 
Introduction 
 Chronic idiopathic inflammatory bowel diseases (IBD), which affect 1.0–1.5 million 
Americans (1), are a heterogeneous group of disorders resulting from continuous enteric 
microbial antigenic stimulation of pathogenic T cell responses in individuals with genetic defects 
in mucosal barrier function, innate bacterial killing or immunoregulation (2). Altered microbial 
composition, defective clearance of bacteria and enhanced mucosal uptake in Crohn’s disease 
and ulcerative colitis increase immune stimulation. Crohn’s disease and ulcerative colitis 
preferentially occur in areas of highest intestinal bacterial concentrations and fecal flow sustains 
inflammation of Crohn’s disease (3). Ciprofloxacin and metronidazole treat colonic Crohn’s 
disease and experimental colitis in a number of rodent models (4). This review describes 
evidence of the roles of commensal bacteria in the pathogenesis of IBD in articles published 
from January 2007 to December 2008.  
Defective bacterial killing in Crohn’s disease 
 Pathophysiologic similarities between Crohn’s disease and chronic granulomatous 
diseases associated with defective phagocyte function, polymorphisms of genes regulating 
clearance of intracellular pathogens and observed defects in innate antimicrobial function have 
led to the hypothesis that a subset of Crohn’s disease is caused by defective clearance of 
commensal, opportunistic or pathogenic bacteria with subsequent initiation of compensatory 
                                                          
1
 This chapter previously appeared as an article in the journal Current Opinion in Infectious Diseases. The original 
citation is as follows: Packey CD, Sartor RB. Commensal bacteria, traditional and opportunistic pathogens, dysbiosis 
and bacterial killing in inflammatory bowel diseases. Curr Opin Infect Dis 2009; 22: 292-301.  
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antibacterial effector T cells that cause tissue damage (2, 5). Secretion of both α- and β-defensins 
is defective in Crohn’s disease (6, 7), with decreased Paneth cell α-defensin production due to 
reduced expression of Tcf-4, a WNT signaling pathway transcription factor (8). The truncation 
mutation of NOD2, which is an intracellular receptor for the peptidoglycan component muramyl 
dipeptide, results in decreased ileal α-defensin production (6). Furthermore, NOD2-deficient 
mice exhibit decreased α-defensin defcr-4 (9), whereas deletion of the autophagy gene ATG16L1 
or the endoplasmic reticulum stress protein XBP-1 results in Paneth cell morphologic changes 
and decreased expression of antimicrobial peptides (10,11). Crohn’s disease is associated with 
genetic polymorphisms of at least two autophagy pathway components, ATG16L1 and IRGM, 
which, like NOD2 and NCF2, regulate intracellular bacterial killing (12–14). Decreased 
antimicrobial peptide secretion could lead to overgrowth, increased mucosal adherence and 
translocation of commensal bacteria, whereas defective clearance of invasive or phagocytosed 
bacteria promotes persistence of viable intracellular bacteria (Fig. 1.1). Both mechanisms could 
result in excessive antigenic stimulation of pathogenic Th1/Th17 cells, chronic granulomatous 
inflammation and susceptibility to infection by traditional and opportunistic pathogens. 
Microbial pathogens 
 Comprehensive culture and molecular-based analyses of the microbiota of IBD patients 
fail to identify consistent enrichment of individual pathogenic species in IBD tissues. However, 
bacterial pathogens continue to reap attention because of similarities between Crohn’s disease, 
ulcerative colitis and enteric infections and the hope of finding a cure analogous to Helicobacter 
pylori in peptic ulcers. 
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Mycobacterium avium subspecies paratuberculosis 
 Mycobacterium avium subspecies paratuberculosis (MAP) causes spontaneous 
granulomatous enterocolitis (Johne’s disease) with diarrhea and wasting in ruminants, making 
this obligate intracellular pathogen a credible causative agent of Crohn’s disease (15). After 
considerable investigation, the link between MAP and Crohn’s disease remains neither 
substantiated nor invalidated. Many investigators continue to measure the MAP-specific 
insertion element IS900 DNA in the tissue and/or blood of IBD patients using polymerase chain 
reaction (PCR) with mixed results. 
 A study conducted at the University of Colorado reported no detectable MAP DNA in 
190 tissue samples from Crohn’s disease, ulcerative colitis and control patients (16). Baumgart et 
al. (17) similarly reported lack of detectable IS900 DNA in ileal Crohn’s disease biopsies. 
Contradictory results were reported by Scanu et al. (18), who detected MAP DNA in 87% of 
Crohn’s disease tissues and 15% of controls in a small cohort. Results are also inconsistent in 
PCR assays for MAP DNA in blood samples (20–22). 
 One recent blinded study offered an alternative method to PCR for identifying MAP in 
patients with Crohn’s disease (25). Coded, paraffin-embedded surgical resections from Crohn’s 
disease and control patients at two centers subjected to acid-fast staining and rRNA in-situ 
hybridization (ISH) for MAP were visualized with oil-immersion microscopy. Both methods 
provided positive results in 10/17 patients with Crohn’s disease [59%, 95% confidence interval 
(CI) 36–78], contrasted with 5/35 control patients [odds ratio (OR) for Crohn’s disease versus 
controls=8.6, P=0.002]. Agreement between the two methods was good, but the time-consuming 
ISH probes could not discriminate between mycobacterial subspecies. 
15 
 
 Defective bacterial killing by innate immune cells could increase risk of infection by 
intracellular pathogens. Two recent studies showed no association between MAP and NOD2 
mutations. No significant association was seen in New Zealand in patients with Crohn’s disease 
for carriage of heterozygous or homozygous NOD2 mutations and MAP status (21), or between 
MAP serologies and NOD2 polymorphisms in a large, population-based study in Manitoba (26). 
A recent epidemiologic study also failed to support exposure to MAP by contaminated milk or 
water (27). Furthermore, consumption of pasteurized milk and fruit was associated with a 
reduced risk of Crohn’s disease, whereas meat intake was associated with an increased risk. 
Finally, a well-designed, 2-year prospective trial of clarithromycin, rifabutin and ethambutol 
failed to show sustained clinical response in patients with Crohn’s disease (28). 
 Recent studies possibly linking MAP to pathogenic mechanisms of Crohn’s disease fuel 
the ongoing debate. Two hundred and thirty-five patients with Crohn’s disease, ulcerative colitis, 
irritable bowel syndrome (IBS) and no known disease were tested for presence of MAP IS900 
DNA and cytokine secretion in intestinal biopsy samples (23). Greater tumor necrosis factor 
levels correlated with the presence of MAP in patients with Crohn’s disease (P<0.05). However, 
there was no correlation of MAP with interleukin (IL)-2, IL-12, IL-10 and interferon (IFN)-γ 
secretion. A separate study linked MAP to active Crohn’s disease via IL-4 and IL-2 cytokine 
profiles in peripheral blood with no differences in IFN-γ or tumor necrosis factor levels (24). 
 Finally, MAP was recently reported to induce experimental colitis in gnotobiotic IL-10
-/- 
mice (29). Germ-free IL-10
-/-
 mice receiving a single oral dose of milk containing 104 colony-
forming units (CFU) of live MAP obtained from a patient with Crohn’s disease developed more 
severe and aggressively progressive colitis, had higher serum amyloid A, IFN-γ and tumor 
necrosis factor levels, and lost more weight than did IL-10
-/- 
mice that received heat-killed MAP. 
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 Despite continued suggestions of a link between MAP and IBD, it remains doubtful that 
MAP is the causative agent of most Crohn’s disease patients, although infection of a subset of 
patients with intracellular killing defects caused by ATG16L1, IGRM or NCF4 needs to be 
investigated. Crohn’s disease-related NOD2 polymorphisms do not appear to be risk factors for 
MAP infection. 
Functional changes in Escherichia coli 
 Darfeuille-Michaud and colleagues (30, 31) reported that adherent/invasive E. coli 
(AIEC) that persist within macrophages and epithelial cells selectively colonize the ileum of 
patients with Crohn’s disease. At least two separate groups have confirmed these observations. 
Baumgart et al. demonstrated AIEC in the ileum of patients with Crohn’s disease, documented 
in-vivo mucosal adherence with fluorescent in-situ hybridization (FISH) and identified AIEC 
virulence factors common to uropathic E. coli strains and E. coli strains isolated from boxer dogs 
with spontaneous granulomatous colitis (17). In a separate study, E. coli comprised 99% of 
invasive bacterial isolates in mucosal biopsies of patients with Crohn’s disease as opposed to 
42% in patients with ulcerative colitis and 2% in normal controls (32). A prototypic AIEC strain, 
LF82, induced in-vitro granulomas using blood-derived mononuclear cells (33). Serum 
antibodies directed against E. coli outer membrane protein C (OmpC) are present in 37–55% of 
patients with Crohn’s disease, in contrast to 5% or less of patients with ulcerative colitis and 
without IBD. High serum reactivity to E. coli OmpC is associated with severe Crohn’s disease 
with longer disease duration, frequent disease progression, small bowel involvement and 
increased resections (34). 
 Mechanisms of epithelial adherence and invasion of AIEC are being elucidated. Studies 
utilizing isogenic mutants of LF82 that lack OmpC and other genes suggest that increased 
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expression of OmpC, particularly at high osmolarities reflecting the gastrointestinal tract, and/or 
induction of the δE regulatory pathway promote adherence and invasion of epithelial cells by 
LF82 independent of the transcriptional regulator OmpR (35). 
 Flagellin is necessary for LF82’s ability to exacerbate dextran sulfate sodium (DSS)-
induced murine colitis (36). Nonflagellated LF82 mutants behaved like the nonpathogenic E. coli 
strain K-12 in this model. An LF82 mutant lacking dsbA, a gene that encodes a periplasmic 
oxidoreductase that determines virulence for several pathogens, expressed neither flagella nor 
type 1 pili, and displayed decreased survival ability (37). In contrast, decreased epithelial 
adhesion and invasion of the LF82 OmpC and OmpR mutants were not associated with 
decreased expression of flagella and type 1 pili. In a separate study, E. coli 083:H1 was 
dependent upon flagellin for its adherent and invasive phenotype (38). Increased expression of 
carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), which acts as a 
receptor for AIEC, by ileal epithelial cells in active Crohn’s disease may mediate increased 
mucosal adherence of AIEC (39). Increased CEACAM6 expression by cultured colonic 
epithelial cells after IFN-γ or tumor necrosis factor stimulation and after exposure to LF82 
indicate that AIEC may promote its own colonization. 
 Monocytes from patients with Crohn’s disease carrying homozygous or heterozygous 
NOD2 polymorphisms displayed reduced secretion of IL-1β, IL-6, and IL-10 to LF82 in vitro 
compared with monocytes from patients with Crohn’s disease without NOD2 polymorphisms 
(40). TLR4 polymorphisms did not influence monocyte response. In preliminary studies, we 
showed that macrophages from NOD2-deficient mice display defective clearance of a murine 
AIEC strain with prolonged secretion of IL-12/23 p40 and tumor necrosis factor (41). These 
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findings demonstrate the importance of genetically programmed host immune responses to 
disease related bacteria in the pathogenesis of Crohn’s disease. 
Enteric pathogens as environmental triggers 
 A case–control study examining medical records of 3,019 US soldiers who developed 
IBD and 11,646 matched controls compared data using a conditional logistic regression model to 
determine that a single episode of infectious gastroenteritis increased the risk of IBD (OR 1.40, 
CI 1.19–1.66) (42). These results suggest that a self-limited enteric pathogen could trigger IBD, 
possibly by breaking the mucosal barrier and initiating an early inflammatory response in a 
genetically susceptible host with immunoregulatory abnormalities (2). Clostridium difficile can 
reactivate quiescent IBD (43) and induce acute experimental epithelial injury by Fas-mediated 
apoptosis (44). Likewise enterotoxigenic Bacteroides fragilis can induce experimental colitis and 
IL-17 production (45). A role for non-pylori Helicobacter in IBD pathogenesis is unlikely based 
on detection of species-specific serum antibodies in only 6/137 IBD patients (46). 
Dysbiosis 
 Recent studies in rodents confirm that bacterial composition changes with colonic 
inflammation and/or infection (47). Use of molecular techniques is clarifying changes in the 
composition of the mucosally associated and fecal microbiota in patients with Crohn’s disease 
and ulcerative colitis and vastly extending previous culture-based studies. 
 Examining DNA libraries of mucosal-associated microbiota, which may be more relevant 
than the fecal microbiota to the pathogenesis of IBD, reveals that patients with Crohn’s disease 
and ulcerative colitis have decreased complexity of commensal bacteria (16). Most notably, 
members of the phyla Bacteroidetes and Firmicutes are decreased in Crohn’s disease and 
ulcerative colitis. These organisms promote gastrointestinal health in multiple ways (59). 
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Reduced Faecalibacterium prausnitzii, a major member of the family Firmicutes, in patients 
with Crohn’s disease (16, 50) was confirmed and associated with a higher risk of postresection 
recurrence of ileal Crohn’s disease (49). In-vitro peripheral blood mononuclear cell stimulation 
by F. prausnitzii decreased IL-12 and IFN-γ production and stimulated secretion of IL-10. Oral 
administration of either live F. prausnitzii or its supernatant reduced the severity of 
trinitrobenzene sulfonic acid (TNBS) colitis and corrected the associated dysbiosis. In parallel, 
the abundance of E. coli is increased in IBD, particularly the B2+D phylogenetic group (17, 48). 
E. coli isolated from patients with Crohn’s disease express uropathic-like virulence factors that 
are postulated to facilitate mucosal invasion (17). The number of mucosal E. coli in situ 
correlates with the severity of ileal disease and invasive E. coli are restricted to inflamed mucosa. 
Compositional changes of the microbiota (dysbiosis) in IBD subsets may contribute to disease 
severity, since abnormal microbiotas correlated with the occurrence of abscesses in patients with 
Crohn’s disease, and IBD patients with dysbiosis underwent surgery at a younger age than those 
with normal microbiotas (16). Finally, fecal and mucosally associated microbial communities of 
patients with Crohn’s disease and ulcerative colitis are consistently less diverse with increased 
temporal instability (16, 53–56). 
 Nonpathogenic bacteria can cause colitis in hosts with immunoregulatory and mucosal 
barrier deficits. When germ-free IL-10
-/-
 and wild-type mice were inoculated with nonpathogenic 
E. faecalis and/or E. coli, dual-associated IL-10
-/- 
(but not wild-type) mice developed aggressive 
Th1/Th17-mediated colitis within 3 weeks that progressed to severe pancolitis by 7 weeks (60). 
A separate study revealed that uptake of nonpathogenic E. coli strains K-12 and HB101 by 
specialized follicle-associated epithelial cells overlying Peyer’s patches (the site of the earliest 
observable microscopic lesions of recurrent Crohn’s disease), is increased in patients with 
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Crohn’s disease, but not in patients with ulcerative colitis (61). Increased E. coli localized within 
dendritic cells of Crohn’s disease mucosa correlated with augmented tissue release of tumor 
necrosis factor. 
 Metabolic products of the microbiota have important effects on mucosal epithelial cell 
and immune function (2). Butyrate and other short-chain fatty acids are the primary metabolic 
substrates of colonocytes, with rectal epithelial cells dependent on this fuel source, whereas 
hydrogen sulfide, nitric oxide and serine proteases produced by a subset of commensal 
microbiota can injure epithelial cells and matrix components (62). Hydrogen sulfide and nitric 
oxide block butyrate metabolism and could lead to a state of epithelial starvation relevant to the 
pathogenesis of ulcerative colitis. 
Probiotics 
 Animal models and human studies suggest that therapeutically manipulating the balance 
between beneficial and detrimental intestinal bacterial species can influence health and disease 
(63). Use of probiotics (viable, nonpathogenic microorganisms that exert health benefits beyond 
basic nutrition), to shift this balance to favor protective species and treat IBD, has been 
extensively reviewed (63, 64, 65, 66, 67), yet the role for probiotics in treating Crohn’s disease 
and ulcerative colitis remains undetermined because most trials are underpowered and therefore 
not definitive. 
 In a TNBS colitis model, oral Lactobacillus acidophilus, Bifidobacterium lactis and 
Lactobacillus casei reduced intestinal inflammation (68). L. casei had more modest protection 
than the other probiotic species, yet in a separate in-vitro study, live L. casei decreased tumor 
necrosis factor, IFN-γ, IL-2, IL-6, IL-8 and CXCL1 secretion by explanted Crohn’s disease 
mucosa and counteracted the proinflammatory effects of commensal E. coli ATCC 35345 (69). 
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This and other studies emphasize host-specific responses to probiotics. Other probiotic species 
control aberrant immune responses in intestinal tissue. Bifidobacterium bifidum (BGN4) 
prevented colitis in a murine CD4
+
 CD45RB
high
 T cell transfer model (70). Lactobacillus gasseri 
expressing manganese superoxide dismutase ameliorated colitis in IL-10
-/- 
mice, demonstrating 
the therapeutic potential of recombinant bacteria engineered to secrete biologically active 
molecules (71). Orally administered Lactobacillus suntoryeus HY7801 ameliorated TNBS-
induced colitis, decreased colonic IL-1β, IL-6 and tumor necrosis factor expression and inhibited 
TLR4-linked NF-κB activation (72). Bifidobacteria-fermented milk enhanced IL-10 production 
in peripheral blood mononuclear cells from patients with ulcerative colitis and inhibited IL-8 
secretion by intestinal epithelial cells (73). Lactobacillus rhamnosus GR-1 and Lactobacillus 
reuteri RC-14 fed in yogurt to IBD patients had peripheral blood anti-inflammatory effects. In an 
in-vitro study, L. reuteri potently suppressed human tumor necrosis factor production by 
lipopolysaccharide-activated monocytes and monocyte derived macrophages from children with 
Crohn’s disease in a strain-dependent manner by inhibiting activation of mitogen activated 
protein kinase-regulated c-Jun and the transcription factor AP-1 (74). 
 Several groups have investigated the probiotic combination VSL#3 as a treatment for 
IBD based on its ability to maintain remission in relapsing pouchitis (75, 76). This combination 
of four live Lactobacillus strains, (L. casei, L. bulgaricus, L. plantarium and L. acidophilus), 
three live Bifidobacterium strains, (B. longum, B. breve and B. infantis), and one live 
Streptococcus strain, (S. thermophilus), dose-dependently ameliorated DSS-induced colitis in 
weanling rats (77). In a small (N=18) open-label study, VSL#3 induced remission in 56% of 
pediatric patients with mild to moderate ulcerative colitis. Six percent showed a response, and 
39% had no response or did worse with treatment (78). Daily oral VSL#3 significantly reduced 
22 
 
the pouchitis disease activity index and expanded the number of mucosal regulatory T cells 
following colectomy with ileal pouch anal anastomosis (79). Two components of VSL#3, B. 
longum and B. breve, in combination with the prebiotic psyllium, were well tolerated at high 
doses and induced remission in 6/10 patients with Crohn’s disease who had failed a regimen of 
aminosalicylates and prednisolone (80). 
 Similar to Sokol et al.’s (49) studies with F. prausnitzii, an Israeli group isolated and 
characterized a new putative protective bacterial species, Enterococcus durans, from the fecal 
microbiota of a healthy human vegetarian (81). In a DSS model of colitis, oral administration of 
E. durans significantly ameliorated colitis compared to controls and mice fed Lactobacillus 
delbrueckii. To properly note negative studies, oral administration of Lactobacillus johnsonii 
failed to prevent early postoperative endoscopic recurrence of Crohn’s disease 12 weeks after 
ileo-cecal resection (82). 
 To date, probiotics appear to be more effective in preventing relapse of ulcerative colitis 
and pouchitis, with poor results in Crohn’s disease. Examining F. prausnitzii in preventing 
postoperative recurrence of Crohn’s disease will be quite interesting and could lay the foundation 
for targeted correction of dysbiotic microbiota in IBD. Use of prebiotics, which are poorly 
absorbed oligosaccharides that stimulate growth and metabolic activity of beneficial microbiota, 
could be a low-cost, nontoxic strategy to correct dysbiosis in IBD patients. 
Conclusion and future directions 
 There remains no evidence that MAP is a causative agent in the pathogenesis of IBD. A 
more likely scenario involves specific E. coli strains and other species with virulence factors that 
allow them to adhere to and invade epithelial cells and persist within macrophages. These strains 
could be viewed as opportunistic pathogens in genetically susceptible hosts with innate killing, 
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mucosal barrier or immunoregulatory defects, with no disease induced in normal hosts. 
Identifying and then eliminating these strains, blocking expression of their virulence factors or 
altering their metabolism and identifying host susceptibility factors could be essential keys to 
treating IBD. Likewise, identifying changes in microbiota composition, gene expression and 
metabolic profiles in different IBD patient subsets using rapidly evolving molecular tools will 
provide important new insights into the pathogenesis and novel treatment of IBD using the 
example of F. prausnitzii (49). Meanwhile, using probiotics and prebiotics to enhance 
concentrations of beneficial species remains promising, although clinical trials lack statistical 
power due to small numbers. Treatments need to be individualized on the basis of compositional 
alterations in patient subsets. Understanding bacterial and host mutalistic interactions will 
determine success in this area. 
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Figure 1.1. Defective containment of commensal bacteria in IBD. 
Crohn’s disease genes that affect bacterial killing result in defective containment of commensal 
bacteria. NOD2 polymorphisms result in defective α-defensin production and clearance of 
intracellular bacteria. Overgrowth of mucosal bacteria occurs with defective secretion of 
antimicrobial peptides (NOD2 and ATG16L1 polymorphisms) or secretory IgA. Inefficient 
killing of phagocytosed bacteria (NOD2, ATG16L1, NCF4 and IGRM polymorphisms) results in 
persistent intracellular bacteria and ineffective clearance of bacterial antigens. Increased mucosal 
permeability leads to overwhelming exposure of bacterial TLR ligands and antigens that activate 
pathogenic innate and T cell immune responses. Modified from (2) and used with permission of 
Elsevier Publishing Company. 
 
25 
 
REFERENCES 
1. Kappelman M, Rifas-Shiman SL, Porter CQ, et al. Direct healthcare costs of Crohn’s 
disease and ulcerative colitis in US children and adults. Gastroenterology 2008; 135: 
1907–1913.  
 
2. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 
134: 577–594. 
 
3. Winslet MC, Allan A, Poxon V, et al. Faecal diversion for Crohn’s colitis: a model to 
study the role of the faecal stream in the inflammatory process. Gut 1994; 35: 236–242. 
 
4. Kang SS, Bloom SM, Norian LA, et al. An antibiotic-responsive mouse model of 
fulminant ulcerative colitis. PLoS Medicine 2008; 5: e41. 
 
5. Korzenik JR. Is Crohn’s disease due to defective immunity? Gut 2007; 56: 2–5. 
 
6. Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell alpha-defensins in ileal 
Crohn’s disease. Proc Natl Acad Sci U S A 2005; 102: 18129–18134. 
 
7. Fellermann K, Stange DE, Schaeffeler E, et al. A chromosome 8 gene-cluster 
polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn 
disease of the colon. Am J Hum Genet 2006; 79: 439–448. 
 
8. Wehkamp J, Wang G, Kubler I, et al. The Paneth cell alpha-defensin deficiency of ileal 
Crohn’s disease is linked to Wnt/Tcf-4. J Immunol 2007; 179: 3109–3118. 
 
9. Kobayashi KS, Chamaillard M, Ogura Y, et al. NOD2-dependent regulation of innate and 
adaptive immunity in the intestinal tract. Science 2005; 307: 731–734. 
 
10. Cadwell K, Liu JY, Brown SL, et al. A key role for autophagy and the autophagy gene 
ATG16L1 in mouse and human intestinal Paneth cells. Nature 2008; 456: 259–263. 
 
11. Kaser A, Lee AH, Franke A, et al. XBP1 links ER stress to intestinal inflammation and 
confers genetic risk for human inflammatory bowel disease. Cell 2008; 134: 724–725.   
26 
 
12. Prescott NJ, Fisher SA, Franke A, et al. A nonsynonymous SNP in ATG16L1 
predisposes to ileal Crohn’s disease and is independent of CARD15 and IBD5. 
Gastroenterology 2007; 132: 1665–1671.  
 
13. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new 
susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. 
Nat Genet 2007; 39: 596–604.  
 
14. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 
distinct susceptibility loci for Crohn’s disease. Nat Genet 2008; 40: 955–962.  
 
15. Sartor RB. Does Mycobacterium avium subspecies paratuberculosis cause Crohn’s 
disease? Gut 2005; 54:896–898. 
 
16. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of 
microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad 
Sci U S A 2007; 104: 13780–13785.  
 
17. Baumgart M, Dogan B, Rishniw M, et al. Culture independent analysis of ileal mucosa 
reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to 
depletion of Clostridiales in Crohn’s disease involving the ileum. ISME J 2007; 1: 403–
418.  
 
18. Scanu AM, Bull TJ, Cannas S, et al. Mycobacterium avium subspecies paratuberculosis 
infection in cases of irritable bowel syndrome and comparison with Crohn’s disease and 
Johne’s disease: common neural and immune pathogenicities. J Clin Microbiol 2007; 45: 
3883–3890. 
 
19. Toracchio S, El-Zimaity HM, Urmacher C, et al. Mycobacterium avium subspecies 
paratuberculosis and Crohn’s disease granulomas. Scand J Gastroenterol 2008; 43: 
1108–1111. 
 
20. Singh AV, Singh SV, Makharia GK, et al. Presence and characterization of 
Mycobacterium avium subspecies paratuberculosis from clinical and suspected cases of 
Crohn’s disease and in the healthy human population in India. Int J Infect Dis 2008; 12: 
190–197. 
 
27 
 
21. Bentley RW, Keenan JI, Gearry RB, et al. Incidence of Mycobacterium avium subspecies 
paratuberculosis in a population-based cohort of patients with Crohn’s disease and 
control subjects. Am J Gastroenterol 2008; 103: 1168–1172. 
 
22. Juste RA, Elguezabal N, Garrido JM, et al. On the prevalence of M. avium subspecies 
paratuberculosis DNA in the blood of healthy individuals and patients with inflammatory 
bowel disease. PLoS ONE 2008; 3: e2537. 
 
23. Clancy R, Ren Z, Turton J, et al. Molecular evidence for Mycobacterium avium 
subspecies paratuberculosis (MAP) in Crohn’s disease correlates with enhanced TNF-
alpha secretion. Dig Liver Dis 2007; 39: 445–451. 
 
24. Ren Z, Turton J, Borody T, et al. Selective Th2 pattern of cytokine secretion in 
Mycobacterium avium subsp. paratuberculosis infected Crohn’s disease. J Gastroenterol 
Hepatol 2008; 23: 310–314. 
 
25. Jeyanathan M, Boutros-Tadros O, Radhi J, et al. Visualization of Mycobacterium avium 
in Crohn’s tissue by oil-immersion microscopy. Microbes Infect 2007; 9: 1567–1573. 
 
26. Bernstein CN, Wang MH, Sargent M, et al. Testing the interaction between NOD-2 status 
and serological response to Mycobacterium paratuberculosis in cases of inflammatory 
bowel disease. J Clin Microbiol 2007; 45: 968–971. 
 
27. Abubakar I, Myhill DJ, Hart AR, et al. A case-control study of drinking water and dairy 
products in Crohn’s Disease–further investigation of the possible role of Mycobacterium 
avium paratuberculosis. Am J Epidemiol 2007; 165: 776–783.  
 
28. Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with 
clarithromycin, rifabutin, and clofazimine for Crohn’s disease. Gastroenterology 2007; 
132: 2313–2319. 
 
29. Singh UP, Singh S, Singh R, et al. Influence of Mycobacterium avium subsp. 
paratuberculosis on colitis development and specific immune responses during disease. 
Infect Immun 2007; 8: 3722–3728. 
 
30. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive 
Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology 2004; 
127: 412–421. 
 
28 
 
31. Barnich N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli and Crohn’s 
disease. Curr Opin Gastroenterol 2007; 23: 16–20. 
 
32. Sasaki M, Sitaraman SV, Babbin BA, et al. Invasive Escherichia coli are a feature of 
Crohn’s disease. Lab Invest 2007; 87:1042–1054.  
 
33. Meconi S, Vercellone A, Levillain F, et al. Adherent-invasive Escherichia coli isolated 
from Crohn’s disease patients induce granulomas in vitro. Cell Microbiol 2007; 9: 1252–
1261.  
 
34. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to 
microbial antigens and complications of small bowel Crohn’s disease. Gastroenterology 
2004; 126: 414–424. 
 
35. Rolhion N, Carvalho FA, Darfeuille-Michaud A. OmpC and the δE pathway are involved 
in adhesion and invasion of the Crohn’s disease-associated Escherichia coli strain LF82. 
Mol Microbiol 2007; 63: 1684–1700.  
 
36. Carvalho FA, Barnich N, Sauvanet P, et al. Crohn’s disease-associated Escherichia coli 
LF82 aggravates colitis in injured mouse colon via signaling by flagellin. Inflamm Bowel 
Dis 2008; 14: 1051–1060.  
 
37. Bringer MA, Rolhion N, Glasser AL, Darfeuille-Michaud A. The oxidoreductase DsbA 
plays a key role in the ability of the Crohn’s disease-associated adherent-invasive 
Escherichia coli strain LF82 to resist macrophage killing. J Bacteriol 2007; 189: 4860–
4871.  
 
38. Eaves-Pyles T, Allen CA, Taormina J, et al. Escherichia coli isolated from a Crohn’s 
disease patient adhere, invade, and induce inflammatory responses in polarized intestinal 
epithelial cells. Int J Med Microbiol 2008; 298: 397–409.  
 
39. Barnich N, Carvalho FA, Glasser AL, et al. CEACAM6 acts as a receptor for adherent-
invasive E. coli, supporting ileal mucosa colonization in Crohn’s disease. J Clin Invest 
2007; 117: 1566–1574. 
 
40. Peeters H, Bogaert S, Laukens D, et al. CARD15 variants determine a disturbed early 
response of monocytes to adherent-invasive Escherichia coli strain LF82 in Crohn’s 
disease. Int J Immunogenet 2007; 34: 181–191.  
29 
 
 
41. Liu B, Schmitz JM, Holt LC, et al. Increased intracellular survival of E. coli NC101 
within macrophages may contribute to its ability to induce colitis [abstract]. 
Gastroenterology. 
 
42. Porter CK, Tribble DR, Aliaga PA, et al. Infectious gastroenteritis and risk of developing 
inflammatory bowel disease. Gastroenterology 2008; 135: 781–786. 
 
43. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory 
bowel disease. Clin Gastroenterol Hepatol 2007; 5: 345–351. 
 
44. Kim H, Rhee SH, Pothoulakis C, et al. Inflammation and apoptosis in Clostridium 
difficile enteritis is mediated by PGE(2) up-regulation of Fas ligand. Gastroenterology 
2007; 133: 875–886. 
 
45. Rabizadeh S, Rhee KJ, Wu S, et al. Enterotoxigenic Bacteroides fragilis: a potential 
instigator of colitis. Inflamm Bowel Dis 2007; 13: 1475–1483. 
 
46. Veijola L, Nilsson I, Halme L, et al. Detection of Helicobacter species in chronic liver 
disease and chronic inflammatory bowel disease. Ann Med 2007; 39: 554–560. 
 
47. Lupp C, Robertson ML, Wickham ME, et al. Host-mediated inflammation disrupts the 
intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host 
Microbe 2007; 2: 119–129. 
 
48. Kotlowski R, Bernstein CN, Sepehri S, Krause DO. High prevalence of Escherichia coli 
belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 2007; 56: 
669–675.  
 
49. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-
inflammatory commensal bacterium identified by gut microbiota analysis of Crohn 
disease patients. Proc Natl Acad Sci U S A 2008; 105: 16731–16736.  
 
50. Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y. Active Crohn’s disease 
and ulcerative colitis can be specifically diagnosed and monitored based on the 
biostructure of the fecal flora. Inflamm Bowel Dis 2008; 14: 147–161. 
 
30 
 
51. Andoh A, Sakata S, Koizumi Y, et al. Terminal restriction fragment length polymorphism 
analysis of the diversity of fecal microbiota in patients with ulcerative colitis. Inflamm 
Bowel Dis 2007; 13: 955–962.  
 
52. Takaishi H, Matsuki T, Nakazawa A, et al. Imbalance in intestinal microflora constitution 
could be involved in the pathogenesis of inflammatory bowel disease. Int J Med 
Microbiol 2008; 298: 463–472. 
 
53. Dicksved J, Halfvarson J, Rosenquist M, et al. Molecular analysis of the gut microbiota 
of identical twins with Crohn’s disease. ISME J 2008; 2: 716–727.  
 
54. Nishikawa J, Kudo T, Sakata S, et al. Diversity of mucosa-associated microbiota in active 
and inactive ulcerative colitis. Scand J Gastroenterol 2008; 30: 1–7.  
 
55. Ott SJ, Plamondon S, Hart A, et al. Dynamics of the mucosa-associated flora in ulcerative 
colitis patients during remission and clinical relapse. J Clin Microbiol 2008; 46: 3510–
3513.  
 
56. Martinez C, Antolin M, Santos J, et al. Unstable composition of the fecal microbiota in 
ulcerative colitis during clinical remission. Am J Gastroenterol 2008; 103: 643–648.  
 
57. Zhang M, Liu B, Zhang Y, et al. Structural shifts of mucosa-associated Lactobacilli and 
Clostridium leptum subgroup in patients with ulcerative colitis. J Clin Microbiol 2007; 
45: 496–500. 
 
58. Vasquez N, Mangin I, Lepage P, et al. Patchy distribution of mucosal lesions in ileal 
Crohn’s disease is not linked to differences in the dominant mucosa-associated bacteria: a 
study using fluorescence in situ hybridization and temporal temperature gradient gel 
electrophoresis. Inflamm Bowel Dis 2007; 13: 684–692. 
 
59. Backhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human 
intestine. Science 2005; 307:1915–1920. 
 
60. Kim SC, Tonkonogy SL, Karrasch T, et al. Dual-association of gnotobiotic IL-10-/- mice 
with 2 nonpathogenic commensal bacteria induces aggressive pancolitis. Inflamm Bowel 
Dis 2007; 13: 1457–1466.  
 
31 
 
61. Keita AV, Salim SY, Jiang T, et al. Increased uptake of nonpathogenic E. coli via the 
follicle-associated epithelium in longstanding ileal Crohn’s disease. J Pathol 2008; 215: 
135–144.  
 
62. Roediger WE. Review article: nitric oxide from dysbiotic bacterial respiration of nitrate 
in the pathogenesis and as a target for therapy of ulcerative colitis. Aliment Pharmacol 
Ther 2008; 27: 531–541.  
 
63. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel 
diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620–1633. 
 
64. Boirivant M, Strober W. The mechanism of action of probiotics. Curr Opin Gastroenterol 
2007; 23: 679–692.  
 
65. Sheil B, Shanahan F, O’Mahony L. Probiotic effects on inflammatory bowel disease. J 
Nutr 2007; 137:S819–S824. 
 
66. Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in 
inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc 2007; 66: 307–315. 
 
67. Isaacs K, Herfarth H. Role of probiotic therapy in IBD. Inflamm Bowel Dis 2008; 14: 
1597–1605.  
 
68. Peran L, Camuesco D, Comalada M, et al. A comparative study of the preventive effects 
exerted by three probiotics, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus 
acidophilus, in the TNBS model of rat colitis. J Appl Microbiol 2007; 103: 836–844. 
 
69. Llopis M, Antolin M, Carol M, et al. Lactobacillus casei downregulates commensals’ 
inflammatory signals in Crohn’s disease mucosa. Inflamm Bowel Dis 2009; 15: 275–283. 
 
70. Kim N, Kunisawa J, Kweon MN, et al. Oral feeding of Bifidobacterium bifidum (BGN4) 
prevents CD4(+) CD45RB(high) T cell-mediated inflammatory bowel disease by 
inhibition of disordered T cell activation. Clin Immunol 2007; 123: 30–39.  
 
71. Carroll IM, Andrus JM, Bruno-Barcena JM, et al. Anti-inflammatory properties of 
Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 
10-deficient mouse model of colitis. Am J Physiol Gastrointest Liver Physiol 2007; 293: 
G729–G738.  
 
32 
 
72. Lee JH, Lee B, Lee HS, et al. Lactobacillus suntoryeus inhibits proinflammatory cytokine 
expression and TLR-4-linked NF-κB activation in experimental colitis. Int J Colorectal 
Dis 2009; 24: 231–237.  
 
73. Imaoka A, Shima T, Kato K, et al. Anti-inflammatory activity of probiotic 
Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells 
from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells. World J 
Gastroenterol 2008; 14: 2511–2516. 
 
74. Lin YP, Thibodeaux CH, Pena JA, et al. Probiotic Lactobacillus reuteri suppresses 
proinflammatory cytokines via c-Jun. Inflamm Bowel Dis 2008; 14: 1068–1083.  
 
75. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment 
in patients with chronic pouchitis: a double-blind, placebo-controlled trial. 
Gastroenterology 2000; 119: 305–309. 
 
76. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic 
therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 1202–
1209. 
 
77. Fitzpatrick LR, Hertzog KL, Quatse AL, et al. Effects of the probiotic formulation 
VSL#3 on colitis in weanling rats. J Pediatr Gastroenterol Nutr 2007; 44: 561–570. 
 
78. Huynh HQ, Debruyn J, Guan L, et al. Probiotic preparation VSL#3 induces remission in 
children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis 
2009; 15(5): 760-8. 
 
79. Pronio A, Montesani C, Butteroni C, et al. Probiotic administration in patients with ileal 
pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal 
regulatory cells. Inflamm Bowel Dis 2008; 14: 662-668.  
 
80. Fujimori S, Tatsuguchi A, Gudis K, et al. High dose antibiotic and prebiotic co-therapy 
for remission induction of active Crohn’s disease. J Gastroenterol Hepatol 2007; 22: 
1199–1204.  
 
81. Raz I, Gollop N, Polak-Charcon S, Schwartz B. Isolation and characterization of new 
putative probiotic bacteria from human colonic flora. Br J Nutr 2007; 97: 725–734.  
33 
 
82. Van Gossum A, Dewit O, Louis E, et al. Multicenter randomized-controlled clinical trial 
of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s 
disease after ileo-caecal resection. Inflamm Bowel Dis 2007; 13: 135–142. 
  
34 
 
 
 
CHAPTER 2: MICROBIAL INFLUENCES ON THE SMALL INTESTINAL RESPONSE 
TO RADIATION INJURY
2
 
Introduction 
 The mammalian microbiome, as it relates to health and disease, has received increasing 
attention in medical research over the last decade. The human body is inhabited by at least 10 
times more bacteria than the number of somatic and germline cells. The National Institutes of 
Health has funded the Human Microbiome Project (HMP) as a roadmap initiative to characterize 
the human microbiome in five body sites from healthy volunteers, including the gastrointestinal 
tract (1). Perhaps not coincidentally, an enhanced interest in probiotic bacteria (those which 
confer health benefits) has developed recently among both the scientific community and lay 
public. The majority of studies addressing pathogenic or beneficial microbial influences on 
gastrointestinal illnesses have focused on irritable bowel and the inflammatory bowel diseases. 
More recently, several lines of evidence have emerged that link the presence and composition of 
the luminal microbiota to the intestinal response to radiation. These include relative radiation 
resistance of germ-free mice, altered intestinal responses to radiation associated with 
colonization by commensal and probiotic bacterial species and recognition that stimulation of, or 
alteration in, innate immune system pathways modifies host responses to radiation. Radiation 
enteropathy remains a common complication for patients receiving abdominal or pelvic 
radiotherapy for cancer. Prophylactic or therapeutic strategies against radiation enteropathy are 
currently limited. However, as in other intestinal disorders, recent studies aimed at elucidating 
functions of the host–microbiome relationship in radiation injury have provided insight into both 
                                                          
2
 This chapter previously appeared as an article in the journal Current Opinion in Gastroenterology. The original 
citation is as follows: Packey CD, Ciorba MA. Microbial influences on the small intestinal response to radiation 
injury. Curr Opin Gastroenterol 2010; 26: 88-94. 
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disease pathophysiology and potential therapeutics. Our opinion will provide a background 
review on radiation-induced intestinal injury while examining in greater detail the data for 
microbial influences on this disease entity. 
Radiation enteropathy in clinical medicine 
 Radiation therapy is used commonly for many forms of solid cancers including those that 
develop within the abdominal or pelvic cavities. A particular challenge that remains for the 
clinician is the lack of an available quantitative biomarker to measure the presence and degree of 
intestinal damage. 
Scope and impact 
 More than 50% of patients with cancer receive radiation as a component of their 
treatment. The small intestine is rarely a primary target in radiotherapy, but by nature of its size 
and extent, it often receives exposure resulting in collateral damage. The rapidly proliferating 
mucosal lining of the small intestine is highly radiosensitive, and the resulting cell death leads to 
symptoms of malabsorption, including bloating, diarrhea and dehydration. Abdominal pain, 
anorexia, nausea and vomiting can also occur and are amplified by concurrent chemotherapy (2, 
3). Symptoms adversely affect patient quality of life and can be severe enough to require 
hospitalization. The damaging effects related to small intestinal injury are a major reason for 
dose limitation and can force discontinuation of radiotherapy, impacting overall chances for cure 
of malignancy. 
 Patients typically experience symptoms from acute small intestinal injury after the first or 
second week of radiotherapy (4). The effect is dosage-dependent wherein low doses lead to mild 
and reversible disease and higher doses result in more severe and potentially irreversible damage. 
Thus, clinical regimens are usually designed to offer fractionated low-dosage (<2 Gy) therapy in 
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multiple sessions over the course of weeks. Extensive planning goes into treatment field design 
for radiation therapy to minimize the amount of small bowel which is exposed. Regardless, it is 
estimated that up to 70% or more of patients experience adverse gastrointestinal side effects by 3 
weeks into therapy. Most of these acute symptoms subside by 2–6 weeks following completion 
of radiation therapy. Chronic severe complications of radiation enteropathy include dysmotility, 
strictures and fistulas, and occur in approximately 6% of patients 1 to 2 years after radiation 
therapy (5). Interestingly, both acute and chronic radiation therapy-related toxicities may be 
more severe in patients with pre-existing conditions of intestinal compromise or microbial 
dysbiosis such as those occurring in patients with inflammatory bowel diseases (6, 7). 
Diagnosis 
 The diagnosis of acute radiation enteropathy is usually presumptively based on symptom 
type and time of onset. Basic laboratories, stool studies and abdominal imaging can be performed 
depending on symptom severity, but are often uninformative. Endoscopic biopsies are rarely 
used, although they may reveal histologic changes consistent with radiation damage. No specific 
biomarkers for radiation enteropathy are in common use; however, new potential serum or stool 
markers are being tested. Citrulline is a nitrogen-containing end product of small bowel 
enterocyte metabolism. Serum citrulline has been evaluated as a biomarker for functional 
enterocyte mass (8). In radiation enteropathy, testing of the feasibility and functionality of this 
biomarker in mice and in humans has revealed that it shows promise as a novel diagnostic test 
(9–11). Fecal calprotectin is another potential biomarker, which has been shown to significantly 
increase after pelvic radiation (11). However, as a neutrophil-derived protein, calprotectin is not 
small bowel-specific. Eosinophilic cationic protein levels (12) and C-reactive protein levels (13) 
have also been found to be increased in patients following pelvic irradiation, although not 
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consistently (11). It is possible that in the future, sequential evaluation of a cluster of markers 
will prove most informative for diagnosis and monitoring. 
Pathophysiology of small bowel radiation injury 
 Acute radiation injury to the small intestine has been well-documented in animal models. 
When interpreting the literature, it is useful to recognize that whereas clinical medicine uses 
small fractionated doses of ionizing radiation, most animal studies evaluating mechanisms of 
disease use higher dose, single-exposure regimens, as would be encountered in accidental or 
warfare-associated ionizing radiation overexposure. Figure 1 (14–18, 19, 20–24, 25, 26, 27) 
summarizes several recent findings. 
Epithelial and endothelial responses 
 Radiation-induced small intestinal injury is characterized by cell loss in the progenitor 
cell compartment (28) and a dose-dependent loss of barrier properties (29–31). Ionizing radiation 
causes a wide diversity of functional disorders in the small intestine, including altered motility 
(32, 33), disrupted absorption of carbohydrates (34), amino acids and bile acids (35), and a more 
thrombophilic endothelium due to the induction of inflammatory cell adhesion to the 
endothelium (36) and increased expression of endothelial von Willebrand factor (37). 
 It has traditionally been assumed that the radiation gastrointestinal syndrome that ensues 
with exposure to high doses of radiation or cumulative lower doses results from the direct killing 
of the rapidly proliferating epithelial stem cells, depletion of the differentiated parenchymal cells 
and subsequent loss of tissue function (38). However, vascular damage also ensues when the 
small intestine is exposed to ionizing radiation (39). A study (14) published in 2001 suggested 
that the radiation gastrointestinal syndrome is a direct consequence of an early (4-h) wave of 
apoptosis in the intestinal vascular endothelial cells. Recently, this assertion was challenged by 
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Schuller et al. (15) who exposed two groups of mice to an equivalent dose of total body 
irradiation (TBI), then directly targeted intestinal endothelial cells in one of the groups of mice 
with up to 27 Gy neutron beam irradiation and found no additional intestinal crypt stem cell loss 
or murine death related to the gastrointestinal syndrome. 
Unanticipated overexposure to ionizing radiation 
 In clinical medicine, small fractionated doses of radiation are used. In mice exposure to 
doses of 8 Gy or higher leads to sterilization of individual small intestinal crypts, a process in 
which all of the actual and potential stem cells are inactivated. The survival of one or more 
clonogenic cells in a given crypt allows the regeneration of that crypt. Doses of 15 Gy and higher 
sterilize virtually all of the crypt stem cells, resulting in complete loss of the intestinal villi and 
death from the radiation gastrointestinal syndrome in 4–5 days (15). This syndrome is 
characterized by breaches in the intestinal mucosa, translocation of commensal intestinal bacteria 
and sepsis, and it is relevant in cases of bioterrorist attacks, nuclear accidents, medical errors and 
in appropriately fractionated dosing of therapeutic radiation to people whose tissues are 
exquisitely radiosensitive. 
Linking the microbiota to the intestinal response to radiation 
 It had previously been observed that germ-free mice have improved survival as compared 
with colonized mice when exposed to equivalent doses of radiation (40). However, the impact of 
the intestinal microbiota on the pathogenesis of the radiation gastrointestinal syndrome was not 
understood until a more recent work by Crawford and Gordon (16). Here, hematopoietic rescue 
by bone marrow transplantation after lethal ionizing radiation was used to demonstrate that 
conventionally raised mice still exhibited earlier death than germ-free mice (16). Using Rag1 
knockout mice, they also showed that mature lymphocytes are not required for the development 
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of lethal radiation enteropathy. Mechanistically, the investigation also suggested that increased 
expression of a fibrinogen/angiopoietin-like protein, fasting-induced adipose factor, which is 
normally suppressed by luminal microbiota, confers endothelial and lymphocyte radioresistance. 
 Recognition of commensal intestinal bacteria or their products by Toll-like receptors 
(TLRs) is necessary for the regulation of intestinal homeostasis (41). It is largely through binding 
to these receptors and the subsequent activation of the nuclear factor-kappa B (NF-κB) family of 
transcription factors that commensal bacteria have been shown to influence the small intestinal 
epithelial response to various forms of injury. Recent animal models have revealed that this is 
true for radiation-induced injury. Egan et al. (17) showed increased intestinal epithelial cell 
(IEC) apoptosis in mice with selected ablation of NF-κB signaling through IκB kinase, a 
common activation pathway for TLR signaling. This finding corresponded with increased 
expression and activation of the tumor suppressor p53. Mice in which the NF-κB p50 gene has 
been disrupted were shown to be more sensitive to TBI-induced lethality than are wild-type mice 
(18). These findings demonstrate the physiological importance of NF-κB activation in protection 
against radiation-induced death in the epithelium in vivo, and directly link intestinal commensal 
bacteria to the regulation of radiation-induced IEC apoptosis. Recent mouse knockout studies 
have revealed that bacterial products also activate signaling pathways other than the NF-κB 
pathway to protect IECs from radiation-induced apoptosis (19). 
 Both endogenous and exogenous sources of prostaglandins have been shown to confer 
protection to intestinal crypts that are exposed to radiation. In mice, parenterally administered 
lipopolysaccharide, a TLR4 ligand, increased endogenous intestinal prostaglandin production, 
thereby improving intestinal crypt survival after irradiation (20). Exogenous administration of a 
prostaglandin E2 (PGE2) analogue prior to radiation also increases the number of surviving 
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intestinal crypts. Several studies have demonstrated that the radioprotective effect of 
prostaglandins on the gut is a cyclooxygenase (COX)-1-dependent, COX-2-independent event. 
Irradiated COX-1
-/-
 mice have increased crypt epithelial apoptosis, decreased clonogenic stem 
cell survival and diminished PGE2 synthesis as compared with wild-type littermates (21). 
Administration of indomethacin, which inhibits both COX-1 and COX-2, to a mouse prior to 
radiation increases radiation-induced IEC apoptosis and decreases intestinal crypt survival (22). 
However, selective COX-2 inhibitors have no effect on crypt survival; likewise COX-2
-/- 
mice 
have a similar response to radiation to wild-type mice. So, the COX-1-dependent production of 
endogenous PGE2 appears to be an important downstream mediator of TLR signaling by which 
bacterial products promote IEC survival and proliferation in the response to radiation (23). The 
biologic effects of PGE2 have been shown to be mediated via AKT activation by the plasma 
membrane G-protein-coupled receptor EP2 (24), thereby preventing Bax translocation to the 
mitochondria (42). 
Human polymorphisms and variations in microbiome 
 There are emerging, although not yet matured, data supporting the role of host and 
microbial genetic influences on the radiosensitivity of the small intestine. A recent study (43) 
identified a correlation between single nucleotide polymorphisms in mice and the amount of 
jejunal crypt cell apoptosis after 2.5 Gy TBI. Gene expression microarrays have also been used 
in attempts to predict the radiosensitivity of normal tissue (44).  
 An intriguing recent study (45) involving a small number of patients used DNA 
fingerprinting with 16S ribosomal RNA denaturing gradient gel electrophoresis (DGGE) to show 
different fecal microbial profiles in people receiving radiation who experienced diarrhea from 
those who received radiation and maintained normal stool consistency. They evaluated stool 
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before, during and after radiation, and proposed that a dysbiosis was linked to changes in bowel 
habits rather than the radiation exposure itself. Interestingly, the microbial profiles of individuals 
before receiving radiation clustered in three similarity sets that matched closely the control, the 
‘no diarrhea’ and the ‘diarrhea’ groups, suggesting that the initial intestinal microbial 
composition of each individual could be a determinant for developing postirradiation diarrhea. 
Current management principles 
 In cancer therapy, use of well-planned (46, 47), fractionated dose regimens with specific 
patient positioning remains key to minimizing symptoms of radiation enteropathy. Additionally, 
numerous pharmacologic therapies have been tested for reducing symptoms. Antispasmodic and 
antidiarrheal agents are effective for some patients. Cholestyramine has been shown to be 
effective in reducing bile salt-associated diarrhea, which can occur with radiation enteropathy 
(48). Amifostine, a broad-spectrum, free-radical scavenging cytoprotectant, is used as an 
adjuvant with treatment of some malignancies (49). Although the benefits of this drug are clear 
for xerostomia, its ability to prevent radiation enteropathy has not been proven and the side effect 
of hypotension has tempered interest in routine use. 
 Most current therapies for radiation enteropathy are initiated only after symptoms 
develop. As the percentage of patients who develop small bowel symptoms is high, widespread 
use of an effective prophylactic agent would likely be adopted if it became available. An ideal 
prophylactic radioprotectant for the small intestine would need to fulfill specific requirements 
including the possession of an ability to preserve or enhance the antitumor efficacy of radiation; 
the provision of wide-ranged normal tissue protection with a low-toxicity profile and the 
allowance of easy, safe and cost-effective administration. 
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Microbial manipulation in therapy or prevention 
 Development of small intestinal radioprotectants has primarily focused on antioxidants 
(50–54), modifiers of inflammation (55–57), growth factors (58–60) and regulators of IEC 
apoptosis (61, 62). Yet, recent evidence suggests that manipulation of the intestinal luminal 
microbiota or the administration of medications adapted from commensal or probiotic bacteria 
holds promise in providing prophylactic and possibly post-exposure enteric radioprotection. 
Bacterial product-based therapies 
 Burdelya et al. (25, 63) recently evaluated a polypeptide drug derived from Salmonella 
flagellin that binds to TLR5 and activates NF-κB signaling. A single injection of this agent 
improved survival in mice exposed to radiation by limiting apoptosis and preserving cell 
proliferation in the epithelial crypts and lamina propria of the small intestine. However, 
protection was conferred only when mice were exposed to doses below those that universally 
cause the radiation gastrointestinal syndrome, and only if the agent was administered 15–60 min 
before exposure. In similar experiments using rhesus macaques, the investigators observed that 
the TLR5 agonist increased survival and had protective effects on bone marrow, although they 
did not provide data on the effect of the agonist on the gastrointestinal tract of the monkeys. 
Remarkably, this drug did not appear to decrease tumor radiosensitivity in the mouse model 
used. Hence, this TLR5 agonist is potentially useful as a prophylactic before therapeutic 
radiation, but may not be adequate as a treatment for the radiation gastrointestinal syndrome, as 
in the case of a nuclear accident or attack. 
Probiotics 
 Probiotics are live microbial organisms, most often bacteria, which confer beneficial 
effects to the host when consumed. With increasing evidence suggesting that imbalance of the 
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intestinal microbiota may play a significant role in the pathogenesis of radiation enteropathy, 
probiotic bacteria are now attracting interest as potential radioprotectants. Single and multi-strain 
probiotic preparations have been evaluated in both animal models and humans over the last few 
decades. In rodents, Lactobacillus species have been shown to reduce radiation-induced small 
intestinal damage, Gram-negative bacteremia, endotoxemia and death (26, 64, 65). Primary 
endpoints were not achieved for probiotics in small trials in which humans underwent pelvic 
radiation for cancer; however, individuals receiving Lactobacillus spp. supplementation showed 
a trend toward having less severe symptoms (27, 66, 67). In the largest human trial (68) to date, 
patients taking the probiotic mixture VSL#3 experienced radiation-induced diarrhea less 
frequently than patients taking a placebo in a double-blind study involving almost 500 patients. 
Timing of probiotic administration, prophylactic versus therapeutic, respectively, may explain 
the more robust results identified in animal studies as compared with human trials. Early reports 
also suggest that soluble secreted factors from probiotic bacteria may be responsible for 
physiologic benefits observed in radiation (26) as in other injury models (69). As probiotic 
bacteria are inexpensive and would be predicted to offer extensive tissue protection with low 
toxicity, further investigation into their role as intestinal radioprotectants is warranted. 
Antibiotics 
 Antibiotics have been considered for decades as a potential treatment option for radiation 
enteropathy (70). Researchers at the Armed Forces Radiobiology Research Institute used 
antibiotics in several radiation mouse models (71–73). Limitations to these studies included their 
focus on the activity of various antibiotics specifically against orally ingested pathogens, their 
use of bacterial translocation to the liver and mortality as primary readouts, and their evaluation 
of radiation doses that were not sufficient to cause the radiation gastrointestinal syndrome. In 
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their most recent review, this group summarized their findings and concluded that the potential 
use of several different antimicrobial agents from various classes may be effective for treating 
infection after exposure to radiation, but they do not identify a superior agent (74).  
 Intestinal commensal bacteria translocate across the intestinal mucosa and cause sepsis 
and early death in response to high doses of radiation. Yet, the aforementioned studies linking 
TLR binding by bacterial products to protection of the intestinal epithelium and the host against 
radiation-induced damage suggest that some commensal intestinal bacterial species provide 
protective functions in the response to radiation. Hence, an antibiotic that uniquely targets 
bacterial organisms that tend to translocate after exposure to radiation, while sparing bacterial 
species that are shown to be protective in the response of the intestinal epithelium and the host to 
radiation, may be optimal. This concept also lends support to the prophylactic and/or therapeutic 
potential of administrating both an antibiotic and a probiotic to people exposed to radiation. 
Conclusion 
 Radiation injury to the small bowel remains an important clinical problem for which few 
therapeutic strategies exist. Several lines of evidence, which were reviewed here, suggest that 
dynamic interactions between the host’s enteric microbiota and innate immune system modulate 
the intestinal response to radiation. Probiotics, antibiotics and bacterial-derived peptides and 
byproducts can modify radiation-induced injury and symptom severity. How to best harness the 
influence of these microbial symbionts remains to be determined. Future laboratory studies 
should be aimed at identifying specific prebiotic, probiotic, antibiotic or all regimens that 
optimize normal tissue radioresistance and tumoral radiosensitization. Bacterial-based 
compounds or secreted products will likely be an area of fruitful investigation. Clinical studies in 
this area should initially focus on clarifying how intestinal microbial compositions shift in 
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response to radiation. Using this knowledge, strain-specific probiotics could be administered to 
increase bacterial species that best confer host radioprotection. Likewise, antibiotic regimens 
could be developed that selectively target bacterial species that are found to proliferate, 
translocate and cause sepsis following exposure to radiation, while possessing minimal activity 
against the protective bacterial populations. Subsequent clinical studies should be aimed at 
determining the safety, efficacy and applicability of the developing therapeutic agents and 
regimens. Recent years have seen an explosive growth in knowledge associating the microbiome 
to human health; the prevention or treatment of small intestinal radiation injury should serve as a 
particularly productive target for future investigations in this area. 
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Figure 2.1. Modifiers of acute small intestinal radiation injury. 
The small intestinal response to radiation is altered by signaling induced by luminal bacteria or 
bacterial-based products. Experimental models and human trials suggest Lactobacillus species or 
their soluble secreted proteins may protect intestinal crypts against damage from radiation 
exposure (26, 27). Flagellin, a TLR5 ligand that activates the NF-κB pathway, protected IECs 
from radiation-induced apoptosis and increased host survival when injected into mice before 
lethal doses of radiation (25). LPS, a TLR4 ligand found in the outer membrane of Gram-
negative bacteria, increased endogenous intestinal prostaglandin production and intestinal crypt 
survival in mice exposed to 14 Gy when injected 2–24 h prior to exposure (20). Endogenous 
PGE2 decreases murine IEC apoptosis and increases post-radiation IEC proliferation (23). 
Conversely, blocking pathways that are activated by bacterial products has detrimental effects on 
the ability of IECs and crypts to survive radiation insults. The E. coli STa is a ligand for GC-C, 
an IEC transmembrane receptor. UGN is a peptide hormone that binds to and activates GC-C. 
Mice in which GC-C or UGN is knocked out have increased jejunal IEC apoptosis 3 h after 5-Gy 
radiation as compared with WT counterparts (19). Indomethacin blocks PGE2 production by 
inhibiting COX-1 and COX-2, thereby increasing IEC apoptosis and intestinal crypt ablation 
(22). Similarly, irradiated COX-1
-/- 
mice have diminished PGE2 synthesis, leading to increased 
crypt epithelial apoptosis and decreased clonogenic stem cell survival (21). Irradiated EP2 
receptor
-/- 
mice have decreased intestinal crypt survival and increase in IEC apoptosis (24). 
Blocking NF-κB activation by deleting the p50 subunit of the NF-κB complex (18) or the 
canonical NF-κB activation kinase (17) results in increased radiation-induced IEC apoptosis in 
mice. Although debate still exists as to the degree of importance of endothelial apoptosis in acute 
intestinal outcomes after high-dose radiation exposure (14, 15), endothelial apoptosis is lower in 
GF than SPF mice (16). COX, cyclooxygenase; E. coli STa, heat-stable enterotoxin of 
Escherichia coli; GC-C, guanylate cyclase C; IEC, intestinal epithelial cell; KO, knocked out; 
LPS, lipopolysaccharide; NF-kB, nuclear factor-kappaB; PGE2, prostaglandin E2; TLR, Toll-like 
receptor; UGN, uroguanylin. Red cross signifies attenuation of acute intestinal injury from 
radiation. Skull and crossbones signify contribution to acute intestinal injury from radiation. 
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CHAPTER 3: MOLECULAR ANALYSIS OF THE LUMINAL- AND MUCOSAL-
ASSOCIATED INTESTINAL MICROBIOTA IN DIARRHEA-PREDOMINANT 
IRRITABLE BOWEL SYNDROME
3
 
Introduction 
Irritable bowel syndrome (IBS) is the most prevalent functional gastrointestinal (GI) 
disorder, affecting 10–20% of adults and adolescents (20). IBS can present as diarrhea-
predominant IBS (D-IBS), constipation-predominant IBS, or mixed-bowel-habit IBS. These 
disorders are associated with a significantly reduced quality of life (17), psychological 
comorbidities (21), and a considerable economic burden (44). The lack of understanding of the 
factors associated with the pathogenesis of this complex group of disorders has resulted in 
limited effective treatment options for IBS patients. Recent studies have implicated new 
etiological factors in the pathogenesis of IBS, including alterations in the normal intestinal 
microbiota, genetic predeterminants, pathogenic bacterial infection, food sensitivity/allergy, 
altered enteric immune function, and intestinal inflammation (2, 30, 34). 
 The intestinal microbiota has been demonstrated to be important for normal GI motor and 
sensory functions (5, 14, 18, 34, 35), and alterations in the intestinal microbiota have been 
suggested as a possible etiological factor in the development of functional GI disorders, 
including IBS (34). Indeed, attempts to alter the composition of the intestinal microbiota using 
antibiotics, probiotics, or prebiotics have resulted in reduced IBS symptoms (8, 13, 27, 31–33, 
35, 39, 43). Several studies have characterized a dysbiosis of the intestinal microbiota in patients 
with IBS. However, there is no consensus among these studies regarding the specific 
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compositional changes of the intestinal microbiota associated with these disorders (4, 6, 9, 15, 
16, 22, 23, 25, 26, 45). Identification of specific alterations in the intestinal bacterial groups that 
are associated with IBS symptoms is complicated by the heterogeneity of the disorders and the 
diversity of the intestinal microbiota (19). In addition, it is unclear whether symptoms of IBS are 
associated with compositional variation of microbial groups in the luminal and/or mucosal niches 
(49). Therefore, the possible association between IBS and the intestinal microbiota must be 
investigated in clinically relevant, well-defined subgroups of patients, and luminal and mucosal 
niches must be analyzed using techniques that explore the composition and diversity of these 
complex microbial communities. The present study used the molecular fingerprinting technique 
terminal-restriction fragment (T-RF) length polymorphism (T-RFLP) (7) to characterize and 
compare the microbiota in fecal and colonic mucosal samples obtained from a subgroup of D-
IBS patients and healthy controls. 
Materials and methods 
 Study population. We studied 16 patients that met the Rome III criteria for D-IBS and 21 
healthy controls. Subjects were recruited from the general population of Chapel Hill, NC, with 
advertising and from the University of North Carolina (UNC) Hospitals outpatient clinics. 
 Inclusion criteria included subjects >18 yr of age and of any sex, race, or ethnicity. 
Healthy controls had no recurring GI symptoms. Subjects with a history of GI tract surgery other 
than appendectomy or cholecystectomy or a history of inflammatory bowel disease, celiac 
disease, lactose malabsorption, or any other diagnosis that could explain chronic or recurring 
bowel symptoms were excluded from the study. In addition, individuals were excluded if they 
had a history of treatment with antibiotics or anti-inflammatory agents, including aspirin or 
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nonsteroidal anti-inflammatory drugs (or steroids), or if they had intentionally consumed 
probiotics 2 mo prior to the study. 
 All subjects were evaluated by a physician to exclude an alternative diagnosis to IBS. 
The study was approved by the UNC Internal Review Board, and all subjects provided written 
consent prior to participation in the study. 
 Sample collection and preparation. Fresh stool samples were collected from all 37 
subjects on site during a single study visit at UNC. Each fecal sample was immediately 
transferred on ice to the laboratory, where it was homogenized, divided into aliquots, and stored 
at -80°C for future DNA extraction and molecular microbiological analysis. 
 Colonic mucosal biopsies (n = 8 per patient) were collected from each subject at a single 
study visit during an unsedated flexible sigmoidoscopy. To avoid possible effects of colonic 
preparation on the composition and diversity of the intestinal microbiota, all biopsies were 
collected from unprepared colons (i.e., subjects did not undergo a bowel cleansing prior to the 
procedure). Cold forceps were used to take mucosal biopsy samples from the rectosigmoid 
colon. Taking biopsy samples from the rectosigmoid junction permits consistent collection of 
samples representative of the distal colon from all subjects and minimizes the discomfort 
associated with the procedure. Once removed from the colon, each biopsy sample was washed in 
1 ml of sterile PBS to remove fecal material. The biopsy samples were then weighed, flash-
frozen in liquid nitrogen, and stored at -80°C for further DNA extraction and molecular 
microbiological analysis. 
 Extraction of DNA. Bacterial DNA was extracted from one fecal and one mucosal sample 
from each of the subjects. DNA was isolated from 18 (7 D-IBS patients and 11 healthy controls) 
fecal and mucosal samples using a phenol-chloroform extraction method combined with physical 
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disruption of bacterial cells and a DNA clean-up kit (DNeasy blood and tissue extraction kit, 
Qiagen, Valencia, CA). Briefly, a 100-mg sample of frozen feces or a mucosal biopsy was 
suspended in 750 µl of sterile bacterial lysis buffer [200 mM NaCl, 100 mM Tris (pH 8.0), 20 
mM EDTA, and 20 mg/ml lysozyme] and incubated at 37°C for 30 min. Then 40 µl of proteinase 
K (20 mg/ml) and 85 µl of 10% SDS were added to the mixture. After 30 min of incubation at 
65°C, 300 mg of 0.1-mm zirconium beads (BioSpec Products, Bartlesville, OK) were added, and 
the mixture was homogenized in a bead beater (BioSpec Products, Bartlesville, OK) for 2 min. 
The homogenized mixture was cooled on ice and then centrifuged at 14,000 rpm for 5 min. The 
supernatant was transferred to a new 1.5-ml microfuge tube, and fecal DNA was further 
extracted by phenol-chloroform-isoamyl alcohol (25:24:1) and then by chloroform-isoamyl 
alcohol (24:1). After extraction, the supernatant was precipitated by absolute ethanol at -20°C for 
1 h. The precipitated DNA was suspended in DNase-free H2O and then cleaned using the 
DNeasy blood and tissue extraction kit (see above) according to the manufacturer’s instructions. 
Additional fecal and mucosal DNA from 19 subjects (9 D-IBS patients and 10 healthy controls) 
was obtained from samples collected in a previous study (6). The study population, inclusion and 
exclusion criteria, and sample collection and handling procedures were identical in both studies. 
 T-RFLP PCR. A complex mixture of bacterial 16S rRNA genes was amplified by PCR 
from each intestinal DNA sample using fluorescently labeled universal primers 
[carboxyfluorescein (FAM)- labeled 5’-AGAGTTTGATCCTGGCTCAG-3’ (forward primer 8F) 
and hexachlorocarboxyfluorescein (HEX)-labeled 5’-GGTTACCTTGTTACGACTT-3’ (reverse 
primer 1492R)], as previously described (10, 40). PCR products were purified using a Qiagen 
PCR purification kit. PCR products of all fecal and mucosal samples were then digested with 
Hha I to generate T-RFs of varying sizes. All fecal samples were also digested separately with 
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Hae III or Msp I (mucosal samples were not digested with Hae III or Msp I because of a limited 
supply of DNA). As a result of polymorphisms in the variable regions of the 16S rRNA gene, T-
RF size corresponds to different bacterial groups. T-RFs were separated by capillary 
electrophoresis on a genetic analyzer (model 3100, Applied Biosystems, Carlsbad, CA). 
GeneMapper software (Applied Biosystems) was used to determine the size (terminal fragment 
length in base pairs), height (fluorescence intensity), and abundance (peak width X height) of 
each T-RF. To attribute specific bacterial groups to T-RFs, we compared the fingerprints 
generated from each sample with a database containing T-RF data from known and unknown 
bacterial groups [Microbial Community Analysis (MiCA) database] (41). 
 Statistical analysis. T-RF size and abundance data from GeneMapper were compiled into 
a data matrix using Sequentix software (Sequentix, Klein Raden, Germany). These data were 
normalized (individual T-RF peak area as a proportion of total T-RF peak area within that 
sample), transformed by square root, and compiled into a Bray-Curtis similarity matrix using 
PRIMER version 6 software (Primer-E, Ivybridge, UK). T-RF data were then subjected to 
multivariate analysis, including hierarchical cluster analysis followed by analysis of similarity 
(ANOSIM). Using ANOSIM, we assessed the similarities between groups (D-IBS patients vs. 
healthy controls) and within groups. We computed the significance in PRIMER version 6 by 
permutation of group membership with 999 replicates. The test statistic R, which measures the 
strength of the results, ranges from -1 to 1: R = 1 signifies differences between groups, while R = 
0 signifies that the groups are identical. The contribution of specific T-RFs to differences in 
bacterial composition between groups was assessed by similarity percentages (SIMPER). 
SIMPER results were used to generate pie charts of percent contribution of T-RFs within each 
group, after a 10% cutoff for low contributors. Biodiversity of each sample was measured by the 
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Shannon-Weiner diversity index, while differences in biodiversity between groups were assessed 
by a nonparametric Mann-Whitney test. 
Results 
 Study population. A total of 37 subjects were investigated. All subjects provided a fecal 
and a colonic mucosal sample. The study population consisted of 75% females with a mean age 
of 36 yr. Demographics and body mass index were similar in the two study groups. 
 A total of 261 different Hha I-generated T-RFs, which represent different bacterial 
groups, were found in fecal and colonic mucosal samples from all subjects. Hae III and Msp I 
generated 252 and 284 T-RFs from fecal DNA samples, respectively. Thirty-six of the Hha I-
generated T-RFs contributed ~90% of the total T-RFs found in all subjects (Fig. 3.1). The 
distribution of T-RFs differed between D-IBS patients and healthy controls and between 
intestinal niches. For example, 20 T-RFs found in fecal samples from healthy controls were not 
present in fecal samples from D-IBS patients. The abundance (peak width X height) of 5’ FAM-
187 and 3’ HEX-402 in the feces was significantly altered between D-IBS patients and healthy 
controls. In addition, 3’ HEX-400 was present in mucosal samples from healthy controls but not 
D-IBS patients, while 5’ FAM-189 and 3’ HEX-131 were found in mucosal samples from D-IBS 
patients but not healthy controls. These data demonstrate compositional differences in the fecal- 
and mucosal-associated microbiota between D-IBS patients and healthy controls. To attribute 
bacterial groups to these T-RFs, the MiCA database was queried (41). This database provided 
bacterial grouping (phylum, class, order, or family) for the majority of T-RFs that contribute to 
the composition of the fecal- and mucosal-associated microbiota in D-IBS patients and healthy 
controls. The majority of T-RFs represented several bacterial groups; however, comparison of 
bacterial groups identified by fecal T-RFs generated by three different enzymes [Hha I, Hae III, 
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and Msp I] revealed that the order Clostridiales and the family Planctomycetaceae were 
consistently associated with T-RFs that contributed 90% of fecal microbiota in healthy controls 
but not D-IBS patients. 
 Biodiversity of T-RFLP profiles. The Shannon-Weiner diversity index was used to 
determine the biodiversity (richness and evenness of T-RFs) of T-RFLP profiles from intestinal 
samples. A significant 1.2-fold decrease (2.7 + 0.65 for D-IBS patients and 3.3 + 0.86 for healthy 
controls, P = 0.008) in biodiversity was found in Hha I-generated T RFs from fecal samples from 
D-IBS patients compared with healthy controls (Fig. 3.2B). Hae III-generated T-RFs for 34 fecal 
samples [13 from D-IBS patients and 21 from healthy controls (3 samples from D-IBS patients 
failed to yield detectable T-RFs following digestion)] demonstrated a significant 1.06-fold 
decrease in biodiversity (3.47 + 0.37 for D-IBS patients and 3.67 + 0.60 for healthy controls, P = 
0.015) in fecal samples from D-IBS patients compared with healthy controls. A 1.04-fold 
decrease in biodiversity in Msp I-generated T-RFs from D-IBS fecal samples failed to reach 
statistical significance (0.979 + 0.02 for D-IBS patients and 0.983 + 0.02 for healthy controls, P 
= 0.296). No significant differences were observed in biodiversity from mucosal samples 
between D-IBS patients and healthy controls (1.6 + 0.89 and 1.6 + 0.84, respectively, P = 1) 
using Hha I-generated T-RFs. 
 We also compared the biodiversity of fecal and mucosal niches within each group. We 
observed a significant increase in biodiversity in the fecal niche compared with the mucosal 
niche in both groups, with a 1.7-fold increase (2.7 + 0.65 for feces and 1.6 + 0.89 for mucosa, P 
= 0.001) in D-IBS patients and a 2.1-fold increase (3.3 + 0.86 for feces and 1.6 + 0.84 for 
mucosa, P = 0.0001) in healthy controls (Fig. 3.2, C and D). 
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 Multivariate analysis of T-RFLP profiles. Nonmultidimensional scaling (nMDs) of T-RF 
profiles generated by Hha I-digested PCR products of samples obtained from all subjects (D-IBS 
patients and healthy controls) demonstrated that the community profiles in fecal and colonic 
mucosal niches are clearly distinct from one another (Fig. 3.3A). Hierarchal clustering analysis of 
T-RF profiles confirmed this observation (Fig. 3.3B). The degree of separation (as determined by 
R value, where R = 1 indicates complete separation between groups) between fecal and mucosal 
niches was more evident when these two niches were compared in healthy controls than in D-
IBS patients, although both were statistically significant (R = 0.41, P = 0.001 in healthy controls; 
R = 0.22, P = 0.001 in D-IBS patients). 
 No distinct separation by nMDs or hierarchal clustering was observed between D-IBS 
patients and healthy controls from fecal or mucosal niches. T-RF profiles were also generated for 
fecal samples (13 from D-IBS patients and 21 from healthy controls) using Hae III or Msp I 
restriction enzymes (3 samples from D-IBS patients failed to yield detectable T-RFs following 
digestion). nMDs and hierarchal clustering of T-RFs generated by Hae III and Msp I did not 
detect a distinct separation between D-IBS patients and healthy controls from fecal samples (R = 
-0.035, P = 0.687 for Hae III; R = -0.001, P = 0.470 for Msp I). 
Discussion 
 Several studies have investigated the composition of the intestinal microbiota in patients 
with IBS and healthy individuals (4, 9, 15, 16, 22, 23, 25, 26, 45). Although these studies 
demonstrated some differences between these two groups, the findings are not consistent. The 
majority of studies that characterized the intestinal microbiota in IBS patients investigated mixed 
populations of IBS patients (4, 42, 45) or focused on a single intestinal niche (4, 15, 16, 22, 23, 
25, 42, 45, 46). Recent reports demonstrating compositional and diversity differences between 
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intestinal luminal- and mucosal associated microbiota in humans highlight the importance of 
characterizing enteric microorganisms in both niches when investigating the role of the 
microbiota in intestinal diseases (11, 29). Only two studies have investigated the intestinal 
microbiota of luminal and mucosal niches in patients with IBS (6, 9). In a recent study, using 
culture and quantitative real-time PCR (6), we investigated the intestinal microbiota in fecal and 
colonic mucosal samples from D-IBS patients and healthy controls. We found a significantly 
lower concentration of aerobic bacteria and a higher concentration of Lactobacillus species in 
fecal samples from D-IBS patients than in healthy controls. These two techniques identified no 
differences in the mucosal-associated microbiota between the groups. However, this study was 
limited to the analysis of a finite number of predetermined bacterial groups within the intestinal 
microbiota. Codling et al. (9) used denaturing gradient gel electrophoresis (an alternate 
fingerprinting technique to the method used in our current study) to investigate the intestinal 
microbiota in a mixed population of IBS patients. Similar to our findings, Codling et al. reported 
a greater variation of denaturing gradient gel electrophoresis profiles in fecal samples from 
healthy controls than IBS patients. However, in contrast to our findings, Codling et al. reported 
no differences in the variability between the fecal- and mucosal-associated microbiota in IBS 
patients. The discrepancy between the two studies may relate to the mixed population, 
preparation prior to mucosal sample collection, or inclusion of only nine IBS patients and no 
healthy controls for the mucosal analysis in the study of Codling et al. Thus our current study is 
the first to use a molecular fingerprinting technique in a comprehensive investigation of fecal and 
unprepared colonic mucosal samples from a large group of patients with a specific subtype of 
IBS (D-IBS) and healthy controls. 
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 Analysis of the contribution of T-RFs to the composition of the intestinal microbiota 
demonstrated a considerable overlap in the predominant T-RFs within the fecal- and mucosal-
associated microbiota in D-IBS patients and healthy controls. However, D-IBS fecal and 
mucosal samples contained T-RFs that were not present in healthy control samples, and vice 
versa. These findings demonstrate obvious compositional differences in specific bacterial groups 
(as represented by T-RFs) in the fecal- and mucosal-associated microbiota between D-IBS 
patients and healthy controls. On the basis of comparisons with the MiCA database, the majority 
of T-RFs for fecal and mucosal samples were associated with multiple bacterial groups. 
However, using three different restriction enzymes on our fecal samples, we were able to 
determine whether a bacterial group(s) was consistently represented by three different enzyme-
generated T-RFs that contributed to the majority of the fecal microbiota. We found that the order 
Clostridiales and the family Planctomycetaceae were consistently represented by Hha I-, Hae III-
, and Msp I-generated T-RFs that contributed 90% of the fecal microbiota in healthy controls but 
not D-IBS patients. Previous reports showed a reduction of Clostridium coccoides in IBS 
patients that is in line with our findings (23). Interestingly, a reduction in the order Clostridiales 
has also been reported in ileal Crohn’s disease (47). The order Clostridiales encompasses many 
bacterial species, including the protective bacterium Faecalibacterium prausnitzii. It is therefore 
speculated that the absence of protective bacterial species from the order Clostridiales may be 
associated with D-IBS. A more sensitive molecular technique that classifies the intestinal 
microbiota at a species level will enable further investigation of this finding. The family 
Planctomycetaceae is a low-abundance member of the normal intestinal microbiota (1). The 
importance of our finding of reduced abundance of this bacterial group in D-IBS patients is 
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unclear, as the role of this group of organisms in the intestinal tract has not been investigated in 
depth. 
 Although we found compositional differences in the fecal microbiota between D-IBS 
patients and healthy controls with respect to specific T-RFs, we did not find a clear separation 
between these two groups with nMDs or hierarchal clustering. This suggests that the differences 
in composition of the microbiota between D-IBS patients and healthy controls are due to the 
relative abundances of specific bacterial groups that do not affect the overall composition of the 
intestinal microbiota. In support of this concept, it has been recently demonstrated that specific 
bacterial species (Klebsiella pneumoniae and Proteus mirabilis) that do not affect the overall 
composition of the intestinal microbiota independently drive colonic disease in the presence of 
the endogenous microbiota in a horizontally and vertically transmissible mouse model of 
ulcerative colitis (12). 
 Our study demonstrates a significantly lower level of fecal microbial biodiversity in 
patients with D-IBS compared with healthy controls. Additionally, our study demonstrates, for 
the first time, a significantly higher level of microbial biodiversity in fecal- than in mucosal-
associated communities within D-IBS patients and healthy controls. The increase in biodiversity 
in fecal compared with mucosal samples is greater in the healthy controls than in D-IBS patients. 
This observation requires further investigation to determine whether the intestinal microbiota in 
D-IBS patients is distributed differently between the fecal and mucosal niches compared with the 
microbiota in a healthy intestine. The biodiversity in the human gut is a result of co-evolution 
between host and microbe (3) and has been shown to be stable over time in healthy individuals 
(48). Thus a departure from the normal biodiversity of the intestinal microbiota may reflect a 
disease state in the gut. For example, a reduction in enteric bacterial biodiversity has been 
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reported in inflammatory bowel diseases (24, 28, 37, 38). It can be speculated that a reduction in 
bacterial biodiversity allows for certain members of the intestinal microbiota to flourish and 
affect intestinal function, such as regulation of inflammation or motility, and therefore perpetuate 
GI symptoms. 
 Despite the meticulous efforts used in our study to preserve and characterize the 
microbiota from different intestinal niches, certain limitations were encountered. 1) T-RFLP was 
unable to provide the resolution necessary to identify the bacterial species in the intestinal 
microbiota that are altered between D-IBS patients and healthy controls. We were able to assign 
a bacterial “phylum, class, order, or family” to most T-RFs. Although this level of 
characterization provides interesting insight into the intestinal microbiota associated with D-IBS 
patients, bacterial families encompass many bacterial genera and species. Thus, on the basis of 
these data sets, it is difficult to make definitive conclusions regarding the association of specific 
bacterial groups with D-IBS. 2) It is important to remember that T-RFLP fingerprinting is 
limited to the analysis of only the predominant members (usually 30–50 T-RFs) of complex 
microbial communities (7). Not surprisingly then, our study found that 34 T-RFs contributed 
90% of the fecal microbiota in healthy controls. Hence, it is possible that differences in less 
abundant bacteria were not detected by this technique. 3) The biopsies analyzed in this study 
were taken during unprepared flexible sigmoidoscopy to avoid the effects of bowel cleansing 
agents on the intestinal microbiota. The biopsies were taken from the distal colon just above the 
rectosigmoid junction. This site was selected because it provides a clear anatomic point to enable 
consistent collection of mucosal samples and to minimize the discomfort of the subject. 
However, the microbiota of this colonic region may not be representative of the microbiota of the 
whole colon, and we did not collect biopsies from more proximal colonic regions. 
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 In conclusion, we have demonstrated compositional and biodiversity differences in the 
intestinal microbiota between patients with D-IBS and healthy controls. Our study does not 
address whether these differences are an etiological cause or an effect of the disorder, but it does 
provide a rationale for further investigation of the role of the intestinal microbiota in the 
pathogenesis of IBS. Our findings emphasize the importance of investigating the fecal- and 
mucosal-associated microbiota in this disorder, as well as the need for techniques with higher 
resolution (e.g., high-throughput sequencing of the 16S rRNA gene), which may enable deeper 
characterization of the intestinal microbiota and identification of the specific bacterial groups 
that are altered in IBS. 
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Figure. 3.1. Terminal-restriction fragment (T-RF) fingerprinting data displaying percent 
contribution of T-RFs within fecal and colonic mucosal samples from patients with diarrhea-
predominant irritable bowel syndrome (D-IBS) and healthy controls. 
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Figure. 3.2. Shannon-Weiner biodiversity index in mucosal samples from healthy controls and 
D-IBS patients (A), fecal samples from healthy controls and D-IBS patients (B; P = 0.008), fecal 
and mucosal samples from healthy controls (C; P = 0.0001), and fecal and mucosal samples from 
D-IBS patients (D; P = 0.001). 
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Figure. 3.3. A: non-multidimensional scaling analysis of T-RF profiles generated from fecal and 
mucosal samples from D-IBS patients and healthy controls. B: hierarchical cluster analysis of T-
RF data from fecal and mucosal samples from D-IBS patients and healthy controls. Red and blue 
circles represent the majority of mucosal and fecal samples, respectively. 
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CHAPTER 4: ALTERED ENTERIC MICROBIOTA ECOLOGY IN INTERLEUKIN 10-
DEFICIENT MICE DURING DEVELOPMENT AND PROGRESSION OF INTESTINAL 
INFLAMMATION
4
 
Introduction 
 Ulcerative colitis (UC) and Crohn’s disease (CD), collectively known as inflammatory 
bowel diseases (IBD), are prevalent in the United States (US), affecting 1.4 million individuals 
(1), and are associated with reduced quality of life (2) and a heavy economic burden that is 
estimated to be $6.3 billion annually in the US (3). The chronic nature, high rate of recurrence 
and lack of safe and curative medical treatments for IBD underscore the need for alternate 
therapeutic approaches for these complex diseases. Although, the precise pathophysiology of 
IBD remains unclear, it is widely accepted that the pathogenesis of IBD involves dysregulated 
immune responses toward microbial and other luminal antigens in a genetically susceptible host 
(4-7). Environmental factors also play an important role in the initiation and reactivation of 
inflammation in IBD (4, 8). An altered composition of the intestinal microbiota (dysbiosis) has 
been reported for both UC and CD (9-11). However, this association is not as profound in recent 
pediatric studies (12, 13). Moreover, the primary versus secondary nature of an intestinal 
microbial dysbiosis in IBD remains unknown. Thus, more in depth characterization of sequential 
enteric microbial changes during early and later phases of the inflammatory process may enable 
the development of better therapeutic strategies for these diseases. 
                                                          
4
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 Among the various rodent models for IBD, interleukin-10 deficient (IL-10
−/−
) mice are 
widely used for mechanistic studies investigating the pathogenesis of spontaneous, immune-
mediated, chronic intestinal inflammation (14-16). IL-10
−/− 
mice maintained in germ-free (GF) 
conditions do not develop intestinal inflammation. However, once colonized with conventional 
or specific pathogen-free (SPF) microbiota, IL-10
−/−
 mice develop intestinal inflammation as 
early as one week following colonization with an SPF microbiota (17).
 
Although alterations in 
the intestinal microbiota in subsets of IBD patients with established disease compared with 
healthy controls have been reported (9, 10, 18), early changes in the composition and diversity of 
this complex 
microbial community at the onset of disease cannot be studied in the human intestinal tract, as it 
is impossible to predict who will develop disease (8, 19). Currently, little is known about the 
changes in composition and diversity of the enteric microbiota of IL-10
−/− 
mice during the onset 
of intestinal inflammation. Molecular methods are effectively used to characterize the intestinal 
microbiota due to the limitations of culture-based methods. A study using 16S rRNA-based 
fingerprinting techniques (denaturing gradient gel electrophoresis [DGGE] and repetitive 
DNA element-based PCR) reported compositional changes in the intestinal microbiota in IL-
10
−/−
 mice over time (20, 21). However, due to the limitations in technology used for microbiota 
analysis, these studies provided limited data regarding the abundances of specific taxa and the 
diversity of the microbiota. Thus, we conducted the current study to characterize the intestinal 
microbiota of IL-10
−/− 
mice during the progression of colitis in comparison with wild-type (WT) 
mice. We controlled for variations in the composition of the microbiota using previously GF IL-
10
−/−
 and WT mice colonized with a microbiota from the same donor. We also characterized 
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changes in diversity and composition of the intestinal microbiota in mice from two genetic 
backgrounds. 
Results 
 16S rRNA gene sequences. The V1–3 regions of the 16S rRNA gene were amplified 
from all fecal DNA samples (n = 30). Following high throughput sequencing, four samples (three 
from week two of the IL-10
−/− 
group and one from week one of the WT group) yielded sequence 
numbers that were too low (< 350 16S rRNA sequences per sample) to be included in our 
analyses. An average of 8,012 16S rRNA sequences per sample were obtained from the 
remaining 26 samples with the following ranges: WT week one (n = 4) 5647–10502 sequences; 
WT week two (n = 5) 6927–11490 sequences; IL-10−/− week one (n = 5) 1115–8116 sequences; 
IL-10
−/−
 week two (n = 2) 9666–12789 sequences; IL-10−/− week three (n = 5) 6162–8467 
sequences; IL-10
−/−
 week four (n = 5) 1340–23189 sequences. To determine the numbers and 
abundances of different bacterial groups in each sample we used 97% similarity between 16S 
rRNA gene sequences as an indicator of a “species level” operational taxonomic unit (OTU). 
Using this procedure we found a total of 479 OTUs in our data set. 
 Intestinal microbial diversity decreases over time in formerly GF IL-10
−/−
 mice. In 
our initial investigation we sought to characterize changes in diversity in the intestinal 
microbiota that arise over time in formerly GF WT and IL-10
−/−
 mice. The microbiota was 
characterized in fecal samples collected weekly for two weeks in WT mice and for four weeks in 
IL-10
−/− 
mice following association with an SPF microbiota. Based on IL-12p40 secretion from 
colonic tissue and composite histology scores, we found that WT mice did not develop 
significant inflammation whereas IL-10
−/−
 mice developed moderate intestinal inflammation four 
weeks following association with an SPF microbiota (Fig. 4.1A and B). 
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 We calculated UniFrac distances for all time points for each group. We found that 
average weighted and un-weighted UniFrac distances significantly increased (p = 0.003 and p = 
8.5 × 10
−5
, respectively) over the two week observation period in the WT group (Fig. 4.2C). We 
investigated the weighted and un-weighted UniFrac distances of the microbiota in fecal samples 
obtained one, two, three and four weeks from formerly GF IL-10
−/− 
mice following association 
with an SPF microbiota. We found a significant decrease in average weighted UniFrac distances 
at the three week (p = 0.005) and four week (p = 0.005) time points compared with the 1 week 
time point (Fig. 4.2A and B). 
 Intestinal microbial richness decreases over time in formerly GF IL-10
−/−
 mice. We 
determined the richness of the intestinal microbiota in all groups using rarefaction analysis. A 
significant increase (p = 0.004) in the number of observed microbial species was found in WT 
mice two weeks following association with an SPF microbiota when compared with the one 
week time point (Fig. 4.3B). In contrast, a significant decrease in the number of observed 
microbial species was found in IL-10
−/− 
mice three (p = 0.02) and four (p = 0.009) weeks 
following association with an SPF microbiota when compared with the one week time point 
(Fig. 4.3A). 
 Ecological succession of bacterial taxa in formerly GF IL-10
−/−
 mice over time. In 
order to determine the dominant bacterial groups that are altered over time in WT and IL-10
−/− 
mice following colonization with an SPF intestinal microbiota we summarized the bacterial taxa 
identified by our 16S rRNA sequences at the phylum level (Fig. 4.4). In WT mice we found no 
significant changes in bacterial phyla between one and two weeks post association with an SPF 
microbiota. In the IL-10
−/− 
group we observed a significant decrease in the levels of 
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Bacteroidetes (20.06%–6.30%, false discovery rate [FDR] = 0.01) and Verrucomicrobia (0.74% 
0.17%, FDR = 0.02) at three weeks compared with the one week time point. These changes were 
further reduced by four weeks: Bacteroidetes (20.06–9.5%, FDR = 0.003) and Verrucomicrobia 
(0.74%–0.09%, FDR = 0.02). At four weeks we observed a significant increase in the levels of 
Proteobacteria (0.17%–7.71%, FDR = 1.5 × 10−5) and Tenericutes (39.21%–70.66%, FDR = 
0.07) compared with the one week time point. In tandem, at four weeks we observed a decrease 
in the levels of Actinobacteria (1.27%–0.53%, FDR = 0.07) and Firmicutes (38.48%–11.46%, 
FDR = 0.03) compared with the one week time point. Additionally, we observed significant 
changes in the abundances of genus-level taxa over time in IL-10
−/−
 mice (Table 4.1) and no 
significant changes in bacterial genera in WT mice over time. 
 Escherichia coli concentrations increase in formerly GF IL-10
−/−
 mice over time. 
Given that E. coli is a member of the Proteobacteria phylum and has been established as a pro-
inflammatory microbe in the context of IBD (22), we used species-specific qPCR to determine 
the levels of this bacterial species in fecal samples from the IL-10
−/−
 group of mice. We found 
that the levels of E. coli in the intestinal microbiota of IL-10
−/− 
mice increased over time and 
became significantly higher at the four week time point when compared with the week one time 
point (Fig. 4.5). The stepwise increase of E. coli over time in the IL-10
−/−
 group closely 
paralleled the increase in Proteobacteria in the same mice, confirming results by two different 
molecular methods (Fig. 4.5). 
 Alterations in the abundance of E. coli in formerly GF IL-10
−/−
 mice over time are 
mirrored in SPF IL-10
−/−
 mice. In order to determine whether inflammation associated 
alterations of specific taxa in formerly GF IL-10
−/−
 mice are also altered in a gut that has 
developed naturally, we investigated the levels of E. coli, Lactobacillus species and Akkermansia 
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muciniphila in WT and IL-10
−/−
 mice raised in an SPF environment. This group of IL-10
−/−
 mice 
developed significant intestinal inflammation at 10 weeks of age compared with WT controls 
that did not develop inflammation (Fig. 4.1C and D). Similarly to formerly GF mice the 
abundance of E. coli was significantly higher in IL-10
−/−
 mice at week ten compared with WT 
mice (Fig. 4.6A). Akkermansia muciniphila was significantly higher in IL-10
−/−
 mice compared 
with WT mice at both eight and ten weeks (Fig. 4.6B). We did not observe any significant 
differences in the abundance of Lactobacillus species in IL-10
−/−
 mice compared with WT mice 
at either time point (Fig. 4.6C). 
Discussion 
 Based on the established association of the intestinal microbiota with IBD and the 
frequent use of the IL-10
−/−
 mouse as a model of spontaneous, immune-mediated colonic 
inflammation, we characterized the diversity and composition of the intestinal microbiota in this 
mouse model during the progression of experimental colitis. Previous studies characterizing the 
intestinal microbiota of IL-10
−/−
 mice focused on viable bacteria or used molecular techniques 
that characterize a limited number of bacterial taxa (20, 21). Our study used a current molecular 
technique that provided a comprehensive characterization of the changes in microbial 
composition and diversity in WT and IL-10
−/− 
mice over time. Additionally, the use of formerly 
GF WT and IL-10
−/−
 mice colonized with the same fecal microbiota provided a highly controlled 
environment to study these changes. 
 In our investigations we observed an increase in microbial richness (as determined by 
rarefaction of bacterial species) and diversity (as determined by UniFrac distances) in formerly 
GF WT mice two weeks following association with an SPF microbiota. This finding suggests 
that the intestinal microbiota in formerly GF WT mice may still be establishing a homeostatic 
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balance two weeks after colonization. UniFrac distances can be calculated in a weighted (relative 
abundance of taxa) or un-weighted (presence or absence of taxa) manner. Low average UniFrac 
distances indicate higher similarity in the composition of the microbiota within a group of 
samples, whereas high average UniFrac distances indicate more dissimilarity within a group of 
samples. We observed an increase in both weighted and un-weighted UniFrac distances two 
weeks post colonization in WT mice, suggesting that the rise in diversity values at this time point 
is due to an increase in both high and low abundance bacterial species. A limitation of our study 
is that we did not investigate the microbial composition and diversity of fecal samples in 
formerly GF WT mice at three and four weeks following conventionalization with an intestinal 
microbiota. Thus we cannot conclude whether the intestinal microbiota has reached equilibrium 
at this point. Interestingly, it has been reported that the microbial composition and diversity of 
cecal contents in formerly GF WT mice, from a different genetic background (C57BL/6), 
exhibited stability seven days post-inoculation (23). 
 We subsequently characterized the richness and diversity of the intestinal microbiota in 
formerly GF IL-10
−/−
 mice up to four weeks following colonization with an SPF microbiota to 
investigate alterations in the intestinal microbiota during the progression of colitis. Indeed, we 
observed moderate inflammation at four weeks post colonization in IL-10
−/−
 mice. A progressive 
decrease in weighted UniFrac distances was observed three and four weeks post colonization in 
comparison with one week values. In addition, the richness of the microbiota was significantly 
decreased in this cohort of mice at these later time points. Interestingly, we did not observe a 
significant decrease in un-weighted UniFrac distances at the three and four week time points 
compared with one week in IL-10
−/− 
mice. These data suggest that the composition of newly 
introduced, complex microbial communities in formerly GF IL-10
−/− 
mice becomes more alike 
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during the progression of colonic inflammation and that high abundance taxa are responsible for 
this change. In the absence of an established fecal marker indicative of intestinal inflammation 
we are unable to conclude whether the alterations in the richness and diversity of the enteric 
microbiota in IL-10
−/− 
mice occur before, during or after the onset of colonic inflammation. In 
previous experiments we found that mild inflammation occurs in formerly GF IL-10
−/−
 mice on 
a 129 SvEv background two weeks following microbial colonization (17).  
 Our current study shows that enteric microbial richness and diversity dramatically change 
at three weeks post association with an SPF microbiota. Thus, we speculate that decreases in 
enteric microbial richness and diversity in IL-10
−/−
 mice occur after the onset of colonic 
inflammation in this mouse model. In tandem with altered enteric microbial richness and 
diversity in the intestinal microbiota of IL-10
−/−
 mice over time, we observed changes in the 
relative abundances of specific bacterial phyla. Most notable was a step-wise increase in the 
levels of Proteobacteria that mirrored a significant increase of E. coli during the onset of colonic 
inflammation. Elevated Proteobacteria levels have been reported in UC and CD patients (9). 
Moreover, adherent invasive E. coli strains are associated with ileal CD (22, 24).
 
A significant 
depletion in the concentrations of the Bacteroidetes
 
and Firmicutes phyla were observed over 
time in IL-10
−/− 
mice,
 
which also reflects changes reported in the intestinal microbiota
 
of human 
IBD (9, 10). Thus, our data demonstrate that the IL-10
−/− 
mouse model of colitis exhibits 
alterations in specific members
 
of the intestinal microbiota that parallel those of human
 
IBD.  
 We also observed significant decreases in the levels of the
 
Actinobacteria and 
Verrucomicrobia phylum, which have not
 
been reported for human IBD and may be a 
consequence of enteric
 
inflammation. It is interesting to note that Bifidobacterium species
 
are 
encompassed within the Actinobacteria phylum and are considered
 
probiotic microbes. 
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Alterations in the Verrucomicrobia
 
phyla may be yet unreported components of a human IBD 
dysbiosis,
 
or alternatively, they may be unique to this mouse model.
 
However, it has been 
reported that Akkermansia muciniphila
 
(a member of the Verrucomicrobia phylum) is depleted in 
the
 
mucus of IBD patients (25). Indeed, in support of this finding,
 
our 16S rRNA sequence data 
revealed a significant decrease in
 
the Akkermansia genus in IL-10
−/−
 mice over time. As bacterial
 
richness and diversity decreased in IL-10
−/−
 mice over time we
 
observed a profound increase in 
the levels of the Tenericutes phylum.
 
This phylum encompasses bacteria that lack a cell wall and 
are thus Gram negative. Tenericutes have been reported to be significantly elevated in fecal 
samples from colonic Crohn’s disease patients but decreased in fecal samples from ileal Crohn’s 
disease and ulcerative colitis patients (10). From our data set the dominant genus within the 
Tenericutes phylum is Allobaculum. However, although taxonomies were assigned to our 16S 
rRNA sequences using the Greengenes database (26), it is interesting to note that the RDP 
database (27) classifies the Allobaculum genus as belonging to the Firmicutes phylum, which 
would make the Firmicutes the dominant phylum in our data set. Nevertheless, it has been 
reported that the Greengenes database, which contains the largest and most diverse set of 16S 
rRNA sequences, is superior to other databases when classifying sequences at the phylum level, 
particularly with respect to the Tenericutes (28).
 
 
It has been reported that GF mice have abnormal mucosal and immunologic maturation 
resulting in increased morbidity in the oxazolone-induced mouse model of colitis when 
compared with SPF mice (29).
 
Thus, we determined the abundances of specific bacterial groups 
in cohorts of WT and IL-10
−/−
 mice that were raised with a normal intestinal microbiota. Even 
though the mice used were of a different genetic background (C57BL/6) to the mice used in our 
GF experiments we observed an increase in the abundance of E. coli in IL-10
−/−
 mice compared 
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with WT mice, suggesting a strong association of this bacterial species with the development of 
intestinal inflammation in this mouse model over time. We also found that although abundances 
of A. muciniphila and Lactobacillus species appeared to decrease over time in IL-10
−/−
 mice 
compared with WT mice, these decreases were not significant. Thus, it is possible that the 
alterations in the enteric microbiota during the development of intestinal inflammation that we 
observed in formerly GF IL-10
−/−
 mice are influenced by host genetics and an abnormal gut 
physiology associated with GF mice.
 
 Our data reports the changes in diversity and composition of the intestinal microbiota in 
the IL-10
−/−
 mouse model of spontaneous, immune-mediated colitis over time. The reduction in 
diversity and most changes in specific bacterial taxa in the intestinal microbiota of this mouse 
model reflect the changes in this complex microbial community observed in human IBD patients. 
Thus, our study validates the use of this mouse model for studies relating to the intestinal 
microbiota and immune-mediated colonic inflammation. The progressive loss of diversity, of 
dominant commensal microbiota and expansion of Proteobacteria, notably E. coli, with 
increasing experimental inflammation suggests that dysbiosis is secondary to the immune 
response in this model. Despite the postulated secondary nature of the observed changes, the 
altered microbiota profiles may still be responsible for perpetuation and amplification of mucosal 
immune responses and inflammation, since we have documented enteric bacterial-specific 
TH1 and TH17 responses in this model (30). 
Materials and Methods 
 Mice. Adult WT and IL-10
−/−
 129 SvEv mice were maintained in a GF state at the 
National Gnotobiotic Rodent Resource Center at UNC-Chapel Hill, NC, USA. One group of WT 
(n = 5) and one group of IL-10
−/−
 (n = 5) mice were used in this study. Formerly GF mice were 
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inoculated with fecal slurry obtained from a common SPF WT 129 SvEv donor mouse via oral 
and rectal swabbing (see Fig. 4.7 for a schematic design of the study). Each experimental group 
(WT and IL-10
−/−
) consisted of mice from the same litter that were housed in separate cages. 
Fresh fecal pellets were obtained weekly from all mice. All fecal pellets collected were flash 
frozen immediately in liquid nitrogen to retain the integrity of the fecal microbiota. 
 In order to translate our findings from GF animals to mice that were raised from birth 
with a normal microbiota, we investigated WT (n = 8) and IL-10
−/−
 (n = 9) C57BL/6 mice 
housed in a specific pathogen-free (SPF) environment. Each experimental group (WT and IL-
10
−/−
) consisted of mice from the same litter that were housed in separate cages. Fecal samples 
were collected from all mice at eight and 10 weeks of age. 
 Assessment of intestinal inflammation. Sections of fixed (10% neutral buffered 
formalin) colons were embedded in paraffin and stained with hematoxylin and eosin. Using a 
well-validated scale (17, 31),
 
the severity of inflammation was blindly assessed. Histological 
scores (0 to 4) were based on the degree of lamina propria and submucosal mononuclear cellular 
infiltration, crypt hyperplasia, goblet cell depletion and architectural distortion. A composite 
histology score was generated by the aggregate scores from the cecum and proximal and distal 
colon. 
 Colonic explant cultures were prepared as previously described (17). Briefly, colonic 
tissue was thoroughly irrigated with phosphate-buffered saline (PBS), shaken at room 
temperature in Roswell Park Memorial Institute medium (RPMI) containing 1% penicillin and 
streptomycin (GIBCO, Grand Island, NY) for 30 min at 280 rpm, cut into 1-mm fragments and 
weighed. Intestinal tissue fragments were then distributed (0.05 g per well) into 24-well plates 
and incubated in 1 mL of RPMI 1640 medium supplemented with 10% fetal bovine serum and 
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1% antibiotic/antimycotic (GIBCO) for 22 h at 37°C. Supernatants were collected and stored at 
−20°C before use for cytokine quantification. Commercially available monoclonal anti-mouse 
IL-12 p40 capture and detection reagents (BD Biosciences PharMingen, San Diego, CA) in an 
enzyme-linked immunosorbent assay (ELISA) were used to measure the levels of IL-12 p40 
secreted constitutively in colonic explant cultures (17, 31). IL-12 p40 levels were measured in 
supernatants and compared with standard curves generated by using recombinant murine IL-12 
p40. 
 Isolation of DNA. Bacterial DNA was isolated from all fecal pellets (n = 47) using a 
phenol/chloroform extraction method combined with physical disruption of bacterial cells and a 
DNA clean-up kit (Qiagen DNeasy® Blood and Tissue extraction kit) as previously described 
(32).
 Briefly, 100 mg of frozen feces were suspended in 750 μL of sterile bacterial lysis buffer 
(200 mM NaCl, 100 mM Tris [pH 8.0], 20 mM EDTA, 20 mg/mL lysozyme) and incubated at 
37°C for 30 min. Next, 40 μL of proteinase K (20 mg/mL) and 85 μL of 10% SDS were added to 
the mixture and incubated at 65°C for 30 min. 300 mg of 0.1 mm zirconium beads (BioSpec 
Products) were then added and the mixture was homogenized in a bead beater (BioSpec 
Products) for 2 min. The homogenized mixture was cooled on ice and centrifuged at 14,000 rpm 
for 5 min. The supernatant was transferred to a new 1.5 ml microfuge tube and fecal DNA was 
further extracted by phenol/chloroform/iso-amyl alcohol (25:24:1) and chloroform/iso-amyl 
alcohol (24:1). Following extraction the supernatant was precipitated by absolute ethanol at 
−20°C for 1 h. The precipitated DNA was suspended in DNase free H2O and cleaned using the 
Qiagen DNeasy® Blood and Tissue extraction kit per the manufacturer’s instructions. 
 454 pyro-sequencing of 16S rRNA genes. Bacterial community composition in isolated 
DNA samples was characterized by amplification of the V1–3 (forward, 8f: 5'-AGAGTTTGAT 
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CMTGGCTCAG-3'; reverse 518r: 5'-ATTACCGCGGCTGCTGG-3') variable regions of the 16S 
rRNA gene by polymerase chain reaction (PCR) as previously described (33).
 
Forward primers 
were tagged with 10 bp unique barcode labels at the 5' end along with the adaptor sequence (5'-
CCATCTCATCCCTGCGTGTC TCCGACTCAG-3') to allow multiple samples to be included 
in a single 454 Genome Sequencer (GS) FLX Titanium sequencing plate as previously described 
(34, 35). 16S rRNA PCR products were quantified, pooled and purified for the sequencing 
reaction. 454 GS FLX Titanium sequencing was performed on a 454 Life Sciences GS FLX 
machine (Roche, Florence, SC) at the Microbiome Core at UNC-Chapel Hill 
(http://www.med.unc.edu/microbiome). 
 Analysis of 16S rRNA sequences using the QIIME pipeline. 16S rRNA sequence data 
generated by the 454 GS FLX Titanium sequencer were processed by the quantitative insights 
into microbial ecology (QIIME) pipeline (36). Briefly, sequences that were less than 200 bp or 
greater than 1,000 bp in length, contained incorrect primer sequences or contained more than 1 
ambiguous base were discarded. The remaining sequences were assigned to WT and IL-10
−/− 
groups based on their unique nucleotide barcodes, including error-correction (34). Sequences 
were clustered into OTUs based on 97% sequence similarity (similar to species level) using 
BLAST
 
(37) with the Greengenes reference database (38). α-diversity (diversity within samples) 
was determined with ten iterations at a maximal sequence depth where all samples could be 
included. β-diversity (diversity between groups of samples) was calculated using weighted and 
un-weighted UniFrac distances (39-41). UniFrac distances are a β-diversity measure that utilizes 
phylogenetic information to compare environmental samples (39, 40). 
 Quantitative real-time PCR (qPCR). qPCR assays were performed using the SYBR® 
Green PCR Master Mix (Applied Biosystems, Carlsbad, CA) with primers that amplify the genes 
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encoding 16S rRNA from E. coli (forward, 5'-GTTAATACCT TTGCTCATTG A-3'; reverse, 5'-
ACCAGGGTAT CTAATCCTGT T-3'), Lactobacillus species (forward, 5'-AGCAGTAGGG 
AATCTTCCA-3'; reverse, 5'-CACCGCTACA CATGGAG-3'), A. muciniphila (forward, 5'-
CAGCACGTGA AGGTGGGGAC-3'; reverse, 5'-CCTTGCGGTT GGCTTCAGAT-3') and all 
bacteria (forward, 5'-TGSTGCAYGG YTGTCGTCA-3'; reverse, 5'-ACGTCRTCCM 
CACCTTCCTC-3'). qPCR assays were conducted in 96-well plates on an Eppendorf Realplex
2 
mastercycler thermocycler (Eppendorf, Hauppauge, NY). Each PCR was performed in a final 
volume of 25 μL and contained the following: 1× SYBR Green Master Mix, 0.5 μM of each 
primer and 10 ng of purified fecal DNA. PCR conditions were as follows: 10 min at 95°C, 
followed by 40 cycles of 95°C for 15 sec, 20 sec at 50°C and 72°C for 30 sec. Each plate 
included duplicate reactions per DNA sample, the appropriate set of standards and a “no 
template” negative control for each primer set. qPCR standards were generated by PCR 
amplification of target sequences from genomic DNA of an appropriate positive control strain. 
Analysis of melting curves confirmed that the fluorescence signal originated from specific PCR 
products and not from primer-dimers or other artifacts. 
 Statistical analyses. Bacterial taxon percentages and average UniFrac value data sets 
were assessed for normality using the D’Agostino and Pearson omnibus normality test. When a 
data set was identified as not having a normal distribution it was transformed by log (10, 42)
 
and 
retested for normality. Normally distributed data sets were compared using a Student’s t-test. All 
statistical comparisons were performed using GraphPad Prism software (v4.0a; Prism). We used 
taxon and phylogenetic-based analyses to compare 16S rRNA gene sequences within WT and 
IL-10
−/−
 groups over time. Taxon-based: the means and standard deviations of abundances of 
bacterial Phyla were calculated and compared between all time-points for each group using the 
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Benjamini–Hochberg procedure (43) to correct for multiple corrections. A p value of less than 
0.05 and a FDR less than 0.1 were considered significant. Phylogenetic-based: phylogenetic trees 
for WT and IL-10
−/− 
groups were generated using the QIIME pipeline (36). Each tree was 
subjected to un-weighted and weighted UniFrac analyses (39, 40)
 
through the QIIME pipeline. 
UniFrac distances represent the fraction of branch length that is shared by any two samples’ 
communities in a phylogenetic tree built from 16S rRNA sequence data from all samples. 
Average UniFrac distances, which represent the similarity or dissimilarity of microbial 
communities within a group, were compared using a student’s t test. 
 For qPCR assays, the percentage of E. coli was determined in all fecal samples ([copies 
16S rRNA gene for E. coli/copies of 16S rRNA gene for all bacteria] × 100). The concentration 
of E. coli group was expressed as a “fold change” with respect to the concentration in the control 
group (WT) at week 1 after colonization. qPCR data were compared between groups using a 
non-parametric Mann-Whitney test. Similarly, the concentrations of IL-12p40 secreted by 
colonic tissue (pg/mL/mg of tissue) were compared between groups using a non-parametric 
Mann-Whitney test. 
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Figure 4.1. Inflammatory changes in the colons of formerly GF mice over time. Levels of IL-12 
p40 secreted by colonic tissues from formerly GF WT and IL-10
−/−
 mice (A) and SPF raised WT 
and IL-10
−/− 
mice (C). The levels of IL-12 p40 in IL-10
−/− 
mice are significantly higher compared 
with WT mice in both formerly GF (p = 0.008) and SPF (p = 0.0001) environments. Histological 
scores for formerly GF WT and IL-10
−/−
 mice (B) and SPF WT (n = 7, as one tissue sample 
degraded during processing) and IL-10
−/− 
mice (D). The degree of histological inflammation is 
significantly higher in IL-10
−/− 
compared with WT mice in formerly GF (p = 0.008) and SPF (p = 
0.001) environments. 
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Figure 4.2. Changes in weighted and un-weighted average UniFrac distances in formerly GF 
wild type (WT) and IL-10
−/−
 mice over time. (A) Average weighted UniFrac distances of the 
intestinal microbiota significantly decrease in IL-10
−/−
 mice three and four weeks following 
colonization with a specific pathogen-free (SPF) microbiota. (B) Average un-weighted UniFrac 
distances of the intestinal microbiota do not significantly alter in the IL-10
−/−
 mice following 
colonization with an SPF microbiota. (C) Average weighted and un-weighted UniFrac distances 
significantly increase in WT mice between one and two weeks following colonization with an 
SPF microbiota. 
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Figure 4.3. Microbial richness of 16S rRNA data. (A) The number of observed bacterial species 
in formerly GF IL-10
−/−
 mice decreases between one and four weeks following colonization with 
an SPF microbiota. (B) The number of observed bacterial species in formerly GF WT mice 
significantly increases between one and two weeks following colonization with an SPF 
microbiota. 
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Figure 4.4. Bacterial taxa alterations over time in formerly GF WT and IL10
−/−
 mice. 
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Figure 4.5. Change in levels of Proteobacteria and Escherichia coli in formerly GF IL-10
−/− 
mice 
over time. Proteobacteria are expressed as the percentage of total 16S rRNA sequences. E. coli 
are expressed as fold increase with respect to baseline (WT at week 1). *The levels of 
Proteobacteria and E. coli are significantly higher at week 4 post colonization compared with 
week 1 (E. coli, p = 0.0001; Proteobacteria, FDR = 1.5 × 10
−5
). 
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Figure 4.6. Change in levels of E. coli (A), Akkermansia muciniphila (B) and Lactobacillus 
species (C) in SPF WT and IL-10
−/−
 mice over time. 
  
97 
 
 
Figure 4.7. Schematic outline of experimental design. Adult WT and IL-10
−/− 
129 SvEv GF mice 
were inoculated with an SPF microbiota from a single donor (black arrow). Fresh fecal pellets 
were obtained from the WT group (n = 5) at 1 and 2 weeks following SPF inoculation. Fecal 
pellets were obtained from the IL-10
−/−
 group (n = 5) at 1, 2, 3 and 4 weeks following association 
with an SPF intestinal microbiota. 
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Taxon % week 1 % week 3 % week 4 p FDR 
Coprobacillus 0.86 0.06  0.004 0.07 
Akkermansia 0.75 0.17  0.007 0.06 
Lactobacillus 1.20 12.83  0.008 0.05 
Staphylococcus 0.50 0.00  0.020 0.10 
Parabacteroides 9.15 4.05  0.023 0.10 
      
      
Raoultella 0.00  0.08 0.002 0.03 
Akkermansia 0.75  0.09 0.003 0.02 
Clostridium 0.02  0.00 0.006 0.04 
Enterobacter 0.10  5.14 0.009 0.04 
Oscillospira 0.83  0.04 0.010 0.04 
 
Table 4.1. Changes in the abundances of genus-level taxa over time in formerly GF IL-10
−/− 
mice 
*False discovery rate (FDR) < 0.1 = statistically significant. 
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CHAPTER 5: MOLECULAR DETECTION OF BACTERIAL CONTAMINATION IN 
GNOTOBIOTIC RODENT UNITS
5
 
Introduction 
 The role of the indigenous microbiota in human health and disease has received a great 
deal of attention in the last decade. Gnotobiotic (from the Greek roots gnotos “known” and bios 
“life”) rodents, reared under germ-free (GF) conditions, with or without subsequent exposure 
during postnatal life or adulthood to single or combinations of microbial species, provide an 
excellent system for controlling microbial community composition and housing conditions. 
Gnotobiology has greatly facilitated our understanding of the contribution of commensal bacteria 
to host developmental, physiologic and pathophysiologic processes (1). It has revealed some of 
the operating principles that underlie host-microbial and microbial-microbial relationships, 
including the discoveries that commensal bacteria affect the structure of mucosal surfaces and 
contribute to the development, organization and function of the immune system (2-5). 
 It is now known that individual bacterial members of the commensal microbiota (6-8) 
have the potential to carry out striking immunomodulatory functions. Perhaps not unsurprisingly 
then, the microbiota also heavily contributes to inflammatory
 
(9-13), autoimmune (14), 
metabolic (11, 15, 16), neoplastic
 
(17), functional (18-20) and treatment-induced (21, 22) 
disorders.  
 
                                                          
5
 This chapter previously appeared as an article in the journal Gut Microbes. The original citation is as follows: 
Packey CD, Shanahan MT, Manick S, Bower MA, Ellermann M, Tonkonogy SL, Carroll IM, Sartor RB. Molecular 
detection of bacterial contamination in gnotobiotic rodent units. Gut Microbes 2013; 4(5): 361-370.  
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 GF rodents, which possess no bacteria, yeast, molds, parasites or viruses, except 
retroviruses, are the foundation of gnotobiology, and provide a critical approach for 
characterizing the properties of the human gut microbiota. GF animals are derived by sterile 
Caesarian section or embryo transfer and maintained in sterile isolators. These animals can be 
selectively inoculated with various microbial species, either singly (monoassociation) or in 
combination, to study their effects on the host. Once colonized, these rodents must be maintained 
in barrier intact isolators with positive pressure filtered air and sterilized bedding, food and water 
to avoid contamination with bacteria, as occurs rapidly in rodents maintained in conventional 
filter top cages. Maintaining these animals requires compulsively maintained sterile technique, 
with periodic monitoring for contamination.      
 The accuracy and reproducibility of gnotobiotic experimental results depend on 
maintaining precise microbial conditions within each isolator with exclusion of undesired 
external organisms. This is achieved with double-sided entry ports, sleeved gloves, a continuous 
flow of filtered air and complete sterilization of all materials entering the isolator. However, this 
unique system is highly labor intensive and vulnerable to contamination. Any interruption in air 
flow, incomplete sterilization of food, water or bedding, (due to an undetected autoclave 
malfunction, for example), or breach in the integrity of the isolator walls, entry ports, filters, 
sleeves or gloves that are used to manipulate the animals will jeopardize isolator sterility. 
 Hence, screening of gnotobiotic units for contamination must be performed on a routine 
basis. The traditional approach to screening relies on aerobic and anaerobic bacterial and fungal 
culturing with or without Gram staining (23-26). However, these methods have considerable 
limitations. First, many bacteria in the mammalian gut microbiota are not easily cultured in a 
laboratory, mainly owing to the lack of appropriate culture media (27). Second, identifying 
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contaminating organisms can be quite tedious and difficult by culture techniques. Finally, the 
interpretation of fecal Gram stains, which is often complicated by the presence of distracters 
such as dietary vegetable fibers, fecal matter and dead bacteria present in autoclaved or irradiated 
chow, can be extremely challenging even to experienced observers.  
 Consequently, we have optimized molecular polymerase chain reaction (PCR)-based 
techniques for the specific purpose of screening for and identifying bacterial contamination of 
gnotobiotic animals with maximal sensitivity and specificity. 16S ribosomal RNA (rRNA) 
sequencing has been utilized to survey bacterial species within the microbiota and the potential 
for using 16S rRNA PCR to verify GF status was recently mentioned in the literature for the first 
time (28). However, the methods to carry out 16S rRNA PCR and quantitative PCR (qPCR) 
screening of gnotobiotic isolators for contamination have not been described to date.   
 In this study, we outline techniques, programs and conditions that we optimized for 
screening gnotobiotic isolators for contamination utilizing PCR and qPCR assays with templates 
of murine fecal DNA and universal 16S rRNA primers that detect a broad range of bacterial 
species, as well as molecular sequencing of the 16S rRNA amplicons to identify contaminating 
bacterial species. Our PCR protocol is able to detect contamination in GF animals, but not in 
animals that have been deliberately colonized with selected microorganisms, as amplification of 
the 16S rRNA gene results in one band when the PCR products are run on a polyacrylamide gel. 
 Therefore, to screen selectively colonized animals for bacterial contamination, we 
utilized Random Amplification of Polymorphic DNA (RAPD) PCR. It has been suggested that 
with meticulous optimization of DNA concentrations, PCR conditions and reagents, RAPD PCR 
can be a reliable, sensitive and reproducible assay to generate high quality genomic DNA 
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profiles from various bacterial strains (29). Recently, RAPD PCR has been used to profile and 
discriminate different strains of Staphylococcus aureus (30), Bacillus cereus (31), Klebsiella 
pneumoniae (32), Lactobacillus paraplantarum (33), and Enterococcus species (30). However, 
there are only a few reports of RAPD PCR being conducted on bacteria isolated from fecal 
samples (35), with two studies reporting the typing of Bacillus subtilis (36) and Lactobacillus 
species (37) from the human gastrointestinal (GI) tract using RAPD PCR. 
 Here we describe our application of RAPD PCR, in addition to more classic PCR 
methods to evaluate the gnotobiotic and GF status respectively of our experimental rodents. 
Gnotobiotic facilities may use these techniques to screen isolators for bacterial contamination at 
their own institutions, as we currently do at the National Gnotobiotic Rodent Resource Center 
(NGRRC) at UNC-Chapel Hill (UNC).   
Results 
 Spectrophotometry. Following isolation of DNA from rodent fecal samples, total fecal 
DNA concentrations were measured using spectrophotometry (Fig. 5.1). While there were 
significant differences between DNA concentrations in putative GF fecal samples and 
spontaneously contaminated ex-GF fecal samples (p=0.0002), an overlap in DNA concentrations 
between these two groups rendered spectrophotometry insufficient for sterility screening. 
Differences between fecal DNA concentrations from putative GF and monoassociated or SPF 
mice were also statistically significant (p<0.0001), and we did not see any overlap with DNA 
concentrations obtained from GF mouse feces. When the DNA extraction protocol was run with 
water and no sample, DNA concentrations were between 2-7 ng/µl. 
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 Detection of bacterial contamination of GF animals using 16S rRNA PCR. DNA 
isolated from GF, gnotobiotic and SPF fecal samples served as templates in PCR assays 
amplifying the 16S rRNA gene. We blindly screened samples obtained from nine isolators at the 
NGRRC with PCR. The PCR results after gel electrophoresis revealed contamination in an 
isolator previously thought to be GF, (Fig. 5.2A, isolator 200; lane marked with a “C” for 
“contaminated”), because cultures and Gram stains of fecal samples derived from mice in this 
isolator did not reveal the contamination. The prominent PCR band from the fecal sample DNA 
from the contaminated isolator was about the same size and at least as dense as those from the 
positive control mice that were dual-associated with E. coli NC101 and E. faecalis OG1RF, (Fig. 
5.2A, isolator 158; lane marked “D” for “dual-associated”), or from mice colonized with specific 
pathogen-free (SPF) bacteria. The seven remaining fecal DNA samples collected from mice 
housed in putative GF isolators did not reveal 16S rRNA amplification (Fig. 5.2A, isolators 124, 
136, 166, 168, 180, 186 and 198; lanes marked by asterisks for GF), and Gram stain and cultures 
of feces from animals in these isolators likewise revealed no bacterial growth. It should be noted 
that there is a larger, much less intense band from isolator #200 as well, although we are unsure 
of its origin. We speculate that it could be random amplification of bacterial or mammalian 
DNA. We did not see this second amplicon from any other samples shown in Figure 2 or in any 
samples not shown in this manuscript.   
 We then blindly screened 10 additional NGRRC isolators using PCR, and included 
samples in our assay from isolators 124 and 180 that had previously been shown with PCR to be 
GF, in order to show that our screening results were reproducible, and also to serve as negative 
controls. Fecal DNA samples derived from mice housed in four gnotobiotic isolators produced 
detectable amplicons using the 16S rRNA PCR assay, including two isolators that contained 
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experimentally monoassociated mice, (Fig. 5.2B, isolators 106 and 112; lanes marked “M” for 
“mono-associated”) and two ex-GF isolators that had been recently determined to be 
contaminated by traditional culture and Gram staining (Fig. 5.2B, isolators 100 and 196; lanes 
marked “C” for “contaminated”). The eight remaining fecal DNA samples collected from mice 
housed in putative GF isolators did not reveal visually detectable 16S rRNA amplification (Fig. 
5.2B, isolators 102, 124, 134, 180, 182, 190, 194 and 202; lanes marked by asterisks for GF), and 
Gram stain and cultures of feces from mice in these isolators verified the lack of presence of 
bacteria in these animals. 
 Next, we blindly screened 14 mouse and two rat isolators at the Gnotobiotic Animal Core 
(GAC) at North Carolina State University (NCSU). Using 16S rRNA PCR, we confirmed the GF 
status of 15 of these isolators, (Fig. 5.2C, mouse isolators 1-3 and 5-14, and rat isolators 1-2; 
lanes marked by asterisks for GF), as well as the contaminated status of a known spontaneously 
contaminated ex-GF isolator (Fig. 5.2C, mouse isolator 4; lane marked by “C” for 
“contamination”). Cultures of fecal samples taken from mice in these isolators provided the same 
results as PCR. 
 qPCR quantitation of bacterial levels in experimental mice. To validate our PCR 
assay, we also used a qPCR assay to determine levels of bacteria in NGRRC and GAC 
gnotobiotic fecal samples by quantifying copies of the 16S rRNA gene per microgram of fecal 
DNA. We found that the 16S rRNA gene was not amplified to detectable levels in the 30 GF 
fecal samples that were also screened with PCR (Fig. 5.3). Meanwhile, spontaneously 
contaminated ex-GF samples identified by PCR, (from isolators #200, #100, and #196 from 
UNC and isolator #4 at NC State), SPF samples (5 samples included in PCR screening plus 5 
additional samples), and selectively colonized samples (samples from dual-associated isolator 
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#158 and monoassociated isolators #106 and #112 at UNC shown in PCR gels, along with a 
sample from a fourth monoassociated isolator at UNC not screened with PCR) contained 10
7
-10
8 
copies of the 16S rRNA gene per microgram of fecal DNA (Fig. 5.3).  
 Melting curves from qPCR assays provide valuable information about the specificity of 
the qPCR assay. Melting curves from our qPCR assays revealed that true amplification of the 
16S rRNA gene occurred at melting temperatures of 83° to 87°C (Fig. 5.4; panels b, c, d). No 
melting curve from GF samples is seen at these melting temperatures (Fig. 5.4; panel a). Finally, 
the two peaks seen in the melting curves of dual-associated fecal DNA samples (Fig. 5.4; panel 
c) most likely represent the individual melting curves of the 16S rRNA PCR products of DNA 
from the two organisms that were deliberately introduced to GF mice, E. coli NC101 and E. 
faecalis OG1RF. While melting curves provide information about qPCR assay specificity, they 
are not a reliable method to determine the number of OTUs colonizing an animal.  
 Chow PCR. To address the possibility that dead bacteria from autoclaved or irradiated 
chow may pass through the GI tract of GF animals and cause false positives when screening 
these animals for bacterial contamination using 16S rRNA PCR of fecal DNA, we sought to 
determine whether or not bacterial DNA that may or may not be present in food sources might be 
detectable by PCR. We tested several types of chow used in various NGRRC isolators using 
PCR. We did not detect the 16S rRNA gene from these samples with PCR (Fig. 5.5A) or qPCR 
(Fig. 5.5B) assays. 
 Identification of contaminating bacterial species by 16S rRNA sequencing. The 
bacterial species contaminating GF mice were identified by sequencing 16S rRNA gene PCR 
products. We were able to identify Staphylococcus lentus as the organism contaminating 
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formerly GF isolator 4 at NC State, and Paenibacillus glucanolyticus as the organism 
contaminating formerly GF isolator 100 at UNC. We also identified what may be the aerobic 
Gram positive rod Bacillus simplex as the contaminant in ex-GF isolator 196, which is included 
in Figure 2B, and in isolator 184, which was not included in our molecular screening. However, 
the % identity for these two sequences were only 94% and 95%, and coupled with the fact that 
one of the sequences is relatively short, we are unable to identify this particular organism with a 
high degree of confidence. By base pair (bp) match length, we refer to the number of bases that 
are shared between the sequence from the given DNA sample and the known 16S rRNA 
sequence of a bacterial species of note. Though weight of fecal samples and DNA concentrations 
are normalized and the DNA extractions are performed the same way each time with the same 
reagents, volumes, storage procedures, etc. we frequently see slight differences in read lengths 
that are probably related to the protocol and the quality of the DNA that remains at the end of 
purification. This explains the slightly different bp match lengths and % identity that we see for 
the two samples that are both presumed to be B. simplex. Monoassociated mice were confirmed 
to be colonized with E. coli and no contaminating organisms.  
 Detection of bacterial contamination in selectively colonized animals using RAPD 
PCR. RAPD fingerprinting revealed unique, reproducible fingerprints for DNA isolated from 
pure cultures of several strains of E. coli, as well as from several Lactobacillus species, 
Pseudomonas species and Staphylococcus species, Klebsiella pneumoniae, Listeria 
monocytogenes, and Salmonella typhimurium (not shown). Unique RAPD fingerprints of DNA 
isolated from pure cultures of E. coli NC101, E. coli K12, E. faecalis OG1RF, and Bacteroides 
vulgatus exhibited a high degree of similarity to fingerprints of fecal DNA from rodents 
monoassociated with each of these bacterial strains (Fig. 5.6A). Inoculation of E. coli NC101 
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monoassociated mice with E. faecalis OG1RF (and vice versa) was easily determined using this 
fingerprinting technique. The RAPD PCR profile of DNA isolated from E. coli NC101/E. 
faecalis OG1RF dual-associated mice was similar to that of DNA isolated from 50/50 and 75/25 
mixtures of pure cultures of E. coli NC101 and E. faecalis OG1RF (Fig. 5.6B). The 7 bacterial 
strains belonging to the simplified humanized microbiota (SIHUMI) cocktail demonstrated 
unique fingerprints. Each of these fingerprints was clearly identifiable when up to 4 constituent 
strains were mixed. RAPD PCR fingerprints of mixtures of E. coli LF82, R. gnavus ATCC 
29149, E. faecalis OG1RF and B. longum ATCC 15707 are shown in Figure 5.7.  
Discussion 
 The current primary methods of screening at most gnotobiotic facilities are culture and 
Gram staining, and while the advantages of these methods are that they are fairly inexpensive 
and they provide instantaneous results in the case of Gram staining, more objective and sensitive 
molecular methods of detecting gnotobiotic contamination are needed. In this study, we describe 
methods to isolate DNA from fecal samples of gnotobiotic rodents and screen for contamination 
using PCR and qPCR assays. The strategies we have developed use PCR assays with universal 
16S rRNA primers as an initial screen for gnotobiotic contamination and 16S rRNA qPCR as a 
means to confirm contamination by determining fecal bacterial concentrations in gnotobiotic 
animals. We have optimized conditions for these PCR and qPCR assays, including 10 ng DNA 
loading used in conjunction with 25-cycle PCR assays. Importantly, DNA isolated from chow 
did not amplify with these conditions nor did documented GF feces show positive results.  
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Using 16S rRNA PCR product sequencing, we identified an organism that may be Bacillus 
simplex contaminating two isolators previously judged to be GF. These discordant results 
illustrate the insensitivity and difficulty in interpretation of traditional culture and Gram stain 
screening methods. We validated our PCR method by blindly identifying E. coli that had been 
deliberately introduced into ex-GF isolators to monoassociate mice and also by identifying 
bacterial species in two isolators determined by Gram stain and/or culture results to be 
contaminated. Identifying contaminating species can be useful in determining the source of 
contamination, potentially preventing future breaches in sterility, and in investigating the 
biological effects or pathogenicity of a contaminating bacterial species. For example, we 
postulate that contamination in GAC isolator 4 by Staphylococcus lentus, a common skin 
organism, arose from a leak in a glove, while the contamination by spore formers B. simplex and 
Paenibacillus glucanolyticus originated from an autoclave malfunction. If multiple, unknown 
contaminants exist in a previously germ-free or selectively colonized isolator, cloning and 
sequencing of animal fecal DNA should be carried out to determine the identity of the 
contaminating microbes. 
 RAPD PCR can also assist in the more difficult detection of contamination in selectively 
colonized isolators. Detection of contamination in GF isolators is relatively straightforward with 
our proposed PCR and qPCR techniques. However, our study reveals that in mice colonized with 
one or two bacterial species, the microorganism(s) reach densities in the GI tract approaching 
that of the complex microbiota in SPF mice. Therefore, quantifying levels of fecal bacteria alone 
is not sufficient to determine whether or not contamination of a selectively colonized isolator has 
occurred. However, we have shown that RAPD PCR can be used to screen selectively colonized 
animals for contamination. RAPD PCR gels showing DNA from several bacterial species can be 
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quite complex and difficult to interpret, but we are confident that based on careful scrutiny, one 
can discriminate between at least 4 bacterial strains that are mixed together based on their unique 
RAPD fingerprints. 
 The advantages of using these molecular techniques compared to traditional culture and 
Gram stain approaches used to screen for contamination are many, including increased 
sensitivity in detecting anaerobic or uncultivable contaminants and more objective results that do 
not depend on Gram stain interpretation. These techniques also provide a definitive 
determination of the presence or absence of contamination, thereby preventing use of 
contaminated animals in scientific studies with subsequent wasted resources and results that 
cannot be interpreted. Finally, these methods permit the identification of contaminating bacterial 
species. The major disadvantages of these molecular methods are that they do not provide 
instantaneous results and they are performed at an increased cost compared to traditional, non-
molecular methods. Because of these limitations, we recommend the continued use of Gram 
staining and culturing for frequent, first-line screening in gnotobiotic facilities. However, in the 
case of un-interpretable or inconsistent results, in a situation of high suspicion of contamination 
despite negative results with traditional techniques, or perhaps before conducting large or 
lengthy experiments, we recommend using these PCR, qPCR and RAPD PCR techniques to 
definitively determine the presence or absence of contamination in gnotobiotic units (Fig. 5.8). 
 We are currently using the PCR assay described herein at the NGRRC at UNC to 
routinely screen gnotobiotic isolators for contamination, with increased sensitivity and 
specificity compared to Gram staining and culturing performed concurrently. We screen stable 
breeding isolators at NGRRC every 2-4 weeks with Gram stain and culture, and slightly less 
frequently with PCR. However, as a general rule, the more an isolator is being used, the greater 
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the risk of bacterial contamination, and hence the greater the frequency of both traditional and 
molecular screening should be. When active investigations are ongoing, ports are being opened, 
animals, food, water or bedding are being imported, or agents are being injected, PCR screening 
should be performed. In addition, it should be kept in mind that some mucosally-associated 
intestinal bacteria are not shed continuously in feces, with resultant insensitive monitoring of 
feces for bacterial contamination. Thus, sampling frequency absolutely plays an important role in 
detecting contamination, whether conventional or molecular techniques are utilized for 
screening. 
  While most microorganisms in the intestine are bacteria, members of Eukarya and 
Archaea are also present (38).
 
Abundant and diverse fungi have been identified in the murine 
intestine (39), and 0.8% of 536,112 unique genes identified in a metagenomic analysis of fecal 
samples taken from 124 healthy Europeans were archaeal
 
(40). Our bacterial-specific 16S rRNA 
primers screened only for bacterial contamination. It may be possible to screen for eukaryotic 
microorganisms as well, however. Recently, methods were described for detecting fungi in 
complex microbial communities using specialized DNA extraction techniques and qPCR (41). 
Primer pairs that amplify rRNA from Archaea
 
have also been described (42), but this is beyond 
the scope of this study. 
 In summary, we describe PCR techniques and conditions using universal 16S rRNA 
primers to screen for bacterial contamination of GF animals. qPCR assays with the same primers 
can be used to determine bacterial concentrations in respective GF animal fecal samples. 
Sequencing of 16S rRNA PCR products can be used to identify contaminating bacterial species 
to potentially determine the source of a GF contamination, or to investigate the biological effects 
or pathogenicity of a contaminating species. We have developed an optimal RAPD protocol that 
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can serve as a highly sensitive and reproducible method to screen selectively colonized 
gnotobiotic animals for contamination that does not require the use of specialized or expensive 
equipment. Finally, we suggest a cost-effective strategy to screen gnotobiotic animals for 
contamination by a combination of traditional and molecular methods.   
Materials and methods 
 Experimental design (Fig. 5.9). Fresh fecal pellets were collected from rodents housed 
in GF, spontaneously contaminated ex-GF, and selectively colonized isolators at the NGRRC at 
UNC and the GAC of the Center for Gastrointestinal Biology and Diseases (CGIBD) at NCSU, 
and SPF rooms. The respective colonization status of each sample was not revealed to the 
investigator performing the analyses until after completion of the testing. Samples from all 
known contaminated isolators were purposefully included in the study. DNA was isolated from 
fecal samples and used as templates for 16S rRNA PCR and qPCR assays. Selected 16S rRNA 
PCR products were sequenced to identify contaminating bacterial species. 
 Extraction of DNA from fecal samples. DNA was extracted from fecal samples using a 
phenol/chloroform extraction method combined with physical disruption of bacterial cells and a 
DNA clean-up kit (Qiagen DNeasy Blood and Tissue Kit). Briefly, fresh fecal pellets were 
collected from mice and rats. Stool was weighed, normalized to 200 mg per sample, suspended 
in 750 μl of sterile bacterial lysis buffer (200 mM NaCl, 100 mM Tris [pH 8.0], 20 mM EDTA, 
20 mg/ml lysozyme) and incubated at 37°C for 30 minutes. Next, 85 μl of 10% sodium dodecyl 
sulfate (Gibco) and 40 μl of 20 mg/ml proteinase K (Qiagen) were added to the mixture, which 
was then incubated at 65°C for 30 minutes. 300 mg of 0.1 mm zirconium beads (BioSpec 
Products) were added and the mixture was homogenized in a bead beater (BioSpec Products) for 
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two minutes. The homogenized mixture was cooled on ice and then centrifuged at 14,000 rpm 
for five minutes at 4°C. The supernatant was transferred to a new 1.5 ml microfuge tube and 
fecal DNA was further extracted by phenol/chloroform/iso-amyl alcohol and chloroform/iso-
amyl alcohol, as described. Following extraction, the supernatant was precipitated by ethanol at -
20°C for one hour. Precipitated DNA was suspended in DNase-free H2O and then cleaned using 
the Qiagen DNeasy Blood and Tissue Kit per the manufacturer’s instructions. Purified fecal 
DNA was eluted in 50 μl volumes. The concentration of each DNA extract was determined by 
spectrophotometric measurement using a Nanodrop 1000 spectrophotometer (Thermo Fisher 
Scientific).   
 Chow was removed from several gnotobiotic isolators, placed in sterile plastic bags, 
crushed with a hammer, weighed and normalized to approximately 200 mg per sample.  DNA 
was then extracted using the above methods. 
 PCR amplification. 10 ng fecal/chow DNA templates in conjunction with the following 
PCR conditions resulted in optimal specificity and sensitivity: 95°C for 5 minutes, then 25 cycles 
of 95°C for 30 seconds, 52°C for 30 seconds, and 72°C for 45 seconds. These cycles were 
followed by 72°C for seven minutes. Reactions were carried out in a final volume of 25 μl 
containing 1 μl of DNA template, 1.5 μl MgCl2, 1 μl of each primer, 2.5 U Taq polymerase 
(Invitrogen), 80 μM each of dATP, dCTP, dGTP and dTTP in 10 mM Tris/HCl buffer (pH 8.3), 
50 mM KCl and 0.001% (w/v) gelatin. “Universal” primers were used to amplify the genes 
encoding 16S rRNA from all bacterial groups: Forward primer, UniF (5’-
GTGSTGCAYGGYTGTCGTCA-3’) and reverse primer, UniR (5’-
ACGTCRTCCMCACCTTCCTC-3’) (18). These Universal primer sequences are 
complementary to highly conserved sequences within the E. coli 16S rRNA gene, which is 1542 
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nucleotides. UniF is complementary to nucleotides 1047 through 1067, while UniR is 
complementary to nucleotides 1174 through 1194. Amplicons generated using these primers are 
147 base pairs. PCR assays were performed in a GeneAmp PCR system 9700 thermocycler 
(Applied Biosystems) under various conditions to optimize results. Reaction products were 
stored at 4°C. Amplified products were separated on a 1% (m/v) agarose (Invitrogen) gel in 
Tris/acetate/EDTA buffer (40 mM Tris/acetate, 1 mM EDTA, pH 8.0) containing 0.5 μg 1% 
ethidium bromide. PCR products were then visualized under UV light.         
 qPCR assays. qPCR assays were performed using universal primers that amplify the 
genes encoding 16S rRNA from all bacterial groups (see above) to quantitate copies of the 16S 
rRNA gene per μg of fecal DNA. qPCR assays were conducted in 96-well plates on a Realplex 
Mastercycler thermocycler (Eppendorf)  Each qPCR assay was carried out in a final volume of 
12 μl and contained: 6 μl SYBR Green qPCR Master Mix (Qiagen), 0.5 μl of each primer and 1 
μl of DNA template.  qPCR conditions were as follows: 95°C for ten minutes, followed by 40 
cycles of 95°C for 15 seconds, 60°C for 20 seconds, and 72°C for one minute. Each plate 
included triplicate reactions per DNA sample and the appropriate set of standards. qPCR 
standards were generated by PCR amplification of the purified target 16S rRNA genes from a 
positive control Escherichia coli NC101 strain used in our monoassociation studies
 
(43). Melting 
curve analysis of PCR product amplification was conducted following each assay to confirm that 
each fluorescence signal originated from specific PCR products and not from primer-dimers or 
other artifacts. All qPCR plates included a “no template” negative control for each primer set.        
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 Bacterial identification by 16S rRNA gene sequencing. We identified contaminating 
bacterial species by sequencing the 16S rRNA PCR products obtained from positive reactions 
using primers that amplify the genes encoding 16S rRNA from all bacterial groups to generate 
longer products for sequencing, 8F (5’-AGAGTTTGATCCTGGCTCAG-3’) and 1391R (5’-
GACGGGCGGTGWGTRCA-3’) (18). After purifying the resulting 16S rRNA PCR products 
with a Qiagen clean-up kit, the products were sequenced by the UNC Automated DNA 
Sequencing Facility using Sanger sequencing, and the results were cross-referenced with The 
National Center for Biotechnology Information (NCBI) Reference Sequence (RefSeq) database 
(44).  
 RAPD PCR assays. We used a single random oligonucleotide 3H primer (5’-
AAGCTTGATTGCCC-3’) and optimized RAPD PCR conditions. RAPD PCR reactions were 
carried out in a final volume of 25 μL containing 10 ng of DNA template, 2 U of Taq 
Polymerase (Invitrogen, Carlsbad, CA), 1.5 μL MgCl2 (50 mM), 2.5 μL primer (20 μM) and 2 μL 
dNTPs (Promega, 10 mM). The PCR reactions were carried out in a GeneAmp PCR system 9700 
thermocycler (Applied Biosystems, Foster City, CA) using the following conditions: 95°C for 5 
minutes, 36 cycles of 95°C for 1 minute, 36°C for 1 minute and 72°C for 2 minutes followed by 
one cycle of 72°C for 7 minutes for completion of DNA extension. PCR products were stored at 
4°C. Finally, 10 μL of each amplified product was separated on a 2% (w/v) agarose (Invitrogen, 
Carlsbad, CA) gel in Tris/acetate/EDTA buffer (40 mM Tris/acetate, 1 mM EDTA, pH 8.0) 
containing 0.5 μg 1% ethidium bromide. The products were then visualized under UV light. 
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 We generated fingerprints from cultures of 30 relevant bacterial strains. To test 
applicability to gnotobiotic screening, we conducted RAPD PCR assays on DNA isolated from 
cultures of defined intestinal bacterial species as well as fecal samples of mice monoassociated 
with the same respective bacterial strains. We performed RAPD PCR on fecal DNA from 
monoassociated mice before and after inoculation with a second bacterium. Finally, we tested 
RAPD PCR’s ability to discern between combinations of the 7 members of the SIHUMI cocktail, 
E. coli LF82, Ruminococcus gnavus ATCC 29149, Enterococcus faecalis OG1RF, 
Bifidobacterium longum ATCC 15707, Faecalibacterium prausnitzii A2-165, Lactobacillus 
plantarum WCFS1, and Bacteroides vulgatus ATCC 8482.    
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Figure 5.1. Fecal DNA concentrations as measured by spectrophotometry. The fecal DNA 
concentrations in putative germ-free (GF) rodents, represented by diamonds in the second lane 
from the left, are significantly different from fecal DNA concentrations in spontaneously 
contaminated ex-GF rodents (squares; middle lane). However, there was slight overlap in the 
respective fecal DNA concentrations between these two groups. This rendered 
spectrophotometry insufficient as a screening tool for bacterial GF contamination. Differences in 
fecal DNA concentrations between putative GF and monoassociated (circles; second from right) 
and specific pathogen-free (SPF) (diamonds; far right) mice were also significant. No 
sample=DNA extraction protocol run without sample present; contam.=spontaneously 
contaminated, ex-GF; mono.=monoassociated; *p=0.0002; **p=0.0001.  
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Figure 5.2. Agarose gel electrophoresis of PCR products of DNA isolated from rodent feces. (A): 
8 National Gnotobiotic Rodent Resource Center (NGRRC) isolators that were thought to be GF 
were screened with 16S ribosomal RNA (rRNA) polymerase chain reaction (PCR) of mouse 
fecal DNA. Bacterial contamination was detected in isolator 200. Dual-associated mouse fecal 
DNA from isolator 158, SPF mouse fecal DNA and Escherichia coli genomic DNA served as 
positive controls for these PCR assays. (B): 12 NGRRC gnotobiotic isolators were blindly 
screened with 16S rRNA PCR of mouse fecal DNA. Fecal DNA isolated from mice from four 
isolators amplified: Fecal DNA from mice in isolators 106 and 112, which were subsequently 
revealed to be monoassociated, and fecal DNA from mice in isolators 100 and 196, which were 
ex-GF isolators that had been recently determined to be spontaneously contaminated. SPF mouse 
fecal DNA and E. coli genomic DNA served as positive controls for these PCR assays. (C): 14 
mouse (lanes marked 1-14) and two rat (lanes marked Rat1 and Rat2) isolators at the Gnotobiotic 
Animal Core (GAC) of the Center for Gastrointestinal Biology and Disease (CGIBD) at North 
Carolina State University were blindly screened with 16S rRNA PCR of rodent fecal DNA. The 
GF status of 15 of these isolators was confirmed, as was the recently-contaminated status of ex-
GF isolator #4. E. coli genomic DNA served as positive controls for these PCR assays. STD=100 
base pair ladder; *=GF; C=spontaneously contaminated ex-GF; D=dual-associated; E. coli=E. 
coli genomic DNA; H20=water negative control template; M=monoassociated. 
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Figure 5.3. Bacterial levels in gnotobiotic rodent fecal samples determined by qPCR. 
Quantitative PCR (qPCR) assays were utilized to determine bacterial levels in gnotobiotic fecal 
samples by quantitating copies of the 16S rRNA gene per microgram of fecal DNA. The 16S 
rRNA gene was not amplified to detectable levels in GF mice (n=30). There were on the order of 
10
7
-10
8 
copies of the 16S rRNA gene per microgram of fecal DNA in spontaneously 
contaminated ex-GF mice (n=4), SPF mice (n=10), and selectively colonized mice (n=4). 
BDL=below detectable limits; contam.=contaminated ex-GF; sel. col.=selectively colonized; 
H20=water negative control template.  
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Figure 5.4. 16S rRNA qPCR melting curves from gnotobiotic and SPF mouse fecal DNA. 
Melting curves from qPCR assays reveal that true amplification of the 16S rRNA gene occurs at 
melting temperatures of 83° to 87°C (B-D). No amplification from GF mouse fecal DNA is seen 
at these melting temperatures (A).  
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Figure 5.5. PCR and qPCR screening of animal chow for bacterial DNA. DNA was isolated from 
several types of chow used in various NGRRC isolators, and there was no detectable 
amplification from these samples with 16S rRNA PCR (A) or qPCR (B). E. coli genomic DNA 
served as a positive control for the PCR assay. 
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Figure 5.6. Distinguishing different individual bacterial strains by RAPD PCR fingerprints. (A) 
Unique rapid amplification of polymorphic DNA (RAPD) fingerprints of DNA isolated from 
pure cultures of E. coli NC101, E. coli K12, Enterococcus faecalis OG1RF, and Bacteroides 
vulgatus exhibited a high degree of similarity to fingerprints of fecal DNA from rodents 
monoassociated with each of these bacterial strains. (B) Inoculation of E. coli NC101 
monoassociated mice with E. faecalis OG1RF (and vice versa) was easily determined using 
RAPD PCR. The 2
nd
 lane from the left shows RAPD PCR products from DNA isolated from 
pure culture of E. faecalis. The second lane from the right shows RAPD PCR products from 
DNA isolated from pure culture of E. coli. Lanes 3, 4 and 5 show mixtures of RAPD PCR 
products of E. faecalis and E. coli pure culture DNA. The 50/50 mixture of E. faecalis and E. 
coli DNA RAPD PCR products in lane 4 matches the fingerprint of DNA isolated from E. 
faecalis/E. coli dual-associated mice, shown in the far right lane. Lanes 3 and 5 show RAPD 
PCR profiles of DNA isolated from 75/25 mixtures of E. faecalis/E. coli and E. coli/E. faecalis, 
respectively. Cult=pure culture DNA; fec=fecal DNA; Ef=Enteroccous faecalis pure culture 
DNA; Ec=E. coli pure culture DNA.  
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Figure 5.7. Distinguishing different bacterial strains in complex microbial communities using 
RAPD PCR. The 7 bacterial strains belonging to the SIHUMI cocktail demonstrated unique 
fingerprints. Each of these fingerprints was clearly identifiable when up to 4 constituent strains 
were mixed. From left to right after the ladder on the left side, E. coli (blue), Ruminococcus 
gnavus (red), E. faecalis (green) and Bifidobacterium longum (orange) are shown, followed by 
combinations of two, three or four of the respective strains. Unique bands for each bacterium are 
highlighted by appropriately colored boxes, including two bands that are unique to E. coli.   
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Figure 5.8. Gnotobiotic unit contamination screening algorithm. The continued use of 
inexpensive Gram staining and culturing for weekly detection of bacterial contamination of GF 
animals is recommended. However, when Gram stain or culture results are difficult to interpret 
or inconsistent, isolator portals are opened, a compromise in a glove, sleeve, or isolator wall 
occurs, an autoclave malfunction is diagnosed, or a large scale experiment is planned, it is 
recommended that these PCR and qPCR techniques be used to definitively determine the 
presence or absence of contamination in GF units. RAPD PCR can be used to screen selectively 
colonized animals for contamination. 
 
 
133 
 
 
Figure 5.9. Experimental design. DNA was isolated from GF rodent fecal samples and used as 
templates for PCR assays using universal bacterial 16S rRNA primers. DNA was similarly 
isolated from selectively colonized rodent fecal samples and used as templates for RAPD PCR 
assays. 
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CHAPTER 6: RECIPROCAL HOST-MICROBIAL INTERACTIONS MEDIATE THE 
RADIATION GASTROINTESTINAL SYNDROME
6
 
Introduction 
 “Radiation gastrointestinal (GI) syndrome”, characterized by epithelial apoptosis with 
breaches in the small intestinal and colonic mucosa, translocation of commensal intestinal 
bacteria and sepsis, can ensue following nuclear power plant accident, terrorist attack, space 
exploration, medical error, or appropriately fractionated dosing of therapeutic radiation in people 
whose tissues are radiosensitive (1).
 
70% of all cancer patients receive radiation as a component 
of their disease treatment, and radiotherapy plays a central role in 25% of all cancer cures (2). 
However, 80% of patients who receive therapeutic radiation experience side effects associated 
with acute radiation enteropathy, and 10-21% experience severe acute intestinal toxicity 
necessitating cessation of treatment (1). Concomitant chemotherapy can improve survival, but 
increases intestinal toxicity risk. The rapidly proliferating mucosal lining of the intestinal tract is 
highly radiosensitive, and epithelial cell apoptosis results in abdominal pain, nausea, vomiting 
and diarrhea. Yet, the pathophysiology of the radiation GI syndrome is poorly understood, few 
therapeutic strategies exist, and there is no FDA-approved treatment (1). 
 The human intestinal mucosa constantly contacts a complex microbial community or 
“microbiota” that contains up to 100 trillion (1014) microorganisms belonging to more than 1,000 
“species-level” phylotypes (3). Most of these phylotypes are bacteria belonging to just a few 
                                                          
6
 This chapter is part of the following manuscript currently being prepared for submission: Packey CD, Maharshak 
N, Shanahan MT, Jobin C, Keku TO, Plevy SE, Carroll IM, Sartor RB. Reciprocal host-microbial interactions mediate 
the radiation gastrointestinal syndrome.  
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phyla (4). The commensal gut microbiota provides many crucial functions to the host, including 
influencing the development and maintenance of a healthy immune system (5). While the 
composition of the adult intestinal microbiota is relatively stable, it undergoes dynamic changes 
in response to certain environmental factors (6). Dysbiosis, the deviation of a microbial 
community from its normal state, may be associated with functional changes in the host that 
predispose to disease development (7). Changes in the composition of the enteric microbiota 
have been associated with a number of diseases including inflammatory bowel diseases (IBD), 
diabetes mellitus, obesity, asthma, and allergic, cardiovascular and neurologic disorders (8). 
 To date, studies exploring the pathogenesis of radiation intestinal injury have 
predominantly focused on responses of the host intestinal epithelium (9), endothelium (10), or 
both (11). The role of the microbiota has received considerably less attention. However, host 
intestinal radiation responses have been linked to bacterial component-stimulated innate 
signaling pathways (12, 13). Investigations that clarify how intestinal microbial populations 
impact radiation enteropathy are badly needed (1), as results can direct studies to identify 
antibiotics, probiotics, prebiotics and bacterial-derived peptides and byproducts that improve 
normal tissue radioresistance. We used gnotobiotic mice to demonstrate that commensal 
microbiota facilitate intestinal epithelial cell (IEC) homeostatic mechanisms early in the 
radiation response, but later contribute to the pathogenesis of the radiation GI syndrome. We 
subsequently employed several molecular 16S ribosomal RNA (rRNA)-based techniques to 
characterize the kinetics of a profound radiation-induced dysbiosis in mucosal and luminal 
communities in several regions of the small intestine and colon, and to show that these 
microbiota compositional shifts were largely independent of inflammation and dietary changes. 
Cecal content transplantation and selective colonization experiments in germ-free recipients 
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demonstrated that intestinal dysbiosis and Escherichia coli directly impact the host response to 
radiation. Finally, we showed that commonly used probiotic and antibiotic treatments confer 
protection from the radiation GI syndrome by inducing small intestinal antimicrobial peptides 
(AMPs) and/or promoting eubiosis. 
Results 
 The enteric microbiota are necessary for early death from the radiation GI 
syndrome, yet contribute to homeostatic intestinal epithelial cell radiation responses. Germ-
free (GF) mice had lower clinical scores and prolonged survival compared to specific pathogen-
free (SPF) mice following exposure to 15 Gy (Fig. 6.1a). 15 Gy is the radiation dose that 
universally causes the GI syndrome in mice bred and housed in our facilities (Supplementary 
Fig. 6.1a, b). To assess the contribution of the microbiota to host IEC radiation responses, we 
exposed GF and SPF mice to 15 Gy total body irradiation and compared the number of apoptotic 
and proliferating IECs in jejunal and cecal crypts at 0, 6, and 24 hours after irradiation. These 
time points were selected based on our time course studies evaluating radiation-induced IEC 
apoptosis (Supplementary Fig. 6.1c, d) and proliferation (Supplementary Fig. 6.1e) in SPF mice. 
SPF mice showed fewer apoptotic IECs than GF mice, in the jejunum (Fig. 6.1b) and in cecal 
crypts (Fig. 6.1c), at 6 hours post 15 Gy, as assessed histologically. Bromodeoxyuridine (BrdU) 
immunohistochemistry (IHC) revealed that SPF mice also had more robust IEC proliferative 
responses than GF mice at 6 hours after radiation, both in the jejunum (Fig. 6.1d) and cecum 
(Supplementary Fig. 6.1f).  
 Radiation induces profound intestinal dysbiosis. To test the hypothesis that radiation 
induces a dysbiosis of the commensal microbiota that could contribute to the pathogenesis of the 
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radiation GI syndrome, we determined mucosal and luminal bacterial composition at three 
different locations of the small intestine and colon of untreated or radiation-exposed mice using 
16S rRNA-based 454 pyrosequencing. First, we calculated and compared average weighted and 
unweighted UniFrac distances. A global analysis of complex bacterial communities from the 
mucosa of the small intestine and colon of healthy control mice and mice exposed to radiation 
indicated that radiation profoundly affected intestinal bacterial community structure (Fig. 6.2a). 
Separate clustering between bacterial communities in healthy control mice and mice exposed to 
radiation was seen in the jejunum mucosa, cecum mucosa, cecum lumen, and distal colon 
mucosa (Fig. 6.2c, d, e, f; Supplementary Fig. 6.2a). Comparison of average UniFrac distances, 
or β-diversity, showed a significant increase in mice exposed to radiation compared to unexposed 
mice, in the small intestine, cecum and distal colon (Fig. 6.2b), indicating that the microbiota of 
irradiated mice are more dissimilar to each other. Hierarchial clustering on operational 
taxonomic units (OTUs) revealed that samples clustered separately based on exposure to 
radiation or lack thereof, in the jejunum mucosa, cecum mucosa, cecum lumen, and distal colon 
mucosa (Supplementary Fig. 6.2b). Fecal bacterial communities from mice exposed to radiation 
also clustered separately from those of healthy control mice by terminal-restriction fragment 
length polymorphism (T-RFLP) analysis (Supplementary Fig. 6.2c), a complementary 
fingerprinting method. Finally, we assessed bacterial richness, or α-diversity, by OTU rarefaction 
and found that richness was higher after radiation in the cecum mucosa, cecum lumen and distal 
colon mucosa and lower in the jejunum mucosa (Supplementary Fig. 6.2d). Increases in both β-
diversity and α-diversity after radiation implicate that the intestinal microbiota are more variable 
in evenness and composition among irradiated mice. Collectively, these results demonstrate that 
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a profound intestinal dysbiosis ensued in the small intestine and colon of mice following 
radiation exposure. 
Radiation exposure results in decreased abundance of intestinal Firmicutes and increased 
Proteobacteria concentrations. To evaluate the effect of radiation on the abundance of specific 
members of the gut microbiota, we utilized deep sequencing and quantitative PCR (qPCR) to 
determine the number of different bacterial groups in each intestinal sample by using 3% 
dissimilarity between 16S rRNA gene sequences as an indicator of a “species level” OTU. The 
abundance of key intestinal bacterial taxa, ranging from phylum to species and identified by 16S 
rRNA V1-V3 region OTU sequence alignments, differed between healthy control mice and mice 
exposed to radiation. At the phylum level, radiation exposure significantly increased levels of 
intestinal Proteobacteria, with concomitant decreases in members of Firmicutes (Fig. 6.3a, 
Supplementary Fig. 6.3a, b, c). Intestinal Escherichia coli, a representative Proteobacteria 
member, increased following radiation, as shown by qPCR (Fig. 6.3b) and 454 pyrosequencing 
(data not shown). In contrast, members of the Lactobacillus genus were decreased in the small 
intestine and colon following radiation, as shown by 454 pyrosequencing (Fig. 6.3c) and 
confirmed by qPCR (Fig. 6.3d). The majority of Lactobacillus species in the C57BL/6 mouse gut 
were Lactobacillus reuteri; this species was almost eradicated 5 days following radiation 
exposure (Fig. 6.3e). Importantly, we showed that radiation-induced shifts in key intestinal 
bacterial groups, including E. coli and Lactobacillus species, occur within the first 24 hours, days 
before maximal epithelial injury and sepsis ensue (Supplementary Fig. 6.3d). In addition, 
radiation suppresses appetite. Therefore, we showed that dysbiosis following radiation is largely 
independent of reduced dietary intake by describing significant shifts in members of the 
commensal microbiota 48 hours after radiation but negligible shifts in E. coli (Supplementary 
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Fig. 6.3e) and Lactobacillus species (Supplementary Fig. 6.3f) in cage-mate littermates 48 hours 
after initiation of severe dietary restriction. 
The intestinal microbiota composition directly impacts clinical responses to radiation. After 
determining that radiation induces an intestinal dysbiosis, we sought to establish whether these 
compositional changes in the microbiota are primary events that drive the radiation GI syndrome. 
Recent studies have shown that colitis (14) and susceptibility to chemical-induced colitis (15) 
can be transmitted with transfer of microbiota alone. To investigate whether changes in the gut 
microbiota are a cause or consequence of the radiation GI syndrome, we transplanted freshly 
obtained 1) post-irradiation cecal contents or 2) healthy control cecal contents into GF recipient 
mice to preserve the complex composition of the transferred organisms. In these studies, any gut 
microbial dysbiosis present in the host would be transferred to the recipient (14). The 
transplanted post-irradiation microbiota conferred accelerated onset of radiation-induced 
morbidity and mortality compared to transplanted microbiota from healthy control mice (Fig. 
6.4a). This suggests that altered gut microbiota observed in mice exposed to irradiation 
contribute to the development of the radiation GI syndrome. When this experiment was repeated 
with SPF recipient mice, we observed similar results (data not shown). Next, we compared 
radiation responses of GF mice selectively colonized with selected species that are increased 
following radiation. E. coli mono-associated mice had increased morbidity and accelerated 
mortality compared to GF mice after 15 Gy; Enterococcus faecalis mono-associated mice 
exhibited intermediate susceptibility to the GI syndrome (Fig. 6.4b). These results indicate that 
individual constituents of the intestinal microbiota differentially contribute to the pathogenesis of 
the radiation GI syndrome. 
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 The antibiotic ciprofloxacin promotes eubiosis and mitigates the radiation GI 
syndrome. Because antibiotics modulate microbiota composition, we tested the ability of several 
clinically-relevant antibiotics and antibiotic combinations to alter the radiation phenotype. One 
of the tested antibiotics, the fluoroquinolone ciprofloxacin (cipro), mitigated radiation intestinal 
injury, prolonged survival (Fig. 6.5a), and prevented radiation-induced dysbiosis in the small 
intestine and colon (Fig. 6.5b). Cipro attenuated radiation-induced increases in Proteobacteria 
and decreases in Firmicutes (Fig. 6.5c). Proliferation of intestinal E. coli following radiation was 
prevented by cipro administration (Fig. 6.5d, e), as were other alterations in the microbiota 
composition. Cipro also prevented increases in microbial diversity in the cecum and colon (data 
not shown).  
 The probiotic VSL#3 induces antimicrobial peptide expression and confers 
protection from the radiation GI syndrome. Combination probiotic VSL#3 treatment reduced 
the incidence and severity of radiation-induced diarrhea in one double-blind, placebo-controlled 
trial (16). Therefore, we tested efficacy of protection and mechanisms by which VSL#3 may 
confer radioprotection using our mouse model. Administration of VSL#3 significantly reduced 
the severity of colitis in mice exposed to lethal irradiation (Fig. 6.6a) and prolonged survival 
(Fig. 6.6b). Radiation reduced jejunal and ileal expression of α-defensins, small intestinal Paneth 
cell-specific AMPs, both at the mRNA (Fig. 6.6c) and protein (Fig. 6.6d, Supplementary Fig. 
6.4) levels. This may be related to excessive radiation-induced apoptosis in the crypt cell 
positions of the Paneth cells in the small intestine (Supplementary Fig. 6.5). VSL#3 induced α-
defensin expression in the jejunum and ileum (Fig. 6.6e), and also promoted eubiosis 
(Supplementary Fig. 6.6a, b, c). 
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Discussion  
 Our study shows the presence of a pathogenetically important enteric dysbiosis in the 
radiation GI syndrome and demonstrates that commensal bacteria have both protective and 
deleterious roles in this condition. Protective roles include attenuation of apoptosis and 
enhancement of proliferative responses of IECs in the first 6-24 hours after radiation exposure, 
which augment previous observations that the microbiota protect against acute dextran sodium 
sulfate (DSS) and radiation-induced intestinal injury through toll-like receptor (TLR) and NF-
κB-mediated pathways (13, 17, 18). Commensal microbiota subsequently contribute to later 
onset radiation-induced mortality through sepsis, consistent with observations by Crawford and 
Gordon (19).  
 Radiation-induced alterations in the small intestinal and colonic microbiota mimic those 
seen in IBD (Supplementary Table 6.1), as demonstrated by high throughput sequencing and 
validated by qPCR. Both inflammation (20) and diet (21) can alter the composition of the 
intestinal microbiota. We show that radiation induces dysbiosis within the first 24 hours after 
exposure, days before inflammation ensues histologically or as measured by intestinal secretion 
of inflammatory cytokines, and the dysbiosis is independent of reduced dietary intake, which can 
occur following radiation exposure secondary to appetite suppression.  
 Numerous reports submit that perturbing the gut ecosystem results in dynamic changes in 
which species that are well adapted to changed environment (22)
 
or perturbation in general
 
(23) 
flourish. We identify three species within the Proteobacteria phylum that have been associated 
with IBD, E. coli, Klebsiella pneumoniae (24), and Pseudomonas fluorescens (25), that bloom in 
the intestine following radiation. Our selective colonization experiments demonstrate that 
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commensal E. coli directly impact the host radiation phenotype, more so than an E. faecalis 
strain. This is important since specific bacterial subsets can selectively induce experimental 
colitis in mice, whereas other subsets do not (26), and individual commensal bacteria can cause 
intestinal inflammation in an age- and site-specific manner (27).  
 The ratio of pathogenic to protective enteric species is considered an important 
determinant of intestinal inflammation versus homeostasis. We demonstrated that not only does 
radiation exposure enrich Proteobacteria species, but also leads to diminished levels of 
Lactobacillus reuteri and Bifidobacterium species, bacteria that possess established anti-
inflammatory properties in the gut and are decreased in human IBD (28, 29). Within the 
Firmicutes phylum, members of the Clostridium coccoides subgroup were also significantly 
decreased following radiation. These colonic regulatory T cell-inducing bacteria (30) are also 
less abundant in IBD patients than in healthy subjects (31). It has been proposed that loss of 
Faecalibacterium prausnitzii, a Firmicute whose low abundance is linked to postoperative 
relapse of Crohn’s disease (32), is an important determinant of intestinal disease activity, but 
levels of this bacterium were not altered in irradiated mice.  
 Three known “autobionts,” commensal bacteria that directly influence host immune cell 
homeostasis or function (5), were among the most significantly altered intestinal species 
following radiation. Bacteroides fragilis, a species that expresses a protective membrane 
polysaccharide that stimulates IL-10-producing Foxp3+ regulatory T cells (33) and that is 
increased in IBD patients (34), was more prevalent following radiation. Conversely, bacteria that 
induce regulatory T cell (C. coccoides)
 
(30) and Th17 cell (SFB) (35) differentiation were 
decreased. Finally, we describe both increased bacterial β-diversity (diversity between groups) 
and α-diversity (diversity within a group), in the cecum and colon following radiation. Increased 
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vaginal bacterial diversity has been associated with disease in that location (36), although 
decreased diversity of commensal microbiota typically accompanies active IBD (31).
 
Understanding microbial diversity is important because high species diversity can enhance 
ecosystem functioning (37), although higher diversity does not always have this effect (38). 
Increased bacterial diversity following radiation could be part of host and/or microbial 
compensatory responses. 
 
 Our cecal content transplantation to gnotobiotic animals demonstrated that dysbiotic 
microbiota predisposes mice to accelerated death from the radiation GI syndrome. Importantly, 
our data verify that the radiation GI syndrome is caused by bacteria found in healthy hosts. These 
results may facilitate the ability to predict radiation induced-injury based on microbiota 
composition, and provide a rationale for restoring normal microbiota with specific interventions 
to prevent injury or reestablish health in patients receiving therapeutic radiation or in people 
accidentally exposed to radiation. While transplantation of feces from normal subjects treats 
Clostridium difficile infection (39)
 
and may treat radiation enteropathy based on our data, we 
identified an antibiotic, ciprofloxacin, and a combination probiotic, VSL#3, that mitigate the 
radiation GI syndrome in mice by promoting eubiosis, precluding the need for intestinal content 
transplantation. We propose that VSL#3 promotes eubiosis and protects the host from the 
radiation GI syndrome by stimulating expression of α-defensins, Paneth cell-produced AMPs 
that are impaired in IBD (40).
 
Since other AMPs promote the spatial segregation of the intestinal 
microbiota (41), α-defensins could regulate microbiota composition and protect against mucosal 
bacterial translocation. 
 The presence of major microbial clustering patterns at body sites including the GI tract 
(42) provides new ways to classify disease risk based on microbiota composition. Substantial 
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progress has been made in developing the tools for inquiry and in defining overarching concepts, 
but studying model animal systems with strong phenotypes is essential to advance this field (8). 
We have identified qualitative and quantitative kinetic changes in specific bacterial components 
of the gut microbiota following radiation in biologically-important mucosal and luminal 
compartments along the longitudinal axis of the small intestine and colon. This comprehensive 
spatial and temporal information will help guide region-specific clinical trials and inform 
personalized medicine (42)
 
based on individual microbial profiles. Our species-level 
characterization of the intestinal bacterial communities following radiation facilitates future 
studies using techniques such as metagenomic sequencing and metabolomics that will describe 
the functional diversity in these communities. 
 There is an immediate need to develop easily administered radioprotectants or mitigators 
with few side effects for first responders at nuclear accidents (43) and for astronauts on long-
term space missions. Development of intestinal radioprotectants has primarily focused on 
antioxidants (44), modifiers of inflammation (45), growth factors (46), and regulators of IEC 
apoptosis (47), and has generated very modest results to date. Our results indicate that selectively 
manipulating the intestinal luminal and/or mucosal microbiota holds promise for preventing and 
treating radiation intestinal injury in humans. Our mouse model avoids limitations of human 
investigations by standardizing the diet during sampling and accessing microbiota in proximal 
intestinal regions. This approach can identify tractable therapeutic manipulations for 
countermeasures against accidental or therapeutic radiation exposure. These results may also 
have important implications for cancer therapy by limiting healthy tissue toxicity, thereby 
improving radiation efficacy and survival rates as well as potentially impacting radiation 
sequelae such as fibrosis, ulcerations, fistulas, obstruction or perforation. However, death from 
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radiation is complicated, involving failure of multiple organs (43), so optimal radiation 
countermeasures will require combined approaches, including ones that target the intestinal 
microbiota. 
Materials and Methods 
 Animals and Animal Care. Conventionally raised specific pathogen-free (SPF) mice: 
Wild-type (WT) mice on a C57BL/6 (B6) background were purchased from Jackson 
Laboratories (Bar Harbor, Maine), bred for multiple generations and maintained in microisolator 
cages (five mice per cage) in the same temperature and light-controlled SPF room at the 
University of North Carolina-Chapel Hill (UNC), matched for gender, and used for experiments 
at 8 to 12 weeks of age. Mice were negative for all Helicobacter species. To avoid confounding 
cage effects on microbiota composition and diversity, we selected mice from multiple litters that 
were housed in separate cages. 
 Germ-free (GF) mice: WT B6 mice originally derived in sterile conditions by embryo 
transfer were maintained in GF conditions at the National Gnotobiotic Rodent Resource Center 
at UNC. Isolator contamination absence was confirmed by Gram stain, aerobic/anaerobic fecal 
cultures and 16S rRNA (16S) PCR. All mouse experiments were approved by the UNC 
Institutional Animal Care and Use Committee.  
 Radiation Gastrointestinal Syndrome Model. Non-anesthetized mice were exposed to 
a single dose of external beam total body irradiation (TBI) using XRad320 x-ray machine 
(Precision X-Ray, North Branford, CT; Filter: 4 mm Cu; 47 cm; 320 kV/s, 12.5 mA; 1.0 
Gy/min). 4 mice were irradiated at a time in a pie cage (Braintree Scientific, Braintree, MA). For 
gnotobiotic experiments, a pie cage with an autoclaved filter top (Braintree Scientific) was used 
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to maintain sterility. Daily water consumption was measured, and clinical scores (0-12) were 
given daily for the duration of experiments, consisting of 0-4 each for weight loss, stool 
consistency and GI bleeding. Upon experiment termination, tissues were dissected for analysis. 
Survival was calculated by the Kaplan-Meier method.  
 Histology and Immunohistochemistry. Animals were euthanized and the entire jejunum 
and cecum were harvested, cut longitudinally, washed, formalin-fixed for 24 hours, paraffin-
embedded, cut and stained with hematoxylin and eosin (H&E) or bromodeoxyuridine (BrdU) 
using a standard protocol after heat-mediated antigen retrieval. (Mice were injected 
intraperitoneally with 120 mg/kg BrdU [Sigma-Aldrich, St. Louis, MO] 2 hours before death.) 
IEC apoptosis and proliferation were quantitated on a cell positional basis by light microscopic 
analysis of 50 half-crypts/mouse (48), using H&E and BrdU IHC, respectively. All crypts chosen 
were >20 cells in height, with cell position 1 located at the crypt base. Scoring was performed by 
2 blinded investigators, including a pathologist. 
 Bacterial Composition Analyses. Extraction of Genomic DNA and Bacterial 16S rRNA 
Amplification: Bacterial genomic DNA was isolated from feces, intestinal mucosa and luminal 
contents using a phenol-chloroform extraction method combined with physical disruption of 
bacterial cells and a DNA clean-up kit (DNeasy blood and tissue extraction kit, Qiagen, 
Valencia, CA), as previously described (57). DNA was quantitated using a Nanodrop 2000c 
spectrophotometer (Thermo/Fisher Scientific, Waltham, MA) and used to PCR amplify the V1-
V3 (forward, 8F: 5’-AGAGTTTGATCMTGGCTCAG-3’; reverse 518R: 5’-
ATTACCGCGGCTGCTGG-3’) hypervariable regions of the 16S gene. Forward primers were 
tagged with unique 10 base pair barcode labels at the 5’ end along with the adaptor sequence (5’-
CCATCTCATCCCTGCGTGTCTCCGACTCAG-3’) to allow multiple samples to be included 
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in a single plate as previously described (49, 50). 16S PCR products were quantified, pooled, and 
purified for sequencing.  
 454 FLX Sequencing and Taxonomic Analysis: Sequencing was performed on a 454 Life 
Sciences Genome Sequencer FLX machine (Roche, Florence, SC) at the UNC Microbiome Core 
(http://www.med.unc.edu/microbiome). 16S sequence data was processed by the quantitative 
insights into microbial ecology (QIIME) pipeline (51). Briefly, sequences were assessed for 
quality and those that were <200 or >1000 base pairs in length or that contained incorrect primer 
sequences or more than one ambiguous base were discarded. Remaining sequences were 
assigned to groups based on their unique nucleotide barcodes, including error correction (49). 
Sequences were clustered into operational taxonomic units (OTUs) based on 97% sequence 
similarity (similar to species level) using BLAST (52)
 
with the Greengenes reference database 
(53).  
 We used taxon and phylogenetic-based analyses to compare 16S gene sequences. Taxon-
based: The means and standard deviations of abundances of bacterial groups (phylum, class, 
order, family, and genus) were calculated and compared between groups of mice. α-diversity was 
assessed and rarefaction curves were generated for each experimental group that measured the 
distribution of bacterial taxa richness. β-diversity used unweighted and weighted UniFrac 
distances (54-56) to generate principal coordinate plots for each sample that visualized the 
similarities or dissimilarities between sample groups. Phylogenetic-based: Phylogenetic trees 
were generated with QIIME
 
(51) by subjecting data to weighted and unweighted UniFrac 
analysis. UniFrac distances represent the branch length fraction that is shared by any two sample 
communities in a phylogenetic tree built from 16S sequence data from all samples (54-56). 
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UniFrac distances were compiled into matrices and average UniFac distances were calculated for 
each group and compared using a Student’s t-test.  
 16S rRNA Gene Quantitative Polymerase Chain Reaction: All assays were performed in 
96 well plates (Eppendorf, Hauppauge, NY) with appropriate standards, duplicate/triplicate 
reactions per sample and “no template” negative controls on an Eppendorf Realplex2 
mastercycler thermocycler using SYBR Green PCR master mix (Applied Biosystems/Life 
Technologies, Grand Island, NY). Each PCR was carried out in a final volume of 25 μl. 
Standards were generated by PCR amplification of target sequences from appropriate positive 
control strain genomic DNA. Standard curves were generated for each bacterial group and used 
to enumerate copy number in individual samples utilizing appropriate bacterial primer sequences 
(Supplementary Table 6.2). Fold change was calculated using the ΔΔCt method relative to 
universal 16S.  
 Terminal-Restriction Fragment Length Polymorphism: The 16S gene was PCR amplified 
using fluorescently labeled universal primers, as previously described (57). Purified products 
were digested with Hae III, (and separately with Msp I), to generate terminal-restriction 
fragments (T-RFs) that were separated by capillary electrophoresis on a genetic analyzer (model 
3100; Applied Biosystems). T-RF size and abundance data were generated using GeneMapper 
software (Applied Biosystems), compiled into a matrix (Sequentix, Germany), standardized and 
compiled into a Bray-Curtis similarity matrix using PRIMER version 6 software (Primer-E, 
Ivybridge, UK), as previously described (57). Data were subjected to hierarchical cluster analysis 
followed by analysis of similarity (ANOSIM), multidimensional scaling plots were constructed 
to illustrate similarity/dissimilarity, and biodiversity of each sample was measured by Shannon-
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Weiner diversity index. Student's t-tests assessed differences in richness or diversity between 
groups.  
 Microbiota Transplantation, Selective Colonization, Antibiotic and Probiotic 
Treatment Experiments. Cecal Content Transplantation: Cecal contents were pooled from 8-
12 SPF WT B6 mice on day #5 after 15 Gy, and from age- and gender-matched untreated 
littermates. Cecal extracts were suspended in 8 ml phosphate buffered saline and administered to 
GF WT B6 mice (n=3-4 mice/group) orally, via rectal swab, in water, on food, and in bedding (2 
ml per cage of 4 mice, including 200 μl orally). 72 hours after transplantation, mice were 
exposed to 10 Gy while sterility was maintained and then returned to cages. The experiment was 
repeated with the same two donor microbiota groups and recipient SPF WT B6 mice (n=5 
mice/group), with microbiota transfer performed similarly 1 hour after 11 Gy. 
 Selective Colonization: Mice were maintained in sterile cages as GF or mono-associated 
with the nonpathogenic murine Escherichia coli NC101 (27) or Enterococcus faecalis OG1RF 
strains by swabbing the snout, fur and anus with 1 X 10
9
 colony-forming units of overnight 
bacterial culture (n=5 mice/group). 24 hours after inoculation, mice were exposed to 15 Gy and 
returned to cages for observation.  
 Antibiotic and Probiotic Treatment of Mice: Mice were treated with various antibiotics 
(Sigma-Aldrich, St. Louis, MO) dissolved in drinking water, starting one hour after radiation: 
ciprofloxacin, metronidazole, ciprofloxacin/metronidazole, rifaximin, trimethoprim and 
sulfamethoxazole or neomycin sulfate (n=8 mice/group). 50 mg/kg/d of each antibiotic were 
administered in initial experiments; 25 and 12.5 mg/kg/d were given in subsequent experiments 
with similar results. In a separate experiment, mice received VSL#3 delivered in drinking water 
(30 mg in 100 ml) for one week prior to radiation. VSL#3 sachets contained 900 billion viable 
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lyophilized bacteria consisting of four strains of Lactobacillus species, (L. casei, L. plantarum, L. 
acidophilus, and L. delbrueckii subsp. bulgaricus), three strains of Bifidobacterium species, (B. 
longum, B. breve, and B. infantis), and Streptococcus salivarius subsp. thermophilus.  
 Quantitative Real-Time Reverse-Transcription Polymerase Chain Reaction 
Antimicrobial Peptide Analysis. Quantitative RT-PCR was performed using TaqMan or SYBR 
Green assays (Applied Biosystems) per manufacturer’s instructions, as previously described 
(58). β-actin was used as an internal control, and ΔΔCt values were calculated to obtain fold 
changes relative to the healthy control group. 
 Acid Urea-Polyacrylamide Gel Electrophoresis. Jejunum and ileum tissue protein was 
extracted using acetonitrile, trifluoroacetic acid and acetic acid, and analyzed by acid urea-
polyacrylamide gel electrophoresis (AU-PAGE), as previously described (58). Extracts were 
analyzed alongside a sample of recombinant α-defensin 4 (rDefa4), and resolved proteins were 
visualized utilizing Coomassie Brilliant Blue staining. 
 Statistical Analyses. Analyses were performed using the GraphPad Prism 5 software 
(GraphPad, La Jolla, CA). Means of normally distributed data were compared using one-way 
analysis of variance (ANOVA), followed by Tukey's multiple comparison testing and 2-tailed, 
unpaired Student's t-tests. When data was not normally distributed, the Kruskal-Wallis test was 
utilized to compare means, followed by Dunn's multiple comparison testing and 2-tailed Mann-
Whitney tests. Data are expressed as mean ± SEM. Statistical significance was defined as 
p<0.05. In point plots, horizontal lines indicate means. 
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Figure 6.1. The enteric microbiota is necessary for the early death of mice from the “radiation GI 
syndrome”, yet it exerts protective effects on intestinal epithelial cells in response to radiation. 
(a) Survival (top), clinical colitis scores at day 5 (middle) and percent of positive blood cultures 
at day 5 (bottom) of GF (n=4) and SPF mice (n=5) treated with 15 Gy. (b) Representative H&E-
stained jejunum sections from GF (middle) and SPF (bottom) mice at 6 hours after 15 Gy. 
Yellow arrows point to apoptotic cells. Quantitation per mouse (50 half crypts) is shown (top). 
(c) Representative H&E-stained cecum sections from GF (middle) and SPF (bottom) mice at 6 
hours after 15 Gy. Yellow arrows point to apoptotic cells. Quantitative comparison (50 half 
crypts per mouse) is shown (top). (d) Representative bromodeoxyuridine (BrdU) 
immunohistochemistry on jejunum sections from GF (middle) and SPF (bottom) mice at 6 hours 
after 15 Gy. Proliferating cells are visible (brown cells with black arrows). Quantitative 
comparison (50 half crypts per mouse) is shown (top). Magnification for all sections shown is 
60X. GF=germ-free; SPF=specific pathogen-free; MLN=mesenteric lymph node; 
BrdU=bromodeoxyuridine.  
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Figure 6.2. Radiation induces an intestinal dysbiosis. (a) Principal coordinates analysis of 
weighted UniFrac distances of 16S rRNA sequences demonstrating clustering according to 
radiation exposure. Symbols represent individual mucosal bacterial communities obtained from 
healthy control mice (orange) and mice exposed to irradiation (blue), in the jejunum (squares), 
cecum (circles), and the distal colon (triangles). (b) A significant increase in average UniFrac 
distances, or β-diversity, was shown in mice exposed to radiation when compared to healthy 
control mice. N= “No radiation” healthy control; R= Radiation. Multidimensional scaling reveals 
separate clustering of bacterial communities based on radiation exposure in the jejunum mucosa 
(c), cecum mucosa (d), cecum lumen (e) and distal colon mucosa (f). Symbols represent 
individual intestinal bacterial communities obtained from healthy control mice (orange) and mice 
exposed to irradiation (blue).  
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Figure 6.3. Transitions in gut bacterial populations associated with radiation exposure. (a) 
Average abundances of bacterial phlya in the jejunum mucosa of healthy control mice (left) and 
mice exposed to radiation (right). Radiation exposure results in an increase in intestinal 
Proteobacteria and a decrease in Firmicutes (p<0.007). (b) Concentrations of Proteobacteria 
phylum member E. coli  were determined in healthy control mice and mice exposed to radiation 
using quantitative PCR (qPCR) of the 16S rRNA gene. Within the Firmicutes phylum, radiation 
specifically reduces Lactobacillus spp., as shown by 16S rRNA 454 pyrosequencing (c) and 
qPCR (d), and Lactobacillus reuteri comprise most of the Lactobacillus species and are almost 
eradicated after radiation (e). Copy number is normalized to total 16S in (b), (d), and (e). 
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Figure 6.4. The intestinal microbiota directly impacts the host response to radiation. (a) In cecal 
transplantation experiments, mice receiving post-irradiation microbiota had increased morbidity 
and accelerated mortality after radiation compared to mice receiving healthy control microbiota 
(p<0.02). (b) Escherichia coli mono-associated mice had increased morbidity and accelerated 
mortality after 15 Gy compared to Enterococcus faecalis mono-associated mice and GF mice. 
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Figure 6.5. Radiation-induced dysbiosis and the GI syndrome are mitigated by ciprofloxacin. 
Ciprofloxacin rescues mice from the GI syndrome (a). cipro=ciprofloxacin; 
MET=metronidazole; TMP-SMX=trimethoprim-sulfamethoxazole. (b) Principal coordinates 
analysis of weighted UniFrac distances between bacterial communities determined from 16S 
rRNA genes. Symbols represent individual intestinal bacterial communities obtained from 
healthy control mice (orange), mice exposed to irradiation (blue), and mice exposed to 
irradiation and treated with ciprofloxacin (red). (c) Average abundances of bacterial phlya in the 
jejunum mucosa of healthy control mice (left), irradiated mice (middle), and irradiated mice 
treated with ciprofloxacin (right). Radiation exposure results in a decrease in Firmicutes 
(p<0.0001) and an increase in Proteobacteria (p=0.05), and these shifts are largely prevented by 
ciprofloxacin (p<0.003). (d) Administration of ciprofloxacin prevents radiation-induced 
proliferation of E. coli species in the jejunum, both in the lumen and the mucosa. N=No 
radiation; R=Radiation; C=radiation/Cipro; BDL=below detectable limits. (e) Ciprofloxacin also 
prevents expansion of fecal E. coli populations after radiation. Copy number is normalized to 
total 16S rRNA copies in (d) and (e). 
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Figure 6.6. Radiation GI syndrome is prevented by administration of the probiotic VSL#3. 
VSL#3 abated clinical colitis scores in irradiated mice as measured at day 5 (a) and prolonged 
survival after lethal irradiation (b). (c) Radiation lessened α-defensin mRNA expression in the 
jejunum on day 3 after radiation. Defa5 (p<0.002), Defa17 (p<0.002) and Defa20 (p<0.006) 
transcript levels are shown. Copy numbers are normalized to β-actin, and fold change is relative 
to the healthy control group. (d) Acid urea polyacrylamide gel electrophoresis demonstrates 
peptide expression patterns of α-defensin isoforms in the ileum of healthy control mice and mice 
exposed to radiation. The first lane is recombinant Defa4 control (Crp4), and each additional lane 
represents protein extracts from an individual mouse. (e) VSL#3 induces small intestinal α-
defensin mRNA expression. Defa5, Defa17 and Defa20 transcripts were measured using 
quantitative RT-PCR of jejunum and distal ileum RNA extracts from untreated and VSL#3-
treated mice. Copy numbers are normalized to β-actin, and fold change is relative to the 
untreated group. J=Jejunum; I=Ileum. 
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Supplementary Figure 6.1. (a) Results of aerobic cultures of cardiac blood, portal blood and 
mesenteric lymph nodes harvested from mice at day 5 after exposure to a range of radiation 
doses (n= 5 mice/group). (b) Mortality in mice exposed to 10-25 Gy total body irradiation (n=8 
mice/group). *=radiation dose causing GI syndrome in all mice. Quantitation of apoptotic cells 
per SPF mouse (50 half crypts or 25 whole crypts) in the jejujum (c) and cecum (d) of mice 0-24 
hours after 15 Gy. (e) Quantitation of BrdU-labelled cells per SPF mouse (50 half crypts or 25 
whole crypts) in the jejunum after 15 Gy. (f) Quantitation of BrdU-labelled cells per 50 half 
crypts in the cecum of GF and SPF mice 0, 6, and 24 hours after 15 Gy. 
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Supplementary Fig. 6.2A. Principal coordinates analysis of weighted UniFrac distances between 
bacterial communities determined from 16S rRNA genes. Symbols represent individual intestinal 
communities obtained from healthy control mice (orange) and mice exposed to irradiation (blue). 
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Supplementary Figure 6.2B. Hierarchial clustering of intestinal microbiota samples based on 
OTUs at 97% sequence similarity. Samples from healthy control mice (orange squares), and 
mice exposed to irradiation (blue circles) are shown. 
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Supplementary Figure 6.2C. T-RFs derived from fecal bacterial communities of the same mice 
before (orange) and after (blue) exposure to radiation were used to generate nonmetric 
multidimensional scaling plots in two (left) and three (right) dimensions. The communities were 
statistically dissimilar before and after radiation based on ANOSIM analysis (p<0.05). 
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Supplementary Figure 6.2D: Rarefaction curves of intestinal bacterial communities from healthy 
control mice (orange) and mice exposed to radiation (blue). Curves are based on α-diversity 
within sample groups for the V1-V3 16S rRNA region. 
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Supplementary Figure 6.3: Average abundances of bacterial phlya in healthy control mice (left) 
and mice exposed to radiation (right). Radiation exposure results in a decrease in Firmicutes and 
an increase in Proteobacteria and Verrucomicrobia, in the cecum mucosa (a), cecum lumen (b), 
and distal colon mucosa (c).  
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Supplementary Figure 6.3. (d) Intestinal dysbiosis begins by 24 hours after radiation and 
progresses thereafter (n=4 mice). Copy number is normalized to total 16S. (e, f) Intestinal 
dybiosis following radiation is not due to changes in dietary intake. (e) E. coli were increased 
from below detectable limits in healthy mice to an average of 20% of all bacteria in the jejunum 
lumen at 48 hours after radiation. In contrast, after 48 hours of severe dietary restriction, two 
mice still had below detectable limits of E. coli, while in two mice only 0.3% of all bacteria were 
E. coli. BDL=below detectable limits; Diet restrict.=diet restricted. (f) There were significant 
differences between contractions of Lactobacillus spp. populations in the jejunum at 48 hours 
after radiation, compared to minimal decreases of these species after 48 hours of severe dietary 
restriction.  
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Supplementary Figure 6.4. Acid urea polyacrylamide gel electrophoresis demonstrates peptide 
expression patterns of α-defensin isoforms in the jejunum of healthy control mice and mice 
exposed to radiation. The 5
th
 lane is recombinant Defa4 control, and each additional lane 
represents protein extracts from an individual mouse.  
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Supplementary Figure 6.5. Radiation induces apoptosis in the small intestinal crypt region of the 
Paneth cells, which produce and secrete the antimicrobial α-defensins. Shown are the number of 
apoptotic cells per 50 half crypts in the jejunum at each respective cell position, both in germ-
free (white) and specific pathogen-free (black) mice, at 6 hours after 15 Gy. 
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Supplementary Figure 6.6. Quantitation of putative protective fecal bacterial species after 
administration of VSL#3. Copy number is normalized to total 16S. Bifidobacterium species (a), 
Lactobacillus species (b) and Faecalibacterium prausnitzii (c) are shown. *p<0.007 compared to 
day 0. **p<0.005 compared to day 0. *** p<0.03 compared to day 0.  
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Bacteria Fold change 
after radiation 
p value 
Escherichia coli  + 14811 <0.0001 
Bacteroides fragilis   +  1749 <0.003 
Klebsiella pneumonia + 1600 <0.02 
Enterococcus faecalis + 110 <0.009 
Pseudomonas fluorescens + 5 <0.0001 
Clostridium coccoides - 24 0.007 
Lactobacillus spp. -  35 0.0003 
Bifidobacterium spp. - 54 0.005 
 
Supplementary Table 6.1. Radiation-induced shifts in clinically-relevant bacterial groups are 
very similar to those seen in human inflammatory bowel diseases. 
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Supplementary Table 6.2. Primer sequences utilized to assess bacterial populations with 
quantitative PCR. 
  
Primer Forward primer Reverse primer 
Universal 5’-
GTGSTGCAYGGYTGTC
GTCA-3’ 
5’- 
ACGTCRTCCMCACC
TTCCTC-3’ 
Lactobacillus spp.  5′-
AGCAGTAGGGAATCTC
CA-3′  
5′-
CACCGCTACACATG
GAG-3′ 
Bifidobacterium spp.  5′-
GGGTGGTAATGCCGGA
TG-3’ 
5′-
CACCGCTACACATG
GAG-3′ 
Faecalibacterium 
prausnitzii  
5′-
GATGGCCTCGCGTCCG
ATTAG-3′  
5′-
CCGAAGACCTTCTT
CCTCC-3′  
Escherichia 
 coli  
5′-
GTTAATACCTTTGCTCA
TTGA-3′  
5′-
ACCAGGGTATCTAA
TCCTGTT-3′ 
Bacteriodes spp. 5’-
ATAGCCTTTCGAAAGR
AAGAT-3’ 
5’-
CCAGTATCAACTGC
AATTTTA-3’ 
Clostridium spp. 5’-
CGGTACCTGACTAAGA
AGC-3’ 
5’-
AGTTTYATTCTTGC
GAACG-3’ 
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CHAPTER 7: CIPROFLOXACIN PREVENTS THE RADIATION-INDUCED 
GASTROINTESTINAL SYNDROME BY INHIBITING ENTERIC DYSBIOSIS7 
Introduction 
 Radiation-induced gastrointestinal syndrome (RIGS) remains the major limitation for 
delivering tumoricidal radiation doses for treatment of abdominal and pelvic malignancies (1). 
Interest surged in the development of medical countermeasures for radiological/nuclear, 
biological and chemical threats after the 2001 terrorist attacks in the United States and further 
intensified after explosions at Japan’s nuclear power plant in 2011 (2). At higher radiation doses, 
the mortality rate of RIGS exceeds that of the hematopoietic syndrome (3-5). Yet, beyond the 
utility of potassium iodide in preventing thyroid cancer, there are no proven drugs to ward off the 
devastating health effects of a large radiation exposure (2). 
 The pathophysiological mechanisms of RIGS involve loss of clonogenic crypt cells, 
depopulation of intestinal villi, mucosal denudation and host death (6-8). Rapid proliferation of 
intestinal epithelial cells (IECs) makes the enteric mucosa particularly susceptible to damage 
following exposure to genotoxic stressors such as radiation. Thus, maintenance of intestinal 
mucosal homeostasis is critical to combating RIGS. Most studies to date have focused on the 
elucidation of radiation effects on the host epithelium or endothelium (1, 9-13) and/or the 
mechanisms by which growth factors, cytokines or other molecules may inhibit IEC cycling to 
promote radioresistance (14-16), enhance IEC proliferation subsequent to insult to facilitate 
recovery (13, 16-21), or prevent radiation-induced endothelial cell death (9, 22-27). Extensive 
                                                          
7
 This chapter is part of the following manuscript currently being prepared for submission: Packey CD, Maharshak 
N, Bowen R, Miller PL, Plevy SE, Keku TO, Shanahan MT, Jobin C, Carroll IM, Sartor RB. Ciprofloxacin prevents the 
radiation-induced gastrointestinal syndrome by inhibiting enteric dysbiosis.  
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experimental studies in these areas have enhanced our knowledge of radiation biology. However, 
translational research using these agents in various RIGS scenarios, such as prophylactic 
adjuncts in radiotherapy or post-exposure treatments for potential victims of radiation accidents, 
has been largely non-existent (5).  
 The radiosensitive human intestinal mucosa is in intimate contact with bacteria that 
outnumber the host somatic and germline cells by at least 10 times (1). These bacteria provide 
critical contributions to intestinal mucosal homeostasis. Gnotobiotic experiments have 
demonstrated that the commensal microbiota are necessary for the pathogenesis of RIGS (28); 
however, their exact role is poorly understood. Cellular signaling through toll-like receptors 
(TLRs) and other pathogen-associated molecular pattern (PAMP) recognition molecules plays a 
key role in the dynamic interactions between the host’s enteric microbiota and innate immune 
system (29-31). It is thus unsurprising that bacterial-derived molecules that activate TLRs (32-
35) or downstream transcription factors (36, 37) may possess radioprotective properties. 
 There are currently no U.S. Food and Drug Administration (FDA)-approved agents for 
the mitigation of the gastrointestinal (GI) consequences of therapeutic, accidental or intentional 
radiation exposure. Following a radiation disaster or act of terrorism, the goal would be to 
provide a potent frontline therapy that increases the chance for survival for exposed individuals. 
Ideally, this therapy would be easy to administer and have minimal deleterious side effects. We 
hypothesized that radiation might induce a clinically-important intestinal dysbiosis, and that an 
antibiotic with appropriate activity might prevent RIGS by inhibiting development of this 
dysbiosis. In the studies presented here, we compared the efficacy of several clinically relevant, 
FDA-approved antibiotics in treating RIGS in mice, and we identified one antibiotic, 
ciprofloxacin (cipro), which rescued mice from RIGS. We showed with clinical scoring, 
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enzyme-linked immunosorbent assays (ELISA) and high definition endoscopy that cipro 
prevented radiation-induced colitis. We demonstrated with high-throughput deep sequencing that 
cipro also inhibited the development of a profound dysbiosis that ensued in both biologically 
important mucosal and luminal bacterial communities in the small intestine and colon following 
radiation exposure. Finally, we utilized a gnotobiotic cecal content transplantation mouse model 
to demonstrate that modulation of the intestinal microbiota by cipro directly impacts host 
morbidity and mortality following irradiation. 
Materials and methods 
 Radiation-Induced Gastrointestinal Syndrome (RIGS) Mouse Model. Specific 
pathogen-free (SPF) mice. All mice used were wild-type (WT) mice on a C57BL/6 (B6) 
background, purchased from Jackson Laboratories (Bar Harbor, Maine), bred for multiple 
generations and maintained in individually-ventilated microisolator cages (five mice per cage) in 
the same animal room at the University of North Carolina-Chapel Hill (UNC), and used for 
experiments at 8 to 12 weeks of age. In all experiments, mice were matched for gender, as 
gender-based genetic differences have been reported in B6 mice that may explain sexual 
dimorphism in IEC apoptotic responses to radiation (38). Mice in the colony were negative for 
all Helicobacter species. We used B6 mice because mice of this genetic background experience 
RIGS similar to that seen in humans, with translocation of bacteria to the blood, sepsis and early 
death, while other mouse strains do not (39). To avoid confounding cage effects on the 
composition and diversity of the intestinal microbiota, each experimental group was comprised 
of mice from multiple litters that were housed in separate cages. All animals were maintained 
under a 12-hour light/dark cycle in a temperature-controlled SPF facility and had free access to 
water and standard laboratory mouse chow unless otherwise specified. 
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 Germ-free (GF) mice. All mice used were WT mice on a B6 background, and were 
maintained in GF conditions at the National Gnotobiotic Rodent Resource Center at UNC. 
Absence of isolator contamination was confirmed by Gram stain, fecal culture on Brain Heart 
Infusion agar with 10% sheep blood ([blood BHI]; Becton Dickinson, Sparks, MD) under 
aerobic and anaerobic conditions, and 16S ribosomal RNA (rRNA) PCR. All mouse experiments 
were approved by the UNC Institutional Animal Care and Use Committee.  
 Irradiation of mice. Mice that were not anesthetized received total body irradiation (TBI), 
with exposure to a single dose of 15 Gy external beam irradiation using an XRad320 x-ray 
machine (Precision X-Ray, North Branford, CT; Filter: 4 mm Cu; 47 cm; 320 kV/s, 12.5 mA; 1.0 
Gy/min). 15 Gy TBI was used for all experiments except cecal content transplantation 
experiments, as this dose causes RIGS in 100% of our SPF B6 mice, consistent with previous 
reports (9, 25, 40). Although many past reports have suggested otherwise, recent evidence 
supports our findings that 15 Gy TBI universally causes RIGS in SPF B6 mice, while doses of 14 
Gy and less do not (1, 26, 40). SPF mice were irradiated in a mouse irradiation pie cage 
(Braintree Scientific, Braintree, MA) that is divided to provide 12 ventilated restraints. Only 4 
mice were irradiated simultaneously to facilitate the placement of all mice in the middle of the 
radiation field away from the periphery. For gnotobiotic experiments, a mouse irradiation pie 
cage with an autoclaved filter top (Braintree Scientific) was used to maintain sterility. Quality 
assessment experiments were performed regularly to confirm that dose and energy output 
remained within range. Experiments were separately performed with a 
137
Cs source and an 
additional x-ray machine, with similar results. 
 Health status monitoring, survival of mice after irradiation and evaluation of animal 
death causes. Well-being of all animals was inspected daily from the initiation of treatment to 
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the end of the study. Daily water consumption was measured, and clinical colitis scores of 0-12 
were given daily for the duration of the experiments, consisting of GI bleeding (0-4), stool 
consistency (0-4) and weight loss (0-4). GI bleeding was assessed by sampling for the presence 
of blood in the stool using a Hemoccult immunochemical fecal occult blood test (Beckman 
Coulter, Brea, CA). Upon termination of the experiment, mice were killed by CO2 inhalation and 
cervical dislocation, and tissues were dissected for further analysis. To assess for bacteremia, 
blood was aseptically aspirated directly from the heart under a laminar flow hood. 0.5 mL 
cardiac blood per mouse was plated onto two blood BHI agar plates. One plate was incubated 
aerobically for 48 hours and the other was incubated anaerobically for 4 days, at which point 
plates were assessed for bacterial growth. Actuarial survival was calculated by the Kaplan-Meier 
method and statistical significance of survival differences were calculated by the Mantel log-rank 
test. Causes of death were evaluated by autopsies. 
 Antibiotic treatment of mice. B6 mice were treated with the following antibiotics (Sigma-
Aldrich, St. Louis, MO) dissolved in their drinking water, starting one hour after radiation 
exposure, unless otherwise noted: ciprofloxacin, metronidazole, ciprofloxacin/metronidazole, 
rifaximin, trimethoprim and sulfamethoxazole and neomycin sulfate (n=8 mice/group). 
Experiments were conducted with administration of 50 mg/kg/day of each antibiotic, and then 
repeated at 25 mg/kg/day and 12.5 mg/kg/day with similar results. Daily fluid intake was 
recorded. 
 Enzyme-linked immunosorbent assays. Colon cultures were generated for assessing 
cytokine levels. Briefly, entire colons were cut longitudinally, gently washed in phosphate-
buffered saline (PBS) to remove contents, and vigorously shaken for 30 minutes in RPMI-1640 
medium (Sigma-Aldrich). Colons were then thoroughly blotted, weighed, divided into 100 mg 
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segments, placed in 24-well Corning Costar cell culture plates (Sigma-Aldrich) in duplicate or 
triplicate, as the amount of tissue permitted, cut into 0.5 to 1.0 cm pieces, and cultured in 1 
mL/well of RPMI-1640 medium supplemented with 50 mg/mL gentamicin, 100 mg/mL 
streptomycin, and 0.25 mg/mL fungizone (antibiotic/antimycotic; Life Technologies [Gibco], 
Grand Island, NY). Cultures were incubated at 37° for 20 hours and then centrifuged, and 
supernatants were collected and stored at −80°C for ELISA. IL-12p40 and IL-1β concentrations 
were determined by sandwich ELISA, according to the manufacturer’s instructions (BD 
Biosciences, San Jose, CA). Concentrations of cytokines were established in triplicate culture 
supernatants by comparison with standard curves generated using the appropriate recombinant 
cytokine.  
 Endoscopic investigation. The presence or absence of colon inflammation was evaluated 
in situ by mini-endoscopy (Karl Storz Veterinary Endoscopy, Goleta, CA). Mice were 
anesthetized with isoflurane (Minrad, Orchard Park, NY). If fecal matter obstructed 
visualization, colons were flushed with 1X PBS. After air inflation, the colonoscopy allowed for 
the real-time evaluation of 3–4 cm of colon from the anus to the splenic flexure. All 
colonoscopic procedures were digitally recorded. Endoscopy was performed on healthy control 
mice (n=2), mice exposed to radiation (day 5; n=3), and mice exposed to radiation and 
administered cipro (day 5; n=3). 
 Antibiograms. Antibiograms were performed on bacteria cultured from the blood of 
untreated, irradiated using the Kirby-Bauer disk diffusion sensitivity testing method. Paper discs 
impregnated with antibiotics were dropped in different zones of the culture on blood BHI agar 
plates. The diameters of the areas of bacterial lysis in millimeters, which can be converted to 
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µg/mL minimum inhibitory concentrations (MIC) using known linear regression curves, were 
recorded.   
 Crypt Regeneration Assay. Healthy control mice, irradiated mice and cipro-treated, 
irradiated mice were killed and the entire small intestine was harvested, cut longitudinally, gently 
washed with 1X PBS to remove contents, splayed out on 1.5 mm Whatman blotting paper (GE 
Healthcare, Little Chalfont, United Kingdom), and fixed in 10% phosphate-buffered formalin 
(Fisher Scientific, Pittsburgh, PA) for 24 hours. Fixed tissue was then rinsed in 1X PBS 
repeatedly, manipulated into Swiss roll conformation to maximize tissue surface area to score, 
embedded in paraffin and stained with hematoxylin and eosin (H&E). Scoring was performed 
blindly and the percentages of regenerating crypts per mouse and per group were determined 
according to a modification of established criteria (6, 41). Criteria for a surviving/regenerating 
crypt were 10 or more chromophilic, tightly packed cells, each with a prominent nucleus and 
little cytoplasm. Non-viable crypts contained no cells, or were sparsely populated by enlarged 
cells with prominent eosinophilic cytoplasm. Only regions that were oriented correctly and did 
not contain Peyer’s patches were scored, as Peyer’s patches influence both the number of crypts 
in a given circumference and the ability of a crypt to survive insult.  
 Bacterial Composition Analyses. Genomic DNA extraction and 16S rRNA 
amplification: Intestinal tissue and luminal samples were snap frozen on dry ice and stored at -
80°C. 250 mg of frozen samples were suspended in sterile bacterial lysis buffer (200 mM NaCl, 
100 mM Tris [pH 8.0], 20 mM EDTA, 20 mg/mL lysozyme [Sigma-Aldrich]) and incubated at 
37°C for 30 minutes. Next, 40 μl of proteinase K (20 mg/mL; Qiagen, Valencia, CA) and 85 μl 
of 10% SDS were added to the mixture and incubated at 65°C for 30 minutes. 300 mg of 0.1 mm 
zirconium beads (BioSpec Products, Bartlesville, OK) were then added and the mixture was 
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homogenized in a bead beater (BioSpec Products) for 2 minutes. The homogenized mixture was 
cooled on ice and then centrifuged at 14,000 g for 5 minutes. The supernatant was transferred to 
a new 1.5 mL microfuge tube and DNA was further extracted by phenol/chloroform/iso-amyl 
alcohol [25:24:1 (v/v); Acros/Fisher Scientific] and then chloroform/iso-amyl alcohol [24:1 
(v/v); Acros].   Following extraction, the supernatant was ethanol precipitated at -20°C for one 
hour. Precipitated DNA was suspended in DNase free H20, cleaned using the Qiagen DNeasy 
Blood and Tissue extraction kit per manufacturer’s instructions, quantified using a Nanodrop 
2000c spectrophotometer (Fisher Scientific [Thermo]), and used to PCR amplify the V1-V3 
(forward primer, 8F: 5’-AGAGTTTGATCMTGGCTCAG-3’; reverse primer, 518R: 5’-
ATTACCGCGGCTGCTGG-3’) hypervariable regions of the 16S rRNA gene. Forward primers 
were tagged with unique 10 base pair barcode labels at the 5’ end along with the adaptor 
sequence (5’-CCATCTCATCCCTGCGTGTCTCCGACTCAG-3’) to allow multiple samples to 
be included in a single plate as previously described (42, 43). 16S rRNA PCR products were 
quantified, pooled, and purified for the sequencing reaction. 
 454 pyrosequencing and analysis. Sequencing was performed on a 454 Life Sciences 
Genome Sequencer FLX machine (Roche, Florence, SC) at the UNC Microbiome core 
(http://www.med.unc.edu/microbiome). 16S rRNA sequence data was processed by the 
Quantitative Insights Into Microbial Ecology (QIIME) pipeline (44). Briefly, sequences were 
checked for quality and sequences that were less than 200 or greater than 1000 base pairs in 
length, that contained incorrect primer sequences, or that contained more than one ambiguous 
base were discarded. The remaining sequences were assigned to groups based on their unique 
nucleotide barcodes, including error correction (42). Sequences were clustered into operational 
taxonomic units (OTUs) based on sequence similarity at 97% sequence similarity (similar to 
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species level) using UC-LUST. A representative sequence for each OTU was chosen for 
downstream analysis based on the most abundant sequence from each OTU. PyNAST was used 
to align sequences with a minimum length of 150 base pairs and a minimum of 75% identity. 
OTUs were assigned to a taxonomy using the Ribosomal Database Project (RDP) Naive Bayes 
classifier. The RDP classifies a 16S rRNA sequence based on Bergey’s manual of determinative 
bacteriology. A bacterial group was designated as unclassified if the 16S rRNA gene sequence 
from an organism did not show significant homology to any known classified bacterium in the 
RDP. β-diversity (diversity between groups of samples) was used to generate principal 
coordinate plots for each sample using unweighted and weighted UniFrac distances. β-diversity 
measurements were combined with each group to produce visualizations (principal coordinate 
analysis [PCoA]) that allow the composition of the intestinal microbiota of the groups to be 
characterized. PCoA plots were used to visualize the similarities or dissimilarities of variables 
that best represent the pair-wise distances between sample groups. We used taxon and 
phylogenetic-based analyses to compare 16S rRNA gene sequences. Taxon-based: The means 
and standard deviations of abundances of bacterial groups (phylum, class, order, family, and 
genus) were calculated and compared between groups of mice. Phylogenetic-based: Phylogenetic 
trees were generated using the QIIME pipeline. Each tree was subjected to weighted and 
unweighted UniFrac analysis. UniFrac distances represent the fraction of branch length that is 
shared by any two sample communities in a phylogenetic tree built from 16S rRNA sequence 
data from all samples. “Weighted” UniFrac analysis refers to microbiota community differences 
between sample groups due to differences in relative taxon abundance, whereas “unweighted” 
UniFrac analysis refers to microbiota community differences between sample groups based on 
the presence or absence of taxa. Weighted and unweighted UniFrac distances were compiled into 
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matrices and average UniFac distances were calculated for each group and compared using 
Student’s t-test.  
 16S rRNA qPCR. All assays were performed in 96 well plates (Eppendorf, Hauppauge, 
NY) with appropriate standards, duplicate/triplicate reactions per sample and “no template” 
negative controls on an Eppendorf Realplex
2
 mastercycler thermocycler. Each reaction was 
carried out in a final volume of 25 μl containing 1X SYBR Green (Life Technologies [Applied 
Biosystems]), 0.5 μM of each primer, and 10 ng of purified DNA. PCR conditions were as 
follows: 10 minutes at 95°C, followed by 40 cycles of 95°C for 15 seconds, 20 seconds at 50°C, 
and 72°C for 1 minute. Melting curves were assessed to confirm that the fluorescence signal 
originated from specific PCR products and not from primer dimers or other artifacts. Standards 
were generated by PCR amplification of target sequences from genomic DNA of an appropriate 
positive control strain. Standard curves were generated for each bacterial group and used to 
enumerate copy number in individual samples using appropriate bacterial primer sequences: 
Universal primers, 5’-GTGSTGCAYGGYTGTCGTCA-3’ (forward primer) and 5’- 
ACGTCRTCCMCACCTTCCTC-3’ (reverse primer); E. coli primers, 5′-
GTTAATACCTTTGCTCATTGA-3′ (forward primer) and 5′-ACCAGGGTATCTAATCCTGTT-
3′ (reverse primer); Lactobacillus genus primers, 5′-AGCAGTAGGGAATCTCCA-3′ (forward 
primer) and 5′-CACCGCTACACATGGAG-3′ (reverse primer); Bifidobacterium genus primers, 
5′-GGGTGGTAATGCCGGATG-3’ (forward primer) and 5′-CACCGCTACACATGGAG-3′ 
(reverse primer); and Faecalibacterium prausnitzii primers, 5′-
GATGGCCTCGCGTCCGATTAG-3′ (forward primer) and 5′-CCGAAGACCTTCTTCCTCC-3′ 
(reverse primer). Fold change was calculated using the ΔΔCt method relative to universal 16S 
rRNA.  
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 Terminal-Restriction Fragment Length Polymorphism (T-RFLP). The 16S rRNA gene 
was amplified by PCR using fluorescently labeled universal primers (carboxyfluorescein [FAM]-
labeled 5’-AGAGTTTGATCCTGGCTCAG-3’ [forward primer 8F] and 
hexachlorocarboxyfluorescein [HEX]-labeled 5’-GGTTACCTTGTTACGACTT-3’ [reverse 
primer 1492R]). PCR products were purified using a Qiagen PCR purification kit and digested 
with Hha1 to generate terminal-restriction fragments (T-RFs) of varying sizes. All samples were 
also digested separately with Msp1. T-RFs were separated by capillary electrophoresis on a 
genetic analyzer (model 3100; Life Technologies [Applied Biosystems]). GeneMapper software 
(Life Technologies [Applied Biosystems]) was used to determine the size (T-RF length in base 
pairs), height (fluorescence intensity), and abundance (peak width X height) of each T-RF. T-RF 
size and abundance data from GeneMapper were compiled into a data matrix using Sequentix 
software (Sequentix, Germany).  
 Microbiota transplantation experiments. Cecal contents were pooled from 1) 12 SPF 
WT B6 mice on day #5 after 15 Gy, 2) 12 age- and gender-matched, non-irradiated littermates, 
and 3) 12 age- and gender-matched, non-irradiated littermates treated with cipro for 7 days. 
Cecal extracts were suspended in 8 mL PBS and administered to GF recipient WT B6 mice (n = 
3-4 mice/group) orally, via rectal swab, in water, on food, and in bedding (2 mL per cage of 4 
mice, including 200 ul orally). Transplanted mice were maintained in sterile cages and monitored 
daily for GI bleeding, diarrhea and weight loss. 72 hours after transplantation, mice were 
exposed to 10 Gy TBI while sterility was maintained, and then returned to cages for health status 
monitoring, continued clinical colitis scoring, and actuarial survival calculation.  
 Statistical analyses. 16S rRNA qPCR analysis. These analyses and others were 
performed using the GraphPad Prism 5 software (GraphPad, La Jolla, CA). Means of normally 
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distributed data were compared using one-way analysis of variance (ANOVA), followed by 
Tukey's multiple comparison testing and 2-tailed, unpaired Student's t-test. When data was not 
normally distributed, the Kruskal-Wallis test was utilized to compare means, followed by Dunn's 
multiple comparison testing and 2-tailed Mann-Whitney tests. Data are expressed as mean ± 
SEM. Statistical significance was defined as p<0.05. In point plots, horizontal lines indicate 
means. 
 T-RFLP analysis. All T-RF data were standardized (individual T-RF peak height as a 
proportion of total T-RF peak heights within that sample), transformed by square root, and 
compiled into a Bray-Curtis similarity matrix using PRIMER version 6 software (Primer-E, 
Ivybridge, UK). To test for differences in global community composition, T-RF data were 
subjected to hierarchical cluster analysis followed by analysis of similarity (ANOSIM). 
Multidimensional scaling plots were constructed to illustrate similarity/dissimilarity. 
Biodiversity of each sample was measured by Shannon-Weiner diversity index while differences 
in richness or diversity between treatment groups were assessed by Student's t test.  
Results 
 Ciprofloxacin prevents the radiation-induced gastrointestinal syndrome in mice. 
Given recent evidence that commensal enteric bacteria play an important role in RIGS, we 
investigated the efficacy of several clinically-relevant antibiotics in treating RIGS in mice. We 
studied several antibiotics that are commonly used clinically to treat diarrheal illnesses and intra-
abdominal infections, including ciprofloxacin (cipro), metronidazole (met), rifaximin (rifax), 
trimethoprim-sulfamethoxazole (TMP-SMX) and neomycin (neo). We found that only one 
antibiotic, cipro, prevented the development of RIGS when administered continuously in 
drinking water starting one hour after radiation exposure. This was the case when 50 mg/kg/day 
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of each antibiotic was delivered, as well as when 25 or 12.5 mg/kg/day of each antibiotic was 
administered. Following radiation, clinical colitis scores were significantly lower in mice 
receiving cipro or the combination of cipro/met compared to mice exposed to equivalent doses of 
irradiation and receiving the same dose of other antibiotics (Figure 7.1A; p<0.0001). Cipro, but 
not other antibiotics, prevented radiation-induced GI bleeding (Figure 7.1B; p<0.0001) and 
diarrhea (Figure 7.1C; p<0.0001). Cipro’s protection appeared to be primarily in the gut, as 
weight loss after radiation exposure was unaffected by cipro (Figure 7.1D). Gut-derived sepsis is 
a critical component of RIGS pathogenesis, and cipro also prevented the development of 
bacteremia following radiation (Figure 7.1E). Untreated mice exposed to 15 Gy died on days 5-7 
post-irradiation, which is consistent with B6 mouse radiation mortality data in the literature (9, 
25, 40). In contrast, mice treated with cipro after 15 Gy died on days 8-12 post-irradiation, which 
is improved survival compared to that achieved in previous studies with administration of growth 
factors or cytokines before lethal irradiation (17, 18, 22-25). Upon necropsy at days 8-12 post-
irradiation, mice treated with cipro were found to have gross GI bleeding and, in some cases, 
intra-abdominal bleeding (Figure 7.1F), likely contributing to death as part of thrombocytopenia 
and the hematopoietic syndrome that ensue in the absence of a lethal RIGS. No gross GI 
bleeding or intra-abdominal bleeding was observed in untreated mice exposed to 15 Gy or in 
mice exposed to 15 Gy and treated with antibiotics other than cipro. These mice underwent 
necropsy 5-7 days after radiation.  
 Ciprofloxacin prevents radiation-induced colitis. We used several methods to 
demonstrate that radiation causes inflammation in the colon in mice. First, we showed that 
colonic weight, which is a non-specific marker of inflammation, is significantly increased in 
mice following radiation (Figure 7.2A; p<0.04). Second, colonic secretion of pro-inflammatory 
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cytokines IL-12p40 (Figure 7.2B; p<0.0001) and IL-1β (Figure 7.2C; p<0.04) is increased 
following radiation, as measured by ELISA. Finally, high definition endoscopy revealed 
erythema and loss of the vascular appearance of the colon in mice exposed to radiation, findings 
consistent with mild to moderate inflammation (Figure 7.2D). Cipro administration prevented 
radiation-induced colitis, as assessed by colonic weight (Figure 7.2A; p<0.002), colonic 
secretion of IL-12p40 (Figure 7.2B; p<0.002) and IL-1β (Figure 7.2C; p<0.02), and mouse 
endoscopy (Figure 7.2D). 
 Ciprofloxacin has strong bactericidal activity against microbes that translocate to 
the blood following radiation exposure. Gut-derived sepsis is believed to be a critical 
component of the pathogenesis of RIGS. We examined the ability of several clinically-relevant 
antibiotics to kill bacteria that translocate to the blood in mice exposed to lethal doses of 
irradiation. Cipro had 100% bactericidal activity against 16 randomly chosen isolates cultured 
from the cardiac blood of untreated, irradiated mice, while other antibiotics demonstrated 20-
67% bactericidal activity against the same isolates (Figure 7.3A). The mean zones of inhibition, 
which were converted to Minimum Inhibitory Concentrations (MICs), were determined for each 
antibiotic against each bacterial isolate. Cipro demonstrated a mean zone of inhibition of 11.3 
mm, while the mean zone of inhibition of other antibiotics ranged from 0.9-7.6 mm (Figure 
7.3B). 
 Events ensuing in the first 24 hours after radiation exposure critically impact host 
morbidity and mortality. Because radiation exposure can occur unexpectedly in the case of a 
nuclear reactor meltdown or nuclear terrorist attack, we set out to determine how soon cipro must 
be administered following radiation exposure to obtain protection from RIGS. We exposed mice 
to 15 Gy TBI, administered cipro continuously in drinking water starting at 0, 1, 12, and 24 
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hours after exposure, and found that significant protection was conferred from RIGS only if 
cipro was started by 12 hours after radiation exposure (Figure 7.4A). Furthermore, only one dose 
of cipro administered directly by mouth 1 hour after radiation was sufficient to confer protection. 
In fact, untreated, irradiated cage mates of mice receiving one oral dose of cipro experienced 
prolonged survival similar to that of their cipro-treated cage mates (Figure 7.4B). IEC apoptotic 
and proliferative responses to radiation, which determine the ultimate fate of intestinal crypts, 
peak within the first 4-8 hours following exposure, then quickly return to near-baseline levels. 
And cipro administration preserved small intestinal and colonic crypts in mice after lethal 
irradiation (Figure 7.4C-D). Cumulatively, these data suggest that there are events in the first 24 
hours after radiation exposure that critically impact host morbidity and mortality. 
 Ciprofloxacin prevents radiation-induced shifts in the overall composition of the 
intestinal microbiota that begin within the first 24 hours. We identified an intestinal dysbiosis 
that ensues within 24 hours of radiation exposure. Principal coordinate analysis (Figure 7.5A) 
and hierachial clustering (Figure 7.5B) of intestinal bacterial communities generated by QIIME 
analysis of 16S rRNA-based 454 pyrosequencing data revealed that a dysbiosis occurs after 
radiation in the small intestine and colon, in both biologically-important mucosal and luminal 
bacterial communities. Cipro largely prevents these radiation-incited shifts in the composition of 
the microbiota in the jejunum mucosa, cecum lumen, cecum mucosa and distal colon mucosa 
(Figure 7.5A-B). Multidimensional scaling plots generated with a second technique, T-RFLP, 
confirmed that cipro alters the radiation-impelled intestinal dysbiosis (Figure 7.5C). T-RFLP also 
suggested that reductions in intestinal bacterial richness initiated by radiation were partly 
prevented by cipro administration (Figure 7.5D). Another measure of the diversity of a complex 
bacterial community is β-diversity, or the diversity between groups. We assessed intestinal 
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bacterial β-diversity by calculating average weighted UniFrac distances of microbial 
communities generated by QIIME, and we found that cipro prevented increases in β-diversity 
actuated by radiation in the cecum lumen (p=0.0001), cecum mucosa (p=0.05) and distal colon 
mucosa (p<0.003) (Figure 7.5E). 
 Ciprofloxacin largely prevents alterations in predominant intestinal bacterial phyla 
following radiation exposure. To evaluate the effect of cipro on the abundance of groups within 
the gut microbiota following radiation, we determined the number of different bacterial groups in 
each sample by using 3% dissimilarity between 16S rRNA gene sequences as an indicator of a 
“species level” OTU. The abundances of different bacterial taxa ranging from phylum to species, 
identified by 16S rRNA V1-V3 region OTU sequence alignments, were found to differ between 
untreated mice exposed to radiation and mice exposed to radiation and administered cipro. At the 
phylum level, radiation exposure resulted in significant decreases in levels of enteric Firmicutes, 
with concomitant increases in Proteobacteria members. Cipro administration largely prevented 
these alterations in phylum level intestinal bacterial community composition (Figure 7.6).  
 Ciprofloxacin inhibits changes in concentrations of important intestinal bacterial 
groups caused by radiation. 454 pyrosequencing revealed increases in intestinal populations of 
the Proteobacteria phylum following radiation that were prevented by cipro administration. To 
determine what members of this phylum were increased by radiation, we used 16S rRNA qPCR 
and bacterial species specific primers. E. coli, Pseudomonas flourescens and Klebsiella 
pneumoniae, all members of the Gamma Proteobacteria class within the Proteobacteria phylum, 
were increased in the gut following radiation, and cipro largely prevented these increases (Figure 
7.7A). Conversely, Lactobacillus species, (members of the Firmicutes phylum that was identified 
by deep sequencing as decreasing in the small intestine and colon following radiation), were 
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reduced by radiation, but cipro administration largely preserved these enteric bacterial 
populations (Figure 7B). Deep sequencing and qPCR revealed that Bacteroides species increased 
after radiation in the cecum mucosa, but not when cipro was administered starting one hour after 
radiation exposure (Supplementary Figure 7.1).  
 Effects of ciprofloxacin on the intestinal microbiota directly impact host morbidity 
and mortality following radiation. To address the question of whether or not the effects of 
cipro on radiation-induced dysbiosis impact host morbidity and mortality following radiation, we 
performed cecal content transplantation experiments. We harvested cecal contents from 3 groups 
of mice and transplanted them into GF recipient mice that were maintained in sterile cages. The 3 
donor groups were: 1) healthy mice 2) mice exposed to radiation 3) mice treated with cipro. 
After a 72 hour post-transplantation equilibration period, all 3 groups of mice were exposed to an 
equivalent dose of radiation. We found that mice transplanted with microbiota from cipro-treated 
mice had significantly prolonged survival after exposure to a lethal dose of irradiation compared 
to mice receiving normal microbiota or post-irradiation microbiota (Figure 7.8; p<0.02). 
Discussion  
 Ionizing radiation is widely used in medicine for treating cancers, in industrial 
radiographic devices, and in generating electrical power in nuclear reactors. Gamma rays and x-
rays easily penetrate body tissues and injure internal organs. Recent world events have reminded 
us that use of nuclear power is not without risk. While nuclear power is clean and sustainable, it 
can cause considerable loss of human health and life. Even with the most stringent measures, the 
risk of radiation exposure cannot be eradicated. Many agents have been investigated as potential 
mitigators of radiation intestinal injury in humans, with negative or very modest results, 
including growth factors (21), cytokines (13, 45), prostaglandins (46, 47), vitamins (48-50), and 
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thiols (51). Almost all studies that claim efficacy of agents against radiation intestinal injury 
investigated radiation doses that do not consistently cause RIGS (13, 20, 21, 33, 35, 45, 49, 50, 
52-59) or did not show protection with post-radiation exposure administration (20, 21, 27, 32, 
35, 45, 49, 50, 52, 55, 57-59). Some investigators have anesthetized mice before delivering 
experimental radiation (14, 20, 33, 56, 60), despite the fact that anesthetics can have 
unpredictable effects on radiosensitivity.  
 Antibiotics have been considered for decades as a potential treatment option for radiation 
enteropathy (1, 61). Yet, the last serious attention that antibiotics received as potential intestinal 
radioprotectors was in the 1990’s when investigators at the Armed Forces Radiobiology 
Research Institute studied the efficacy of antibiotics in several radiation mouse models (62-64). 
These studies were limited by their focus on activity of antibiotics against orally ingested 
pathogens, their use of hepatic bacterial translocation and mortality as primary readouts, and 
their evaluation of radiation doses that do not cause RIGS. In a 2004 review, these authors 
concluded that they were not able to identify an antibiotic that was most effective among those 
studied (65).  
 Here, we report that the mean survival of mice exposed to 15 Gy is approximately 10 
days when they are administered the antibiotic ciprofloxacin, and cipro is effective when 
administered between 1-12 hours after exposure. In comparison, three of the most noteworthy 
previous studies reported genetic or pharmacologic protection of a total of 54 mice from 
radiation doses of 15-16 Gy, with a mean survival of 8.2 days in treated mice (9, 23, 25). In 
addition, the evaluation of intestinal radioprotection in mice should be multiparametric (25), and 
we employed an intestinal crypt regeneration assay, Kaplan-Meier dose survival analysis, and 
autopsy evaluation of every experimental animal at the time of death. In addition, we did not 
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anesthetize animals prior to radiation in order to avoid the potential impact of these drugs on 
intestinal radiosensitivity.  
 Humans undergoing radiation therapy for abdominal or pelvic malignancy receive lower, 
fractionated doses of radiation. While our studies focused on single doses of radiation, it is 
possible that cipro may also confer intestinal radioprotection from similar total doses that are 
fractionated therapeutically. If this is the case, quality of life of cancer patients undergoing 
radiation treatment may be improved by cipro’s reduction of adverse side effects including 
diarrhea and by cipro’s contribution to the maintenance of intestinal mucosal integrity. This may 
allow for radiation dose escalation and, hence, improved cancer cure rates. By preserving the 
intestinal mucosa, cipro may also prevent the development of fibrosis and potentially life-
threatening fibrosis-related sequelae months to years after radiation treatment or exposure. It is 
important to note that we did not study the effect of cipro on tumor radiosensitivity. These are 
fruitful areas for future investigations.  
 This study raises the possibility of using oral cipro as a radioprotective agent in man and 
provides insight into the timing and mechanism of cipro-mediated protection from RIGS. In an 
era of increased risk for radiological accident and terrorism, medical contingency plans and 
preparedness are crucial to saving lives. Effective radiomitigators are key to the success of 
preparedness. Yet, there are no FDA-approved agents to mitigate the lethal effects of RIGS. Our 
findings suggest that cipro may serve as an intervention that mitigates death from RIGS through 
its prevention of profound enteric dysbiosis. Ciprofloxacin is an approved oral drug, available in 
the market and thus may be easier to be developed as a medical countermeasure for RIGS in 
humans. The single, oral, low dose of cipro required for its radiomitigation effects underscores 
its potency, safety, ease of administration, and low expense. Oral delivery provides a quick route 
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of administration in the event of a nuclear disaster without the need for specialized personnel. In 
addition, cipro can be used in combination with agents that have been approved as treatments for 
the radiation hematopoietic syndrome, such as granulocyte-colony stimulating factor (G-CSF) 
(66). Given its favorable safety and expense profile as an FDA-approved generic antibiotic, cipro 
could be rapidly and cheaply disseminated to all individuals in the vicinity of a radiological 
event, even in the absence of knowledge of actual level of radiation exposure. As such 
ciprofloxacin fulfills a mandate of the United States Department of Health and Human Services 
Public Health Emergency Medical Countermeasures Enterprise, a national security measure 
designed to protect the American public from the use of weapons of mass destruction, consistent 
with the goals of the President’s Biodefense for the 21st Century and National Strategy for 
Medical Countermeasures against Weapons of Mass Destruction directives. 
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Figure 7.1. Ciprofloxacin (cipro) prevents radiation gastrointestinal syndrome (RIGS). (A) 
Antibiotics were administered to mice in drinking water, starting one hr after 15 Gy TBI (n=8 
mice/group). Clinical colitis scores at day 5 after radiation are shown. Mean clinical colitis 
scores for untreated, irradiated mice and irradiated mice treated with metronidazole (MET), 
rifaximin (RIF), trimethoprim-sulfamethoxazole (TMP) or neomycin (NEO) were 8.4-9.9. Mean 
clinical colitis scores for irradiated mice receiving cipro or cipro/MET were 4.0 and 3.2, 
respectively. (B) Untreated mice and mice treated with MET, RIF, TMP or NEO after radiation 
have guaiac positive stools 5 days after radiation, while irradiated mice treated with cipro or 
cipro/MET have no evidence of GI bleeding. (C) Untreated mice and mice treated with MET, 
RIF, TMP or NEO after radiation have loose stools 5 days after radiation, while irradiated mice 
treated with cipro or cipro/MET have normal stools. (D) Cipro had no effect on weight loss 
following radiation exposure. (E) Radiation exposure results in bacteremia. Cipro reduced the 
percentage of irradiated mice with positive blood cultures from 100% to 8%. (F) Mice treated 
with cipro or cipro/MET after radiation live 5-9 days longer than untreated mice or mice treated 
with other antibiotics. At necropsy, 62.5% of mice treated with cipro after radiation are found to 
have gross blood in their intestinal contents, while 75% of mice treated with cipro/MET after 
radiation have gross GI bleeding. Irradiated mice that are untreated or treated with other 
antibiotics die of presumed sepsis and have no evidence of GI bleeding. 37% of irradiated mice 
treated with cipro and 62.5% of mice treated with cipro/MET have intra-abdominal bleeding at 
necropsy, while untreated, irradiated mice and irradiated mice treated with other antibiotics have 
no intra-abdominal bleeding. cipro=ciprofloxacin; MET=metronidazole; TMP-
SMX=trimethoprim-sulfamethoxazole; GI=gastrointestinal. 
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Figure 7.2. Ciprofloxacin prevents radiation-induced colitis. (A) Colon weight, a non-specific 
marker of inflammation, is increased in untreated mice on day 5 after radiation, but not in 
irradiated mice treated with cipro (p<0.002). (B) Radiation results in significant secretion of the 
pro-inflammatory, Th-1-mediated cytokine interleukin-12p40 (IL-12p40) by ex vivo colonic 
tissue explants at 5 days after exposure, as measured by ELISA. Cipro and cipro/MET 
administration after radiation reduce colonic IL-12p40 secretion, but MET alone does not. (C) 
Colonic tissue secretion of pro-inflammatory, Th-1-mediated cytokine IL-1β is also increased at 
18 hours after radiation exposure, and cipro administration prevents this increased secretion. (D) 
High-resolution endoscopy revealed evidence of mild to moderate colonic injury 5 days after 
radiation (middle; n=3), while cipro-treated, irradiated mice have colonic mucosa (right; n=3) 
that is similar in appearance to that of a healthy mouse (left; n=2).  
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Figure 7.3. Cipro has strong bactericidal activity against microbes that translocate to the blood 
following radiation exposure. Antibiograms of bacteria cultured from the blood of untreated mice 
after 15 Gy using the Kirby-Bauer disk diffusion sensitivity testing method. (A) 100% of isolates 
(n=16) were susceptible to killing by cipro, compared to 67% susceptibility to aztreonam (n=15), 
37% to vancomycin (n=16), 25% to trimethoprim-sulfamethoxazole (n=16), 21% to rifampin 
(n=16), and 20% to clindamycin (n=15). The mean zone of inhibition of bacterial growth was 
11.3 mm with cipro, compared to 1.6 mm with vancomycin, 0.9 mm with trimethoprim-
sulfamethoxazole, and 3.9 mm with rifampin. Cipro=ciprofloxacin; vanco=vancomycin; TMP-
SMX=trimethoprim-sulfamethoxazole; rifamp=rifampin; clinda=clindamcyin; 
doxy=doxycycline. 
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Figure 7.4. Events ensuing in the first 24 hours after radiation exposure are critical to host 
morbidity and mortality. (A) Delaying cipro treatment until 24 hours after radiation exposure 
results in mortality similar to that seen in untreated, irradiated mice, even when cipro is 
administered continuously in drinking water. Median survival after 15 Gy is 5 days without 
intervention. Median survival after 15 Gy  is 11.5 days when cipro is administered continuously 
starting one hour after radiation exposure. However, median survival after 15 Gy is only 6 days 
when cipro is administered continuously starting at 24 hours after radiation exposure. n=4 mice 
per group. (B) Just one dose of cipro, 50 mg/kg administered orally by pipette one hour after 
radiation, prolongs survival in mice and in their untreated, irradiated cage mates (p<0.003). (C) 
Representative histology (n=6) from paraffin-embedded mid-jejunal sections of healthy mice 
(left), mice exposed to radiation (middle), and mice exposed to radiation and treated with cipro 
starting one hour after exposure (right). Magnification 20X. Hematoxylin and eosin staining 
demonstrates loss of intestinal crypt architecture following radiation, compared to preservation 
of crypt and villus structure with cipro administration. Crypt regeneration assay quantitates crypt 
preservation by cipro following lethal irradiation (D; p<0.0001), and this is seen as early as 24 
hours after radiation exposure. 
  
208 
 
 
Figure 7.5. Ciprofloxacin inhibits development of radiation-induced intestinal dysbiosis. (A) 
Principal coordinates analysis (PCoA) of weighted UniFrac distances of 16S rRNA sequences. 
Symbols represent individual intestinal mucosal bacterial communities obtained from healthy 
control mice (orange), mice exposed to irradiation (blue), and mice exposed to radiation and 
treated with ciprofloxacin (red). Shown are communities from the jejunum mucosa (top left), 
cecum lumen (top right), cecum mucosa (bottom left), and distal colon mucosa (bottom right). 
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Figure 7.5. (B) Hierarchial clustering of intestinal microbiota samples based on OTUs at 97% 
sequence similarity. Samples from healthy control mice (orange squares), mice exposed to 
irradiation (blue circles) and mice exposed to irradiation and treated with cipro (red triangles) are 
shown. Jejunum mucosa (top left), cecum lumen (top right), cecum mucosa (bottom left) and 
distal colon mucosa (bottom right) are shown.  
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Figure 7.5. (C) Cipro alters radiation-induced shifts in the composition of the intestinal 
microbiota. T-RFs derived from fecal bacterial communities of mice exposed to radiation (dark 
blue) and mice exposed to irradiation and treated with cipro (light blue) were used to generate 
nonmetric multidimensional scaling plots. The communities in mice exposed to radiation and 
those exposed to irradiation and treated with cipro were statistically dissimilar based on 
ANOSIM analysis (p<0.05; n = 8-16 mice/group). (D) Cipro administration attenuates the 
reduction in fecal T-RFs seen after radiation exposure.  
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Figure 7.5. (E) Average weighted UniFrac distances of microbial communities from healthy 
control mice (left), irradiated mice (middle), and irradiated mice treated with ciprofloxacin 
(right). Jejunum mucosa (top left), cecum lumen (top right), cecum mucosa (bottom left) and 
distal colon mucosa (bottom right) are shown. 
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Figure 7.6. Cipro largely prevents alterations in predominant intestinal bacterial phyla following 
radiation exposure. Average abundances of bacterial phlya in the intestine of healthy mice (left), 
mice exposed to irradiation (middle), and mice exposed to irradiation and treated with 
ciprofloxacin (right). Cecum mucosa (top), cecum lumen (middle) and distal colon (bottom) are 
shown. Radiation exposure results in a decrease in Firmicutes and an increase in Proteobacteria, 
and these shifts are largely prevented by administration of ciprofloxacin. 
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Figure 7.7. Ciprofloxacin administration prevents alterations in concentrations of specific 
intestinal bacterial groups following radiation exposure. (A) Quantitation of intestinal bacterial 
species are shown, using quantitative PCR of the 16S rRNA gene. Radiation exposure results in 
increases in intestinal populations Proteobacteria phylum members, and cipro largely prevents 
these increases. Copy number is normalized to total 16S.  
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Figure 7.7. (B) Quantitation of intestinal bacterial species is shown, using quantitative PCR of 
the 16S rRNA gene. Radiation exposure results in decreases in Firmicutes phylum members, and 
cipro largely prevents these decreases. Copy number is normalized to total 16S.  
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Figure 7.8. Effects of cipro on the intestinal microbiota directly impact the host response to 
radiation. GF WT mice received transplantation of 1) normal microbiota, 2) post-irradiation 
microbiota or 3) microbiota from ciprofloxacin-treated mice. Mice receiving microbiota from 
cipro-treated mice had prolonged survival after exposure to a lethal dose of irradiation compared 
to mice receiving normal microbiota or post-irradiation microbiota (p<0.02). 
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Supplementary Figure 7.1. Quantitation of intestinal bacterial species is shown, using 454 
pyrosequencing (left) and quantitative PCR of the 16S rRNA gene (right). Radiation exposure 
results in increases in increases in intestinal Bacteroides species, and cipro largely prevents these 
increases. Copy number is normalized to total 16S.  
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Discussion 
 The human gut is the natural environment for a diverse and dynamic microbial 
ecosystem, whose structure and functions are presently a major target of biomedical research. A 
better understanding of the human microbiota and how to manipulate it safely may lead to better 
ways to prevent harm and promote health with minimum toxicity (1). We have utilized novel 
gene sequencing technologies and powerful bioinformatics analysis tools to provide insights into 
the composition, structure and activities of the gut microbiota in several rodent models of 
intestinal injury and inflammation, including the interleukin 10-deficient (IL-10
-/-
) mouse model 
of chronic, spontaneous, immune-mediated colitis (chapter 4) and a radiation-induced 
gastrointestinal (GI) syndrome mouse model (chapters 6 and 7), as well as in humans with 
diarrhea-predominant irritable bowel syndrome (D-IBS; chapter 3). We have developed 
procedures for subjecting germ-free, selectively colonized, and conventionalized mice to 
manipulations while maintaining their gnotobiotic environments (chapters 4, 6 and 7). We have 
also validated procedures for transplanting cecal microbial communities into germ-free mouse 
recipients (chapters 6 and 7).  
 Collecting a stool sample is easy and noninvasive, and so unsurprisingly the great 
majority of the information that is available on the gut microbiota composition derives from 
studies on fecal samples that merely serve as surrogates for the colonic luminal microbiota (2, 3). 
However, the stool represents a significantly different environment than the intestinal mucosa, 
where host-microbial interaction takes place (4, 5). In addition, there are differences in bacterial 
concentrations, host cell exposure time to the microbiota, and mucin organization (6) between 
the colon and small intestine, and even between different regions of the colon (7). For these 
reasons, we have investigated bacterial communities in the jejunum, (chapters 6 and 7), cecum 
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(chapters 6 and 7), and colon (chapters 3, 6 and 7). The biological importance of differences 
between mucosa-associated and luminal bacteria is unclear (8-13), so we also studied microbial 
communities in both of these compartments (chapters 3, 6, and 7). All mouse experiments 
included age- and gender-matched, young adult animals, as it has been suggested that the age 
(14) or sex (15) of an adult may impact the microbiota composition. Finally, while high temporal 
stability has been observed in the adult microbiota (16), we have accounted for potential 
temporal variations in the microbiota by performing kinetic analyses, assessing microbial 
communities both at several time points in near succession, and over longer periods of time 
(chapters 4, 6 and 7).  
 Utilizing gnotobiotic animals, we demonstrated that commensal bacteria play a protective 
role early in the host response to radiation intestinal injury, by contributing to intestinal epithelial 
cell proliferation and limiting excessive intestinal epithelial cell apoptosis (chapter 6). We also 
showed that commensal bacteria contribute to the pathogenesis of the radiation GI syndrome, 
which had been shown previously by Gordon and Crawford (17). We subsequently confirmed 
our hypothesis that radiation induces a profound intestinal dysbiosis that can explain the dual 
role of gut bacteria early and late in the host radiation response, respectively (chapters 6 and 7). 
 We identified a reduction of enteric Firmicutes in both mice with immune-mediated 
colitis (chapter 4) and radiation intestinal injury (chapters 6 and 7; table 1), similar to that 
previously described in patients with Crohn’s disease (18, 19). Within the Firmicutes phylum, we 
determined that Lactobacillus reuteri comprised the great majority of Lactobacillus spp. in the 
healthy C57BL/6 mouse intestinal tract and were largely eliminated in the gut following 
radiation (chapter 6). These data identify this bacterial species as an important potential 
therapeutic target for the radiation GI syndrome. It is possible that L. reuteri could provide 
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protection from radiation intestinal injury through a number of potential mechanisms, and 
selective colonization experiments involving L. reuteri monoassociated animals and animals dual 
associated with L. reuteri and a pathogenic bacterial strain could provide valuable information. 
Lactobacillus species are among the most frequently used bacteria in probiotic products (20), as 
they are regarded as safe for human use, even for immunocompromised individuals, children 
(21), neonates and the elderly (22). Lactobacillus species have been shown to provide benefits in 
humans with atopic dermatitis (23, 24), viral infections (25), and allergies (26), and they 
contribute to the treatment of Helicobacter pylori infection (27) and colitis (28) in mice, and 
gastric ulcers in rats (29). Mechanistically, Lactobacillus species possess the ability to adhere to 
intestinal epithelial cells via mannose-binding (30) and pili (31), enhance tight junctions (32, 33), 
modulate cellular pathways (34-38), induce production of mucin by goblet cells (39) and 
defensins by Paneth cells (40), modulate dendritic cell functions (41-43), stimulate production of 
IL-12 (44, 45) and IL-10 (45, 46) by monocytes/macrophages, degrade pro-inflammatory 
chemokines (47), produce bacteriocins (48-51), and improve gut function parameters (52-54). 
However, L. reuteri have not yet received a great deal of attention, although they have been 
shown to treat hypercholesterolemia (55). For the application of probiotic species, considerable 
in vitro, in vivo, and clinical evidence must justify their use (56), safety must be ascertained (22) 
and undesired effects must be identified (57). 
 We found that Enterobacteriaceae exist in very small concentrations in the healthy mouse 
gut, consistent with previous reports in humans and mice (58-60). In line with previous reports in 
human inflammatory bowel diseases (IBD) (61-67) and in chemical- (68, 69), pathogen- (70, 
71), and immune defect-induced (72, 73) colitic mice, we observed dramatic increases in relative 
abundance of intestinal Enterobacteriaceae, particularly Escherichia coli, (members of the 
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Proteobacteria phylum), in mice exposed to radiation (chapters 6 and 7; table 1) and in mice 
experiencing spontaneous, chronic, immune-mediated intestinal inflammation (chapter 4; table 
1). Hypotheses are emerging regarding mechanisms by which host responses shape the microbial 
community structure and drive the proliferation of Enterobacteriaceae, particularly E. coli, 
(which have been found in higher abundance in people with IBD [74-80]), in settings of 
intestinal injury, which certainly could pertain to the radiation GI syndrome. One recent report 
proposed that nitrate generated by the host as a by-product of inflammation can be used by E. 
coli and likely by other commensal Enterobacteriaceae to edge out competing microbes that rely 
on fermentation to generate energy for growth (81, 82). In fact, there is accumulating evidence 
that E. coli are able to thrive not only in the setting of intestinal inflammation, but in the setting 
of general stress directed by or at the host. For example, E. coli have been shown to be more 
abundant during pregnancy (83), weaning (84), fasting (85), and starvation (86), and following 
surgery (87). Furthermore, expression of E. coli stress genes is stimulated in the inflammatory 
environment (88).  
 The biodiversity in the human gut is a result of coevolution between host and microbe 
and has been shown to be stable over time in healthy individuals (89). Thus a departure from the 
normal biodiversity of the intestinal microbiota may reflect a disease state in the gut. We 
performed thorough analyses of intestinal microbial biodiversity in our studies, assessing both α- 
and β-diversity. A reduction in intestinal bacterial biodiversity is consistently present in children, 
adolescents (90-93), and twins with ulcerative colitis (94), as well as other subsets of IBD 
patients (95). In line with these previous studies in IBD, we found decreased fecal microbial 
biodiversity in patients with D-IBS (chapter 3; table 1) and in mice with spontaneous, chronic, 
immune-mediated colitis (chapter 4). We also noted differences in microbial biodiversity 
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between fecal and colonic mucosal communities, with decreased biodiversity in the colon 
compared to the feces (chapter 3). Interestingly, we found that radiation exposure largely 
resulted in increased biodiversity in the intestinal microbiota (chapter 6).  
 We characterized significant shifts in the composition of the microbiota in several forms 
of intestinal disease (table 1), including D-IBS (chapter 3), spontaneous, chronic, immune-
mediated colitis (chapter 4), and radiation enteropathy (chapter 6 and chapter 7). What has been 
lacking in studies of human dysbioses is the determination of the biological and clinical 
significance of community imbalances. The question remains: Are the changes in intestinal 
microbiota that are observed in intestinal disorders necessary determinants of initiation and/or 
perpetuation of pathogenesis, or are the microbiota alterations simply consequences of chronic 
inflammation/injury? Frank et al. presented four possible causal relationships between intestinal 
disease and dysbiosis (96): 1) Dysbiosis is a primary trigger that leads to pathogenesis. 2) 
Disruption of the commensal microbial community and its functions contributes to the duration 
or severity of the disease state. 3) The pathological condition itself causes a secondary shift in 
microbial community structure that does not impact the pathogenesis of disease. 4) Dysbiosis 
arises in parallel with pathogenesis secondary to etiological factors but does not serve as a causal 
factor of disease.  
 The strongest evidence that dysbiosis contributes to human disease could be obtained 
through double-blind, randomized controlled experiments utilizing agents that create dysbiosis in 
healthy individuals or that normalize dysbiotic communities in diseased individuals (96). Under 
these conditions, any exact causal relationships that exist between dysbiosis exposure and 
subsequent pathological development could be defined. However, there are obvious ethical 
considerations that render these experiments difficult if not impossible to carry out in humans. 
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Alternatively, we designed experiments employing animal models of disease that contributed 
important insights into the timing and mechanistic basis of disease pathophysiology in relation to 
altered microbiota. We generated a mouse model of radiation intestinal injury and used 
molecular-based technologies to characterize a radiation-induced intestinal dysbiosis that closely 
matches that described in other intestinal disorders, namely IBD. We were able to utilize this 
model to artificially create a reproducible dysbiotic microbiota that we used in mechanistic 
studies incorporating microbiota transplantation and selective colonization of gnotobiotic mice, 
combined with targeted experiments to determine causal relationships and further define 
mechanisms of action (chapters 6 and 7). 
 Revisiting the aforementioned hypotheses offered by Frank et al., we can use our findings 
described within this thesis to begin to disavow some of the postulates while perhaps 
strengthening support for one supposition in particular. The first hypothesis is that dysbiosis is a 
primary trigger that leads to pathogenesis. First, we have shown that alterations in the gut 
microbiota that we identified in patients with IBS (chapter 3) and in mice with immune-mediated 
colitis (chapter 4) and radiation enteropathy (chapters 6 and 7) are very similar to those seen in 
human IBD (61, 62, 65, 97-99), as well as in a mouse model of Clostridium difficile colitis (100). 
One would expect that if dysbiosis is a primary trigger of disease, then each respective disease 
with unique pathophysiology would be caused by a singular dysbiosis with distinguishing 
features. Yet, this does not seem to be the case. Second, we performed longitudinal observational 
studies with conventionalized wild-type and (IL-10
-/-
) mice in an attempt to assess the causal 
relationship between dysbiosis and the development of spontaneous, chronic, immune-mediated 
colonic inflammation in IL-10
-/-
 mice (chapter 4). While exact timing of disease onset was 
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difficult to define, it did not appear that dysbiosis preceded the onset of colonic inflammation in 
these mice, suggesting that at least in this animal model, dysbiosis does not initiate disease. 
 The second hypothesis is that disruption of the commensal microbial community and its 
functions contributes to the duration or severity of the disease state. We have shown that changes 
in the microbial community structure characterized by an increased mucosal and luminal 
abundance of Enterobacteriaceae can be transferred to other animals, resulting in an exacerbation 
of intestinal injury (chapters 6 and 7). This phenomenon has been shown previously in an 
immunodeficient mouse that spontaneously develops colitis (72, 101). In addition, selective 
colonization gnotobiotic experiments revealed that individual bacterial species relevant to 
radiation dysbiosis, E. coli and Enterococcus faecalis, have differential abilities to induce 
radiation morbidity and mortality (chapter 6). Together these data support the hypothesis that 
dysbiosis and/or its components contribute to the severity of disease, and contradict the 
hypothesis that the pathological condition itself causes a secondary shift in microbial community 
structure that does not impact the pathogenesis of disease, as well as the hypothesis that 
dysbiosis arises in parallel with pathogenesis secondary to etiological factors but does not serve 
as a causal factor of disease. 
 One of the ultimate goals of these lines of research is to identify interventions that will 
alter dysbiosis and to determine whether these interventions alter the course of disease. As an 
example of a previous success story, past descriptions of phylum level changes in the intestinal 
microbiota during C. difficile infections, (reductions in Bacteroidetes and relative increases in 
Proteobacteria and Verrucomicrobia), resulted in the creation of a new macrocyclic, the 
Bacteroides-sparing antibiotic fidamoxicin, which reduced initial C. difficile infection relapse 
rates by 50% compared to the antibiotic vancomycin (102). We have identified an FDA-
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approved antibiotic, the fluoroquinolone ciprofloxacin (cipro), which prevents radiation-induced 
shifts in the microbiota and rescues mice from the radiation GI syndrome (chapters 6 and 7). One 
of our aims is to guide the discovery of narrow-spectrum antibiotics that will even more 
optimally restore the normal gut microbiota in patients exposed to radiation or with other forms 
of intestinal injury. 
 Cipro prevents the radiation GI syndrome through several mechanisms (chapter 7). It 
prevents the development of sepsis, but interestingly there is a window of protection for the 
administration of cipro. If delivered 24 hours after radiation exposure or thereafter, protection is 
not seen. Furthermore, one dose delivered at one hour after radiation exposure was sufficient to 
protect not only irradiated mice from the GI syndrome, but also their untreated, irradiated cage 
mates. These findings strongly suggested that there is a cipro-preventable event(s) that occurs 
within the first 24 hours after radiation exposure that is critical to the pathogenesis of the GI 
syndrome. We identified a dysbiosis that ensues within the first 24 hours of radiation exposure, 
and we demonstrated that cipro inhibits this dysbiosis. It is reasonable to assume that as agents 
that lyse bacterial cells and/or prevent their proliferation, antibiotics are able to affect the 
composition of the microbiota, and unsurprisingly recent studies have shown that this is the case 
(103, 104). In fact, the administration of cipro to humans affected the majority of bacterial taxa 
in the gut (105). Importantly, we showed that cipro prevented the proliferation of E. coli 
observed in the gut after radiation. It has been proposed that antibiotic administration results in 
blooms of enteric commensal E. coli populations (106-109), but this was not the case with the 
delivery of cipro in our animal model of radiation enteropathy. 
 We found that radiation selectively reduces expression of α-defensins (chapters 6 and 7), 
antimicrobial peptides (AMPs) that are produced and secreted by small intestinal Paneth cells. 
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Delivery of cipro both preserves expression of these AMPs in SPF mice exposed to radiation and 
induces their expression in germ free mice, independent of the presence of microbes. This is 
important because a growing number of infections are caused by antibiotic-resistant bacteria and 
there is a shortage of new families of antibiotics that could compensate for resistance to existing 
antibiotics due to the high costs of development (110, 111). In addition, the administration of 
broad-spectrum antibiotics can lead to detrimental effects on the commensal microbiota (96, 
112-113). As a result, there is a dire need for the development of new antimicrobials that can be 
used in clinical settings, and AMPs that are produced by intestinal epithelial cells or bacteria 
might warrant serious consideration as alternatives to traditional antibiotics. It is possible that 
antibiotics other than cipro have the ability to modulate the microbiota through similar direct 
effects on the host. To date, this has been largely unexplored. 
 We also identified a probiotic (VSL#3) that induces α-defensin expression in SPF mice, 
promotes eubiosis and mitigates the radiation GI syndrome (chapter 7). There is growing interest 
in developing strategies to therapeutically improve the physiological quality of the human gut 
microbial ecosystem. Various interventional approaches have emerged, including the use of 
probiotics, prebiotics or techniques for microbial reconstitution through fecal transplantation. 
These strategies are aimed at combatting overgrowth of opportunistic community members 
and/or providing metabolic substrates or live micro-organisms for the promotion of the growth 
and activity of beneficial species. Probiotics are defined as “live micro-organisms which, when 
administered in adequate amounts as part of food, confer a health benefit on the host” (114). 
Prebiotics are “selectively fermented ingredients that permit changes in the composition and/or 
activity of the intestinal microbiota that confer benefits upon host well-being” (115). An exciting 
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concept is that of the “synbiotic”: the combination of probiotics and prebiotics aimed at 
optimizing the impact of probiotics on the gut microbial ecosystem (116). 
 The results from our cecal content transplantation experiments demonstrate that the 
composition of the microbiota impacts the clinical response of the host to radiation (chapters 6 
and 7). These data may guide the rational design of healthy, resilient and robust microbial 
communities that can be used to maintain or restore human health following radiation, and 
perhaps in patients suffering from intestinal diseases of other etiologies. Fecal microbiota 
transplantation (FMT) has been used sporadically over the last 50 years (117), but an epidemic of 
C. difficile infections in the USA and Europe (118-120) has resulted in the increased use of FMT 
to treat this disorder (121, 122), which is characterized by a dysbiosis (123) and is frequently 
unresponsive to antibiotics (102, 124). Three systematic reviews of recurrent C. difficile cases 
treated with FMT found that 83%, 90% and 92% of patients were cured, respectively (121, 125, 
126). FMT induced response in 7 patients with ulcerative colitis in two studies (127, 128), but it 
has been suggested that repeated FMT may be required to effectively treat IBD (129).  
 Nonetheless, diseases that result from microbiota-related dysfunction invite the 
investigation of FMT as a potential treatment, including radiation intestinal injury. FMT 
overcomes a quantitative limitation of probiotic therapeutics: Oral probiotic doses are typically 
3-4 orders of magnitude lower than the 100 trillion microorganisms that are native to the colon 
(121), and the numbers are likely further reduced after passage through the harsh environment of 
the stomach. In addition, probiotics rarely persist in the gut beyond 14 days (130), while donor 
flora persists at 24 weeks post-transplantation (131). When utilizing FMT, which can be 
delivered by colonoscopy (132-134) or retention enema (135), the donor microbiota should be 
optimized for the maximal benefit of the recipient. Next generation sequencing techniques 
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should be used to profile the donor stool to ensure a balance of biochemical pathways is present 
that will complement those of the host. The enterotypes (136) of the donor and recipient should 
also be considered. The history, screening of donors, pretreatment processes, patient preparation, 
routes of administration, and methodology for FMT have been reviewed (137-139), and formal 
standard practice guidelines for performing FMT have been published (140). However, the 
technical aspects of FMT are likely to rapidly evolve over the next few years with its increased 
use. Specifications for storage, quantification, and preparation of donor material should become 
more stringently standardized as FMT randomized controlled trials are performed for C. difficile, 
IBD, and other intestinal disorders, and the results are assessed along with molecular analyses of 
the microbiota.  
 It should be noted that radiation is delivered therapeutically during treatment of solid 
tumors of the abdomen and pelvis in fractionated doses of 1.5-2.0 Gy at a time. Our studies 
focused on single doses of 15 Gy because this is the minimum dose of radiation that universally 
causes the radiation GI syndrome in mice. Therefore, these studies are directly relevant to people 
who are exposed to large doses of radiation as a result of nuclear meltdown, terrorist attack, 
space exploration, or medical error. They may also be relevant to people who receive 
appropriately fractionated radiation doses, but who are exquisitely susceptible to radiation 
intestinal injury, due to genetic predispositions or other risk factors. 
 Future studies in these areas should include a focus on: 1) The effect of common 
intestinal diseases and potential therapies on functional secretion of AMPs by Paneth cells or 
colonocytes. Techniques must be developed that can accurately and reliably assess AMP 
secretion. 2) The role of compromised barrier function in these diseases. We did not assess 
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barrier function in our studies, but it is invariably important in the pathogenesis of these 
intestinal disorders, and it could prove to be a promising therapeutic target. 
 Our studies have improved the knowledge of how the host and bacteria interact during 
intestinal inflammation and injury and how the microbiota responds and are regulated in settings 
of irritable bowel syndrome, spontaneous, chronic, immune-mediated colitis, and radiation 
exposure. Given the abrupt rise in incidence and prevalence of intestinal disorders that appears to 
have coincided with socioeconomic development and dietary changes, expeditious progress in 
this area of research is crucial in order to impede the dramatic acceleration of the prevalence of 
these diseases. These data may yield valuable clinical tools in restoring a healthy microbiota to 
prevent or treat intestinal disorders without administering broad, immunosuppressive 
medications that are accompanied by severe side effects. 
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Table 1. Compositional shifts in the enteric microbiota in intestinal disorders. SI=small intestine; 
E. coli=Escherichia coli; K. pneumoniae=Klebsiella pneumoniae; P. fluorescens=Pseudomonas 
fluorescens; C. coccoides=Clostridium coccoides; E. faecalis=Enterococcus faecalis; 
SFB=segmented filamentous bacteria. 
 
  
Disease Bacteria Effect Location Paper Technique 
IL-10
-/-
 Proteobacteria Increased Feces IV 454 
Radiation Proteobacteria Increased SI, colon VI, 
VII 
454 
IL-10
-/-
 E. coli Increased Feces IV 454, qPCR 
Radiation E. coli Increased SI, colon VI, 
VII 
454, qPCR 
Radiation K. pneumoniae Increased Feces VI qPCR 
Radiation P. fluorescens Increased Feces VI qPCR 
IL-10
-/- 
Firmicutes Decreased Feces IV 454 
Radiation Firmicutes Decreased SI, colon VI, 
VII 
454 
Radiation Lactobacillus spp. Decreased SI, colon VI, 
VII 
454, qPCR 
D-IBS Clostridiales Decreased Feces III T-RFLP 
IL-10
-/- 
Clostridium spp. Decreased Feces IV 454 
Radiation C. coccoides Decreased Feces VI qPCR 
IL-10
-/- 
Tenericutes Increased Feces IV 454 
Radiation Bacteroides spp. Increased Cecum, feces VI 454, qPCR 
Radiation E. faecalis Increased Feces VI qPCR 
Radiation Porphyromonadaceae Increased Cecum none 454 
IL-10
-/- 
Bacteroidetes Decreased Feces IV 454 
IL-10
-/- 
Actinobacteria Decreased Feces IV 454 
IL-10
-/- 
Verrucomicrobia Decreased Feces IV 454 
IL-10
-/- 
Akkermansia Decreased Feces IV 454 
Radiation Bifidobacterium spp. Decreased Feces VI qPCR 
Radiation SFB Decreased Feces VI qPCR 
Radiation Lachnospiraceae Decreased Cecum none 454 
D-IBS Biodiversity Decreased Feces III T-RFLP 
IL-10
-/- 
Biodiversity Decreased Feces IV 454 
Radiation Biodiversity Increased SI, colon VI, 
VII 
454 
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